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Abstract 
In 2016 alone, it is projected that over forty thousand Americans will succumb to pancreatic 
cancer. One avenue that holds promise in developing accurate predictive tools and effective 
therapeutic agents to mitigate cancer mortality lies in the analysis of circulating tumor cells 
(CTCs). CTCs describe a subset of tumor cells that have acquired the ability to disseminate from 
primary and metastatic sites and intravasate into the circulatory system to subsequently spur new 
metastases.  As such their detection in peripheral blood has been recognized as a potential tool in 
the diagnosis of cancer and in the prevention of metastasis. CTCs can be accessed from facile, 
non-invasive patient blood draws compared to complex surgical procedures traditionally 
employed to obtain tumor tissue biopsies. However these cells are quite rare, occurring on the 
order of 1:1 billion among other blood cells. Therefore the need to enrich these cells to achieve 
better detection is exigent.  
This thesis delineates the development and the implementation of an integrated, polymer-based 
microfluidic CTC sorting device that enables significant enrichment of CTCs in a continuous, 
high-throughput manner (24mL/hr). The device operates via strategic combination of size-based 
inertial cell sorting, on-chip CTC immunomagnetic-microbead labeling, and magnetic cell 
sorting. Targeted isolation of as few as 10s of cancer cells from millions of WBCs with average 
CTC purities of 82.5%±23.5 (n=14) is enabled through this process. Moreover, CTCs were 
detected in 100% of patient samples, at >13 CTCs/mL across all patients, (median = 69 
CTCs/mL, mean = 146± 231 CTCs/mL), demonstrating the ability of the approach to distinguish 
between diseased and healthy samples. 
Subsequently, the work outlines CTC molecular characterization, by way of both messenger- and 
micro- RNA profiling, of CTCs isolated using the optimized integrated device. Messenger RNA 
(mRNA) profiling revealed that expression of seven mRNAs, Zeb1, KLF4, cMYC, BRCA1, 
HER2, CD3D, and HPRT1 were significantly higher in metastatic versus borderline profiles. 
Also, CTC microRNA profiling showed that miRs-221-3p, -23a-3p, -143-3p and -21-5p, were 
among those most abundantly expressed. These miRNAs have all been previously reported to be 
PDAC associated. Also, we report that miRs 17-5p, 19b-3p, 320b and let7a-5p were among those 
most highly expressed by the profiled PDAC CTC samples. Through network analysis of the 
miR expression data, we also found that pathways involving MAP2K1/2 and Smad2/3 are 
implicated in PDAC CTC biology.  
 xii 
 
Additionally, two separate studies, which analyze distinct aspects of the heterogeneity that exits 
among CTCs, have been reported. In one study, CTCs were sorted and compared according to a 
continuum of expression of EpCAM, a surface protein of paramount interest. Interestingly, CTCs 
of varying EpCAM levels were isolated from patient samples using this sorting method 
suggesting an observable level of heterogeneity at the protein level among these patients CTCs. 
In another study, CTCs have been studied based on a dual isolation approach where a 
combination of surface protein of interest, EpCAM and CD44, have been used to 
immunomagnetically enrich and probe these rare cells. Among borderline patients, CTC mRNA 
profiles hint at differences at the molecular level between patients classed as resectable from 
those not identified as resectable. Finally, preliminary studies on the synthesis and use of 
differentially synthesized micron particles, with the potential to isolate unique cancer cell 
subpopulations have been reported.  
The development of an integrated platform to isolate CTCs with high purities allows for CTC-
specific downstream genomic characterization. Molecular characterization of pancreatic cancer-
derived CTCs revealed several mRNAs and microRNAs that were associated with the patient 
disease. Furthermore, studies were carried out to characterize CTCs based on their heterogeneity, 
a phenomenon that appears to be indispensable to cancer metastasis. Ultimately, sensitive CTC 
interrogation as described opens the doorway to identifying biological pathways and molecular 
targets that can be exploited in the fight against cancer. 
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Chapter 1 
Introduction  
 
1.1 Motivation  
The coming of age of more sensitive and reproducible techniques for detection, capture and 
isolation of circulating tumor cells (CTCs) has led to the emergence of these rare, blood-borne 
cells as potential biomarkers in the prognosis and treatment of many solid tumors including 
breast, prostate, lung, pancreatic and colon cancers. Furthermore, through the availability of 
improved isolation platforms, more research avenues have opened up to explore the role of CTCs 
beyond rudimentary CTC enumeration, towards disease prognosis and therapeutic testing. 
Notwithstanding the major developments in CTC isolation platforms, CTC isolation purities 
have been moderate, which has ultimately led to suboptimal CTC molecular assays. The need for 
improved CTC isolation purities via methods that provide viable cells has been recognized. This 
thesis describes the development of an integrated microfluidic immunomagnetic platform that 
was used in the isolation and study of CTCs in pancreatic disease. Through the ultra-pure 
isolation of viable CTCs, the potential to perform CTC-specific molecular characterization was 
demonstrated, the results of which will be further presented. 
1.2 Microfluidic Applications in the Study of Cancer  
 
1.2.1 Circulating Tumor Cells in the Study of Cancer  
 2 
 
The ability of a subset of tumor cells to disseminate from a primary tumor through the 
vasculature to an anatomically distant site, while still maintaining similar traits to the tumor of 
origin, was first reported in the nineteenth century by Ashworth.
1
 Evidence suggests that tumor 
cell dissemination may be a result of passive shedding of tumor cells or as a result of acquired 
characteristics of cells through a process of epithelial to mesenchymal transition (EMT).
2, 3
 These 
cells, which are known as circulating tumor cells, (CTCs), are believed to be responsible for the 
persistence and spread of cancer in many solid tumor cancers even after the resection of 
detectable tumors.
4
 In fact, it is believed that metastasis, which is ultimately responsible for 90% 
of cancer-induced fatalities, initiates when primary tumor growth occurs coupled with processes 
of angiogenesis, alongside the transition of a small subset of tumor cells from an epithelial 
phenotype to a more mesenchymal-like cell. The mesenchymal-like cells, which become more 
motile then extravasate from the primary tumor site into the blood stream and invade a distant 
site, leading to the process of metastasis (see Figure1.1). 
5, 6
  
 
 
Figure 1.1: Role of CTCs in the metastatic cascade. A small fraction of tumor cells have the 
ability to extravasate from the primary tumor into the blood stream and then intravasate into a 
distal organ where there colonize the new organ in the process of metastasis.  
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The number of circulating tumor cells in peripheral blood is typically quite low (~1 CTC 
for every 10
7
 blood cells), which leads to significant technical challenges in their detection and 
isolation from other blood components. Yet the anticipated breadth of clinically relevant 
information that can be harvested from these rare cells has spurred great efforts to develop 
sensitive platforms that help to identify, enrich and then study CTCs. As such, these efforts have 
resulted in routine access to CTCs from a simple blood draw and therefore represent what has 
been described as a liquid biopsy, since these cells originate from the tumor.
7
  
Numerous platforms have been developed to isolate these rare cells, the majority of 
which can be categorized under immunoaffinity based methods or as approaches that exploit the 
distinct physical properties of CTCs compared to other blood cells (see Figure 1.2) Isolation of 
these cells presents a non-invasive alternative to ultimately diagnose and treat cancer. 
Furthermore, with the potential for real time access to CTCs via routine blood sampling during 
cancer treatment, a patient’s response to therapy can be sensitively monitored. Overall, it can be 
seen that CTCs represent a potent tool in the treatment and management of cancer. 
Several studies involving solid tumor malignancies such as metastatic breast, colorectal, 
prostate and lung cancers, have demonstrated preliminary correlations between CTC burden and 
clinical outcomes.
8-11
 For instance, in a study using CellSearch system, (Janssen Diagnostics, 
Raritan, NJ) to isolate CTCs, Cristofanilli and colleagues set out to determine whether the level 
of CTCs in patients with metastatic breast cancer, (MBC) would yield any predictive value. 
Their study demonstrated that progression free survival and overall survival could be predicted 
independently by the level of CTCs a patient had before treatment.
8
 In a follow up study 
involving the same cohort of MBC patients, it was found that the levels of CTCs measured in the 
blood were indicative of disease progression during treatment and overall survival.
9
 Similarly, 
Moreno et al found that in a study involving patients with metastatic prostate cancer, higher 
levels of CTCs in a patient’s blood correlated with poorer overall survival.10 Cohen et al reported 
in a study of metastatic colorectal cancer (mCRC) patients, that unfavorable baseline CTC levels 
(>3 CTCs/7.5mL of blood) correlated with shorter progression free survival (PFS) and overall 
survival (OS). 
11
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Figure 1.2: CTC isolation approaches. Methods that exploit both the physical or biochemical 
properties of CTCs that make them different form other blood cells are employed in their 
isolation.  
 
More recently, another CTC study that involved patients with non-small-cell-lung cancer, 
(NSCLC) demonstrated that stage IV (more advanced) cancer patients had higher numbers of 
CTCs than patients with either stage IIIB or IIIA (less advanced) cancer. Furthermore, the study 
showed that among other indicators, CTC levels was the strongest predictor of OS and that PFS 
and OS were shorter for patients having ≥5 CTCs/7.5mL of blood.12 Nesteruk et al studied CTCs 
in nonmetastatic patients with rectal cancer who were treated with preoperative radiotherapy. 
They reported that CTC detection in peripheral blood 7 days after surgery independently 
predicted local disease recurrence among the patients.
13
 Earlier findings as such, have inspired 
efforts towards the development of more sensitive platforms, with higher sample processing 
capacities to meet the challenge of CTC enrichment, in anticipation of the clinical utility of CTC 
studies.  
For many solid tumor cancers, evidence points to the heterogeneity among CTCs even 
within the same patient. For instance, differences have been observed among CTCs that are shed 
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from the primary tumor, tumor cells that encompass the primary tumor and tumor cells sourced 
from secondary metastases within the same patient. 
14-16
 One aspect of CTC heterogeneity is in 
the range of cell diameters observed, with reported sizes for breast and castrate resistant prostate 
cancers being 7.05-8.94µm and 15-30µm respectively.
17, 18
 Using fiber-optic array scanning 
technology in a study of 659 breast cancer CTCs from a single patient, Marrinucci and 
colleagues reported that a significant extent of pleomorphism was observed among the CTCs, 
inclusive of the nuclear to cytoplasm ratio, and phenotypic changes associated with different 
stages of apoptosis.
16
  
Microfluidic-based single cell CTC transcriptional analysis of breast cancer CTCs also 
demonstrated remarkable transcript heterogeneity when profiled for 87 cancer-associated and 
reference genes, compared to cell lines which showed tight transcription clustering.
19
 In fact, a 
significant extent of heterogeneity was observed among CTCs shed from the same tumor in 
breast, prostate and gastrointestinal cancers.
15, 19
 It is believed too, that CTCs shed from 
secondary metastases are responsible in part for the heterogeneity observed among the CTCs. 
20, 
21
 Physiological changes associated with EMT may also be another source of CTC heterogeneity. 
While the concept of EMT still holds elements of a controversial nature, evidence points to 
capacity of epithelial tumor cells to progressively take on a more mesenchymal phenotype and 
thereby acquire greater motility, resistance to apoptosis as well as invasiveness in many 
epithelial cancers.
22-24
   
In several cancer types, cancer stem cells (CSCs) have been studied in the context of 
representing a subset of CTCs of particular interest. In fact data in preclinical models suggests 
that CSCs may be an important component of CTCs
25
. The identification of a subpopulation of 
pancreatic cancer cells having CD44+CD24+ESA+ surface markers that were highly 
tumorigenic and demonstrated self-renewal abilities was reported by Li et al.
26
 These cells which 
were identified as CSCs were found to comprise 0.2-0.8% of human pancreatic cancer cells and 
showed the capacity to give rise to differentiated progeny. CSCs were observed to play a 
regulatory role in signaling pathways involving sonic hedgehog and Bmi-1.
27
 What makes these 
cells of particular interest in the study of metastasis is their resistance to standard therapies which 
may contribute to the malignant nature of pancreatic and other types of cancer.  
In a mouse model study of circulating pancreatic cells (CPCs) that was reported by Rhim 
et al, cells were found to invade and enter the blood stream, even before any signs of malignancy 
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were detected. Interestingly, these cells demonstrated stem cell properties.
25
 The study found that 
the CPCs seeded the liver and that invasiveness was abundant at inflammatory foci, with induced 
pancreatitis increasing the CPC counts.
25
 While such studies point to the importance of stem 
cells in disease progression, more thorough studies in human samples are required to affirm the 
role of CSCs in CTC biology. Indeed there is data to support the clinical role that CTCs can 
facilitate in various forms of cancer and the relatively non-invasive means of ascertaining these 
rare cells make them an attractive tool in studying disease progression. With many forms of 
cancer, there is significant difficulty in routinely accessing tumor tissue. Moreover, 
understanding of the complexities involved in disease onset and progression are limited. 
Studying CTCs has the potential to improve our insights on disease advance and in the long run, 
develop tools that can effectively fight cancer in a practical manner. 
1.2.2 Exploiting Microfluidic applications to isolate CTCs  
The design and development of devices with micron-size dimensions proffer precise 
control of tiny volumes of fluids under flow, whether during processes of transporting, mixing or 
separation.
28
 These devices, collectively known as microfluidic devices, offer many benefits 
when handling small entities like blood cells, which are on the same length-scale as features in 
these devices.
29
 In fact, microfluidics represents an expansive avenue of CTC enrichment, where 
quite a number of technologies have been developed to isolate CTCs from blood samples under 
flow in devices, with features and channels on the micron scale.  
In 2007 Nagrath et al reported on the feasibility of a microfluidic based method for viable 
CTC capture form whole blood.
30
 In addition they demonstrated that this approach was more 
sensitive than previously used platforms, yielding higher number of CTCs. Blood samples were 
assessed for CTCs from patients with metastatic lung, prostate, pancreatic, breast and colon 
cancer using a microfluidic approach, the “CTC-Chip.”30  The platform which consists of an 
array of 78,000 microposts coated with EpCAM, demonstrated the ability to detect CTCs in 
more than 99% of patients. Patient blood sample is flowed through the device at 1mL/h and as 
cells expressing the EpCAM antibody encounter the EpCAM coated microposts, they become 
attached to the microposts. To preserve and identify CTCs, on-chip fixation and 
immunofluorescent staining take place subsequently. The transparent device allows for 
visualization of fluorescently labeled CTCs for enumeration where CTCs events are those cells 
that have cytokeratin and DAPI nuclear stains while they are negative for CD45.
30
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Since then, additional microfluidic platforms that incorporate immunoaffinity CTC 
capture have emerged. Table 1.1 summarizes some of these methods. One such platform is the 
“herringbone chip”. It represents an advance to the CTC-chip by employing a ridged upper wall 
which produces micro-vortices that increase the collision frequency and therefore the chance of 
capture of CTCs with the EpCAM coated micro-posts.
31
 Related is the establishment of the 
which consists of nano pillars coated with EpCAM on a silicon substrate with sinuous micron 
channels that give rise to enhanced mixing when flow is established. This in turn allows greater 
capture efficiency of microvilli and filopodia of EpCAM expressing CTCs.
32, 33
 The nano-velcro 
chip technology has since been incorporated in an optimized version.
34
 While such platforms 
have improved the sensitivity of CTC detection and capture, the low flow rates necessitated by 
these platforms are not conducive to processing appreciable volumes of patient samples for 
higher yields of CTC capture. Moreover, immobilizing CTCs on fixed surfaces raise problems 
with cell release from the surface for subsequent genomic analysis and cell based assays. 
Quite a few more platforms have incorporated surface enhancement of the microfluidic 
chips through chemical or physical means to improve CTC capture. For example Hughes et al 
developed a microfluidic CTC capture device functionalized with epithelial markers and E-
selectin, that was enhanced with halloysite nanotube coating. They used the device to isolate 
CTCs form 12 patient samples with a reported isolation range of 20-704 viable CTCs per 
3.75mL of blood and purities of 18-80%.
35
 Gleghorn et al developed a geometrically –enhanced 
differential immunocapture (GEDI) microdevice that they used to isolate prostate cancer CTCs. 
The device consisted of staggered obstacle arrays that could maximize how streamlines of fluid 
containing CTCs would interact with prostate specific membrane antigen (PSMA) coated posts, 
based on their size compared to other non-target blood cells. Purities of 62% were reported using 
this platform. 
36
Adams et al reported on a high aspect ratio microchannel device containing 51 
channels coated with EpCAM antibody that could detect low numbers of CTCs as the channels 
divide the whole blood samples into 190μL volumes for probing the samples. The channels are 
arranged sinusoidally and the chip was augmented with a conductivity sensor that could detect 
and enumerate CTCs released from the chip using trypsin. Since the CTCs could be detected 
without the need for staining, this makes the process more time efficient and less expensive.  
Recovery rates of 97% were reported with almost 100% detection rates of cancer cells with the 
single cell conductivity sensor.
37
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Earhart et al reported on the ongoing development of the magnetic sifter, a magnetic 
separation device that isolates CTCs from whole blood through immunomagnetic capture, where 
CTCs prelabeled with magnetic nanoparticles are temporarily captured by magnetic pores on a 
microfluidic chip. Blood samples are processed by mixing the nanomagnetic particles with the 
samples in a bulk fashion before magnetic CTC isolation using flow rates of 10mL/hr. The 
device is made of a dense array of magnetic pores, with 200pores/mm2 and once the magnetic 
field is removed, cells can be released from the pores. Six metastatic NSCLC patients were 
evaluated using the device and CTCs were detected in all samples ranging from 31-96 
CTCs/mL.
38
 
Our group recently reported on the OncoBean Chip, a microfluidic platform which 
exploits the velocity gradients that develop from radial flow compared to linear flow in order to 
enhance CTC capture from whole blood. Additionally, microposts were designed with a bean 
shape to enhance capture efficiency, even at a flowrate of 10mL/hr. CTCs were detected from 
lung, breast, and pancreatic cancer patient samples.
39
Additionally we developed a microfluidic 
CTC capture chip for sensitive cell capture with as little as 3-5 CTCs/mL through the use of 
graphene oxide (GO) nanosheets affixed to patterned gold posts. The nanosheets are 
functionalized with EpCAM to capture CTCs from patient samples, at a flow rate of 1mL/hr. 
Cancer cell recoveries of 73%±32.4 (n=10) at spike rates of 3-5cells/mL, with 100% recovery in 
5 of 10 samples were demonstrated. The high sensitivity of the platform enabled CTCs to be 
detected even among early stage BC patients.
40
 
One drawback of methods that depend solely on affinity based capture to sort CTCs, such 
as the use of EpCAM based approaches, is the discrepancies in the level of EpCAM or other 
surface antibodies that CTCs express even within the same patient sample. A few studies done 
among breast cancer patients have demonstrated that EpCAM expression can range from 35% to 
100% among different patients.
41-44
 While Went et al reported that adenocarcinomas of the 
pancreas showed 78% of tumors having strongly positive EpCAM expression, CTCs are 
believed to undergo epithelial to mesenchymal transition which may result in decreased 
expression of EpCAM among these circulating cancer cells.
41
  
Microfluidic device technologies primarily based on the physical properties of CTCs and 
on size-sorting CTCs have also been reported in their successful isolation and enrichment. Table 
1.2 summarizes some of these methods. One such method was reported by Lim et al in the 
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design of a silicon microsieve with pores to enrich CTCs from blood based on both the size and 
deformability of CTCs compared to other blood cells. The device was augmented with a 
peristaltic pump to regulate flow rate of samples with a process rate of 1mL/min. A cancer cell 
recovery rate of >80% was reported using this platform.
45
 
Another such method, though dependent on immunoaffinity, combines selective size 
amplification (SSA) and multiple obstacle architecture (MOA), and has been designated SSA-
MOA. This approach amplifies the size of CTCs by polymer microbead coverage through 
immunoaffinity, followed by applying a filter chip system to isolate the CTCs with a reported 
92% tumor cell recovery rate. The platform was tested for specificity of EpCAM bead coverage 
with breast cancer cell lines that were either EpCAM positive (MCF-7) or negative (MDA-MB-
231), the results of which showed that the polymer beads specifically bind to, and size-enhance 
the EpCAM positive cancer cells. The filter gaps on the filter chip ranged from 8-30µm to 
facilitate the heterogeneity of CTC radii. 
46
  Kim et al report using flow rates of 20µL/min. While 
the platform shows high recoveries and purities, efficiency of bead labeling in whole blood may 
not be as high as pre-spiked cells and therefore, the device performance with patient samples 
may not yield as high recoveries. Furthermore, CTCs are rare in blood and so appreciable CTC 
yields may necessitate high sample volumes and so higher processing rates.  The relatively low 
flow rates and throughput of the system may limit its clinical applicability.
46
  
The use of microtraps designed with a series of crescent shaped, perforated gaps that 
specifically trap CTCs and allow other smaller cells to squeeze through the perforations, has also 
been reported. This technology takes advantage of both the size and deformability differences of 
CTCs compared to other blood cells. CTCs can be recovered by applying a backflow of buffer to 
recover the cells that are not immobilized by chemical bonds, with a reported CTC recovery rate 
of 80%.
47
 This platform allows for recovery of viable cells and allow for isolation of a wider 
range of CTCs irrespective of surface protein expression, compared to affinity and immune-
based methods. Tan et al were able to demonstrate the applicability of the method to a range of 
adenocarcinomas.
48
 Some of the drawbacks of this approach would be the relatively low flow 
rates that such an approach would require, the nonspecific capture of contaminating cells that the 
microtraps capture, as well loss of CTCs that occur if microtraps are already occupied along the 
path of a CTC through the device. Zheng et al developed a 3D microfilter device for CTC 
capture by incorporating 2 parylene filters through which 1mL of patient sample is processed. 
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The additional lower filter is supposed to support the cells and promote viability of the enriched 
CTCs. Recovery rates of ~86%, comparable to a 2D model previously reported, was again 
reported. 
49
 
Additionally, size dependent inertial sorting has been reported for CTC enrichment where 
hydrodynamic forces focus blood cells at distinct streamlines in fluid under flow, based on the 
diameter of the cells.
50-53
 Since the different cell types in blood typically behave as spheres with 
unique radii characteristic of the cell type, inertial forces which are directly dependent on radii 
are able to separate cells at distinct streamlines along a microfluidic channel. Device outlets can 
be designed to collect the stream enriched for a target cell type. For instance CTCs can be 
separated from other blood cells using such an approach. Once again, stand-alone technologies 
like inertial sorting that are based on size inevitably isolate non-target blood cells that are of 
similar size or lose CTCs that are outside of the predicted CTC size range of the technology.  
Some platforms have enhanced size-dependent inertial sorting of CTCs through device 
modifications that allow for more specific CTC isolation from samples under the given flow 
conditions. For instance, Sollier et al combined inertial size-based particle focusing with 
generation of on-chip micro-scale vortices to separate CTCs from patient samples in a viable and 
high throughout manner. They tested 4 breast cancer patients and detected 25-51 CTCs/7.5mL of 
blood and 8 lung cancer patients, where CTCs ranged from 23-317/7.5mL blood.
54
 
Other platforms have leveraged the use of additional inertial focusing that arises from 
more detailed channel geometry and design. Bhagat et al developed a method they described as 
pinched flow couple shear-modulated inertial microfluidics for isolating CTCs from patient 
blood where the channels were patterned with a contraction-expansion array. This pattern 
allowed particles to be aligned based on their size such that CTCs would focus in the middle of 
the channel. They report that the device allows for 80% recovery of cancer cells. The process 
requires that blood be diluted to x20 and flow rates of 400μL/min were achieved using this 
platform.
55
 Hou et al designed an inertial spiral microchannel that also exploits the predicted size 
of CTCs where patient blood sample flowing through the microfluidic channel gives rise to  
inertial forces that focus the CTCs away from other blood cells based on the radii of the CTCs 
and other blood components. Through introduction of curvature to the channels Dean forces arise 
that further focus smaller particles away from the CTCs to improve the purity of the CTCs. The 
method, termed Dean flow fractionation, demonstrated 85% recovery of viable CTCs in 
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suspension from whole blood. This label-free approach precludes the need for additional cell 
release from the device. Furthermore, the absence of a reliance on immunoaffinity should leads 
to recovery of CTCs regardless of the level of their surface marker expressions.
55, 56
 
Similarly, Sun et al reported on a double spiral microchannel that allows for label free 
separation of CTCs from other blood components using hydrodynamic forces that arise when 
diluted blood under flow is driven through the microchannel. The double spiral design proved to 
enhance focusing of smaller blood components compared to a single spiral channels which led to 
improved depletion of other contaminating blood cells. To test the system, whole blood was 
diluted x50. A recovery rate of 88.5% of cancer cells was reported. 
57
  
Also Warkiani et al developed a slanted inertial microfluidic spiral chip with a 
trapezoidal cross-section to isolate CTCs from blood using flow rate of 1.7mL/min with isolation 
efficiency ranging from 80-90%. The slanted design of the channel allowed for enhanced 
focusing of smaller cells so that CTCs could be collected in a distinct device outlet, away from 
the other contaminating blood cells. 
58
 
Regarding isolation methods that leverage the physical properties of CTCs, it is known 
that CTCs express heterogeneity in size and therefore to rely on a technology that predicts a size 
range for CTCs will inevitably lead to losses from cells that fall outside the predicted range of 
CTC radius. Furthermore, it has been shown that malignant tumor cells are irregular in shape and 
that metastatic potential of cells is associated with changes such as increased nuclear to 
cytoplasmic ratio.
59, 60
 The overlap of physical dimensions and properties of CTCs with 
leukocytes coupled with the fact that leukocytes far outnumber CTCs remain a challenge for 
separating CTCs from leukocytes.  
Ideally, the capacity of a platform to reach both high rates of purity and yield of viable 
CTCs, together with high throughput, increase its desirability. With the current state of the art 
technology that allows for single cell manipulation for genetic profiling studies, having high 
number of isolated CTCs may not be as crucial as the purity rate of the CTCs. For studies that 
require CTC enumeration, the ability to get high CTC yields is important so as to accurately 
reflect the level of CTCs in patient blood.  
More recently, several microfluidic platforms have incorporated a combination of both 
size based and immunoaffinity based approaches to develop integrated systems that improve 
CTC recovery, as well as purity at which CTCs are isolated from other blood cells. For instance 
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Ozkumur et al reported on the i-chip which is a microfluidic device that combines hydrodynamic 
sorting, inertial focusing and then magnetic sorting of pre-labeled CTCs from blood. The 
platform is amenable to both EpCAM positive selection and then negative WBC depletion using 
CD45 and CD15 WBC surface markers. It consists of an array of microposts with 32μm gaps for 
deterministic lateral displacement, used for waste cell depletion. The second component allows 
for additional CTC purification through inertial sorting in an asymmetrically curved channel 
while the third component uses immunomagnetic cell sorting. The i-chip, which operates at 
8mL/hr of whole blood, demonstrates a purity rate of >0.1% purity.
61
 Another integrated 
microfluidic approach, IsoFlux was reported by Harb et al in which CTCs are isolated through 
immunomagnetism. The method also allows for instant molecular assaying of the CTCs that are 
retrieved.
62
  
Chang et al recently developed a parallel flow micro-aperture chip system that enriches 
CTCs by mixing samples with antibody functionalized magnetic beads, then processing the 
sample through an 8μm filter aperture chamber to which a magnet is attached, at the bottom of 
the filter system. Magnetically labeled cells are drawn through the filters to the magnets. A 
detection system has also been added to the device to quantify CTCs on chip. The parallel flow 
system allows for multiple circulation of the patient sample through the system to improve 
separation of CTCs from other contaminating cells. Cancer cell recovery rates of 89% were 
reported and CTC detection in 49/50 patients with either NSCLC or pancreatic cancer was also 
reported. 
63
 
Some level of blood cell contamination persists with the CTC isolation platforms 
reported. Microfluidic platforms have demonstrated significant improvements in the purity and 
recovery rates for tumor cells and offer the advantage of being relatively cost effective to 
produce. A number of platforms have reported on high throughput devices that can process 
patient sample in a timely manner, giving results that are reproducible. Furthermore, the devices 
allow for subsequent analysis and characterization of CTCs whether on chip in the case of 
capture platforms or in suspension with platforms that allow for substrate free CTC isolation. 
Indeed, as platforms continue to emerge that demonstrate greater levels of purities and yield, the 
increased availability of CTCs may lead to more telling studies about the process of metastasis. 
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Table 1.1: Immunoaffinity based CTC Isolation Methods. 
 
Method Enrichment (%) Capture 
Efficiency 
Volume Throughput Detecti
on 
Number 
of Patients 
CTC Detection Summary Reference 
Immunoaffinity 
EpCAM beads with 
MagSweeper 
51±18 62±7 9mL 9mL/hr IF 17 100% in metastatic breast cancer patients (Talasaz, Powell et al. 
2009) 
EpCAM beads with 
MagSweeper 
-- -- 9mL 9mL/hr RT-
PCR 
50 70% in primary and metastatic breast 
cancer patients 
(Powell, Talasaz et al. 
2012) 
EpCAM beads with 
Magnetic sifter 
17.7±9.3 91.4% 0.9-
3.3mL 
10mL/hr IF 6 100% in lung cancer patients (Earhart, Hughes et al. 
2014) 
AdnaTest® 
BreastCancer 
-- -- 10mL -- RT-
PCR 
42 52% in metastatic breast cancer patients (Tewes, Aktas et al. 
2009) 
AdnaTest® 
BreastCancer 
-- -- 10mL -- RT-
PCR 
86 
70 
19% in Pre surgery ovarian cancer 
27% in Post Chemotherapy ovarian 
cancer 
(Aktas, Kasimir-Bauer 
et al. 2011) 
AdnaTest® 
BreastCancer 
-- -- 10mL -- RT-
PCR 
502 19% in primary breast cancer  patients (Kasimir-Bauer, 
Hoffmann et al. 2012) 
EpCAM microposts 
with CTC chip 
>47 >60 0.9-
5.1mL 
1-2mL/hr IF 123 99% in metastatic and early prostate 
cancer patients 
(Nagrath, Sequist et 
al. 2007) 
PSMA microposts  
with GEDI chip 
68±6 85±5 1mL 1mL /hr IF 20 90% in prostate cancer patients (Gleghorn, Pratt et al. 
2010) 
EpCAM microposts 
in herringbone chip 
14±0.1 91.8±5.2 4mL 1.5-2.5mL/hr IF 15 93% in metastatic prostate cancer  
patients 
(Stott, Hsu et al. 2010) 
EpCAM beads / 
CD45, CD15 Beads with 
iChip 
0.02-4.3 98.6±4.3 6-12 8mL/hr IF 42 88% in metastatic cancers  patients (Ozkumur, Shah et al. 
2013) 
EpCAM nanopillars  
with Nano-Velcro chip 
-- >95 1mL 1mL/hr IF 26 77% in prostate cancer  patients (Wang, Liu et al. 
2011) 
Selectin with 
EpCAM/PSMA 
microtubes 
66±3.9 50 7.5 4.8mL/hr IF 14 100% in metastatic cancers  patients (Hughes, Mattison et 
al. 2012) 
EpCAM medical 
guidewire 
-- -- 3-6L/hr 1.5-3L IF 24 92% in breast and lung cancer  patients (Saucedo-Zeni, 
Mewes et al. 2012) 
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EpCAM bean-shaped 
microposts with 
OncoBean Chip 
1060-
1240WBCs/mL; 
390-740 WBCs/mL 
>80% 10mL/hr 1, 10mL/hr IF 6 100% in breast (2), lung (2), pancreatic 
cancer patients 
(Murlidhar, Zeinali et 
al. 2014) 
EpCAM/EGFR/VMT 
or EpCAM/CEA 
magnetic beads  with 
10E3.6-10E4 89% 2mL/min 8mL IF 38 
12 
100% in NSCLC patients 
91% in pancreatic cancer patients 
(Chang, Huang et al. 
2015) 
 
Table 1.2: Isolation methods based physical properties of CTCs.  
 
Method Enrichment  Capture 
Efficiency  
Volume  Throughput  Detection Number 
of Patients  
CTC Detection Summary  Reference  
Physical Properties  
Density gradient 
separation with Ficoll-
Paque® 
-- -- 10mL -- RT-PCR  58 41% in colorectal cancer  (Weitz, Kienle et al. 
1998) 
Density gradient /size  
separation with 
OncoQuick® 
*632  87 10-30mL -- RT-PRC 37 30% in gastrointestinal carcinoma 
patients 
(Rosenberg, Gertler et 
al. 2002) 
Density gradient /size  
separation with 
OncoQuick® 
-- 70.6 20mL -- IF 123 24% in primary and metastatic breast 
cancer patients  
(Muller, Riethdorf et al. 
2012) 
Density gradient /size  
separation with 
OncoQuick® 
  15mL  IF 61 23% in metastatic carcinoma patients  (Balic, Dandachi et al. 
2005) 
Leukapheresis  with 
CellSearch®  
  4.5L  IF 29 72% of carcinoma  patients (Fischer, Niederacher et 
al. 2013) 
Microfilter ISET® 
method  
  6mL  Cytomorp
h-ology 
44 52% in primary liver cancer patients  (Vona, Estepa et al. 
2004) 
Microfilter ISET® 
method 
  7.5mL  Cytomorp
h-ology 
60 95% of metastatic cancer patients  (Farace, Massard et al. 
2011) 
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Microfilter ISET® 
method 
10E7 92±14 7.5mL 225mL/hr IF 57 89% of metastatic cancer patients  (Lin, Zheng et al. 2010) 
Size/deformability  
with crescent microtraps  
-- -- 1-3mL -- IF 5 100% in metastatic lung cancer 
patients  
(Tan, Lakshmi et al. 
2010) 
Inertial  size-based 
pinched flow  device  
*5.5-7.1 80% -- 1.2mL/hr -- -- -- (Bhagat, Hou et al. 
2011) 
Inertial size-based 
microvortex device  
57-94% 20.7% 7.5mL 22.5mL/hr IF 12 100% in breast and lung cancer 
patients  
(Sollier, Go et al. 2014) 
Inertial  size-based 
Spiral  cell sorter  
10% >85% 6mL 3mL/hr IF 20 100% in metastatic lung cancer 
patients  
(Hou, Warkiani et al. 
2013) 
Inertial  size-based 
double spiral cell sorter  
*19 88.5% -- 20mL/hr IF -- -- (Sun, Li et al. 2012) 
 16 
 
1.3 CTCs in the study of Pancreatic Cancer  
1.3.1 Background 
Over 85% of all pancreatic cancers originate in the pancreatic duct, a condition termed 
pancreatic ductal adenocarcinoma (PDAC).
64
 To date pancreatic cancer, apart from most other 
cancers, has been associated, categorically, with the term “lethal” 64, 65. This association stems 
from the fact that pancreatic cancer has a median survival rate of less than 6 months after 
diagnosis, and a bleak 5-year survival rate of 3-5 percent.
64
 PDAC demonstrates a particularly 
aggressive biology with resistance to both conventional and targeted therapeutics so that by the 
time a patient receives diagnosis, the disease has already advanced to an incurable state.
64
 
Frequent and early dissemination of the disease coupled with ambiguous symptoms and the 
absence of early biomarkers for detection inevitably result in late detection.
66, 67
  
Furthermore, obtaining tissue from pancreatic cancer patients has significant challenges 
that prevent early histological diagnosis because the pancreas has limited anatomic accessibility. 
The inherent difficulty in obtaining and studying tumors and their pharmacodynamic responses 
during clinical trials limit the ability to develop predictive information about PDAC. Indeed, the 
paucity of extensive, temporal studies of pancreatic tumor biology perpetuates a lack of 
predictive information about PDAC. In turn, lack of early and reliable screening tests are said to 
be responsible for the fact that 80% of patients have already reached the terminal stage at the 
time of diagnosis.
67
 With the use of CTCs derived from PDAC patients, the hope is that they can 
be used as reliable biomarkers for early detection, and other clinically relevant indicators such as 
prognostication and therapy monitoring, among others. 
Furthermore, studies have been reported that support the significance of heterogeneity 
among PDAC primary tumors and metastatic growths, as well as the existence of inter-tumor 
heterogeneity. 
68-70
 In an effort to identify the molecular subtypes of PDAC, Collisson et al 
combined transcription profiles of primary tumor samples from multiple studies as wells as 
profiles from human and mouse cell lines and used the data to identify three PDAC subtypes.
68
 
They were able to demonstrate that the three subtypes, namely classical, quasi-mesenchymal and 
exocrine-like had associated with them, gene signatures, clinical outcomes and therapeutic 
response.  
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Recently, proteome studies of metastasized liver, lung and peritoneum cells from a single 
pancreatic cancer patient were reported which were geared at understanding the extent to which 
genetic heterogeneity in PC affects proteomics and signaling pathways. Interestingly, cells from 
the three metastatic sites showed distinct patterns of proteome expression as well as tyrosine 
kinase activity, which in turn affected the unique sensitivity of the different sites to targeted 
small molecule kinase inhibitors. 
70
 
Taken together, these studies highlight the necessity of understanding PDAC tumor 
subtypes as the information gathered can potentially inform decisions that affect patient 
treatment and outcomes. The ability to isolate and study CTCs that contain information about 
these tumor subtypes, holds promise for improved understanding about how cancer metastasizes 
and therefore in identifying effective drug targets to manage cancer. Ultimately, CTC studies 
may facilitate in the development of personalized therapeutics to treat the different nuances of 
PDAC cases.  
The advantages of access to CTCs as a “liquid biopsy” have been explored in several 
types of malignancies including pancreatic cancer. Pancreatic cancer is unique among other type 
of cancers as it is the single major cancer in which the 5 year survival rate remains in the single 
digits.
71
 While more recent advances in imaging to diagnose pancreatic cancers, there are 
instances that specifically warrant biopsy procedures such as with preoperative tissue diagnosis. 
Moreover, biopsies are required in the recognition of rare tumors, in deciding to administer 
adjuvant and neo-adjuvant therapy, in disease confirmation for the purpose of counseling and in 
instances of diagnostic doubt, for example.
71
 However, the modest results associated with biopsy 
techniques such as the low sensitivities, characteristic of brush cytology, and the safety concerns 
raised with fine needle aspiration biopsies (FNAB), have led to a diminished reliance on tissue 
biopsies. Indeed, with increasing studies geared towards developing reliable fingerprints of 
CTCs and disease prognosis and staging, CTCs hold potential for safer, less painful and less 
risky biopsies.  
 
1.3.2 Isolation Approaches in Pancreatic Cancer  
To date, several studies have been published describing the use of a variety of isolation 
strategies to detect CTCs in patients with pancreatic cancer.  Here we describe studies in which 
15 or more pancreatic cancer patients were enrolled in the study to determine CTC counts and or 
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biomarker information based on CTC analysis. Preliminary investigations into CTC counts were 
reported as well as limited findings on biomarkers from the CTCs, without any attempts to 
correlate findings to disease prognosis or survival outcomes. Table 1.3 gives a summary of these 
studies.  
One of the earlier CTC studies was done by Allard et al in 2004 to determine the 
effectiveness of CellSearch in isolating CTCs from 12 major carcinomas including pancreatic 
cancer. The CellSearch system which allows for positive selection of EpCAM cells in 
circulation, employs the criterion of >5 CTCs in 7.5mL of patient blood as confirmation of CTC 
detection in a given sample.
7, 72, 73
 Of the 16 pancreatic cancer patients examined, 37.5% showed 
detectable CTCs in 7.5mL of blood. The study found that pancreatic cancer had one of the lowest 
CTC detection rates among all the cancers tested using the platform.
7
 
In a landmark study that demonstrated significant improvements upon existent methods 
to detect and capture CTCs with increased sensitivity and specificity, Nagrath et al reported on 
the use of the CTC chip to detect CTCs in 99% of 115 patient samples tested. Of the 115 
patients, 15 of them were metastatic pancreatic cancer patients. They found that CTCs ranging 
from 9-831/mL could be detected in patient samples compared to 0 CTCs in healthy controls. 
The device showed a cancer cell yield of 99% and a purity rate of >47%. Additionally, temporal 
studies of therapy response in 3 pancreatic cancer patients treated with chemotherapy revealed 
that CTC numbers decreased with tumor volume.
30
 The prognostic value of CTCs has been 
studied in a number of cancers where CTC counts have been monitored throughout the course of 
patient treatment to determine any associations involving treatment response.  
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Table 1.3 CTC Enumeration Studies in Pancreatic Cancer 
 
Method Detection # of 
Patients 
Markers Summary References 
Density gradient 
separation  
Nested RT-PCR  28 CK-20 mRNA 79% of patients  CK-20 mRNA positive ; no significance between CK-20 mRNA levels 
and CEA or CA19-9 level 
(Chausovsky, 
Luchansky et al. 
1999) 
EpCAM beads  with 
CellSearch 
IF 16 CK-19, CK-18, 
CK-8 
6/16 patients with detectable  CTCs (Allard, Matera 
et al. 2004) 
EpCAM microposts 
with CTC chip  
IF 15 CKs 15/15 patients with detectable CTCs ranging from 9-831/mL (Nagrath, 
Sequist et al. 
2007) 
RBC lysis  before 
CD-45 WBC  
depletion  
Immunocyto-
chemistry  
41  CK8/18, 
CA19-9  
33/41 patients with detectable CTCs before  chemotherapy and  12/41 patients 1 week 
after chemotherapy  
(Ren, Han et al. 
2011)  
EpCAM beads  Nested PCR  25 CK-20, CEA, 
h-TERT, C-
MET mRNAs 
21/25 CK-20 mRNA positive ; 20/25 CEA mRNA positive ; 25/25 patients h-TERT 
mRNA positive , 20/25 C-MET mRNA positive  
(Zhou, Hu et al. 
2011) 
None Immunocyto-
chemistry  
18 CKs 9/18 patients  with CTCs detected  (Marrinucci, 
Bethel et al. 
2012) 
Size-Based filtration 
with ScreenCell  
Cytomorphology 
CA19-9 serum 
levels 
40 CA19-9 15/27 patients with detectable CTCs. Diagnostic accuracy of CTCs was 70% compared 
to 85% with FNA. CTC detection sensitivity and specificity were 55.5% and 100% 
respectively.  No statistical association with CTC detection and  tumor size, metastatic 
status,  vascular invasion, CA19-9 levels, lymph node involvement  
(Iwanicki-Caron, 
Basile et al. 
2013) 
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Capillary action, 
size-based filtration 
with MetaCell  
Histochemistry 
Immunocyto-
histochemistry  
24 CK-18 CTCs detected in 16/24 patients; 88.9% of grade III tumor patients with detectable 
CTCs. Same percentage of CTCs detected in metastatic and nonmetastatic patients  
(Bobek, Gurlich 
et al. 2014) 
 
Table 1.4 CTCs and Prognosis in Pancreatic Cancer 
Method Detection #of 
Patients  
Markers Summary  References  
Density  gradient 
separation 
Immunocyto
-chemistry 
105 CK-19, CK-7, CK-
20,  AE1/AE3, 
glycoproteins 
CTCs detected in 3/32 resectable patients, in 24/73 unresectable patients;  
Trend towards association  between CTC detection and disease progression.  
(Z'Graggen
, Centeno et 
al. 2001) 
Density  gradient 
separation 
Nested PCR 20 CEA mRNA 6/20 patients CEA  mRNA-positive; 5/6 of them with disease recurrence while 2/12  
CEA mRNA-negative patients with recurrence (p=0.007) 
(Mataki, 
Takao et al. 
2004) 
Density  gradient 
separation 
Nested PCR 154 CK-20 mRNA  52/154 patients with detectable CTCs; CTC detection correlated with shorter overall 
survival (p=0.05) 
(Soeth, 
Grigoleit et 
al. 2005) 
RBC lysis, 
Density  gradient 
separation 
Compared  
Nested PCR to 
RT-qPCR  
37 CK-19  mRNA RT-qPCR detected 24/37 patients CK-19 mRNA  positive before surgery. Levels 
decreased after surgery; trend towards association between CK-19mRNA  detection 
and survival  
(Hoffmann, 
Kerner et al. 
2007) 
EpCAM beads 
with CellSearch 
IF  26 CK-19, C18, CK-8 CTCs detected in 11/26 patients ; CTC detection correlated with shorter overall 
survival (p<0.001) 
(Kurihara, 
Itoi et al. 
2008) 
EpCAM beads IF, 53 EpCAM CK-19, ISET detected more CTCs; trend towards decreased survival for patients with CTCs (Khoja, 
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with CellSearch; 
ISET 
immunocyto-
chemistry 
CK-18, CK-8, CK-7, 
Vimentin, E-Cadherin  
detected y CellSearch  Backen et al. 
2012)  
RBC lysis  then 
density gradient 
separation  
RT-qPCR  48 EpCAM mRNA  12/48 patients EpCAM mRNA positive  before surgery compared to 31/48 after 
surgery; trend towards association  between EpCAM mRNA levels and survival  
before surgery  
(Sergeant, 
Roskams et 
al. 2011) 
EpCAM/MUC-1 
magnetic beads  
RT-qPCR 34 EpCAM, CK-19, 
MUC-1, CEACAM-
5, BIRC-5  mRNAs 
16/34 patients with at least 1 detectable CTC mRNA ; correlation with CTC mRNAs 
and shorter progression free  survival  
(de 
Albuquerque, 
Kubisch et al. 
2012) 
Various Various 623 Various  markers  Meta-analysis  of 268 CTC-positive and 355 CTC-negative patients  with Stata 12.0; 
Significant association with poor PFS and CTC positive  patients  (p=.001). Worse  
OS in CTC positive versus negative patients (p<.001) 
(Han, Chen 
et al. 2014) 
CD-45 depletion, 
antibody microposts 
capture  
IF 22, 3, 6 FISH (CEP-8), CK 22 pancreatic cancers, 3 borderline  pseudopapillary tumors, 6 benign tumors tested; 
Enriched cells classified as  CK+/CD45-/DAPI+/CE8=2, CK+/CD45-/DAPI+/CE8>2, 
CK-/CD45-/DAPI+/CE8>2, CK-/CD45-/DAPI+/CE8=2 and 
CK+/CD45+/DAPI+/CE8>2 or =2. Based on CTC criteria CTC counts decreased 3 
days after surgery  and increased 10days after surgery. CTC positive patients showed 
metastasis and worse OS at 1.5 years follow-up 
(Zhang, 
Wang et al. 
2015) 
EpCAM beads with 
CellSearch 
IF 79 EpCAM CTCs detected in 5% patients before treatment and 9% patients after treatment; CTCs 
of LAPC patients assessed  before and 2 months after chemotherapy; CTC detection 
associated with poor tumor differentiation (p=0.04) and shorter OS (p=0.01) 
(Bidard, 
Huguet et al. 
2013) 
cell capture with 
collagen adhesion 
matrix  
DNA 
microarray 
analysis 
50 Gene Expression  Prospective clinical trial with advanced PDAC patients; Chemotherapy regimens 
predicted as effective using previous PGx model provided clinical benefit  compared 
to those predicted as ineffective with respect to PFS (10.4 mo vs 3.6 mo , p<0.0001) 
and OS (17.2 mo vs 8.3 mo, p=0.0249) 
(Yu, 
Ricigliano et 
al. 2014) 
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Ren et al performed a similar study among 41 advanced pancreatic cancer samples from 
patients who were previously untreated. Through CTC enrichment via immunomagnetic negative 
depletion of leukocytes from patient samples, the team examined the effect of the chemotherapy 
agent 5-fluorouracil on CTC counts as well as on expression levels CA 19-9, a sensitive 
pancreatic cancer marker. The study found that after the first cycle of chemotherapy, the 
percentage of patients with >2 detectable CTCs dropped from 80.5% (range of 0-59) before 
treatment, to 29.3% (range of 0-40) after 7 days of treatment. Among advanced cancer patients, 
they also found that apoptotic CTCs could be observed after chemotherapy, and may be 
indicative of chemotherapy efficacy in patients. Additionally, the appearance of granular, 
bubble-like CTC morphologies with CA19-9 and CK8/18 staining were observed, which the 
study reported could be reflective of apoptosis.
74
 The use of negative depletion sought to 
decrease the chances of losing CTCs through targeted antibody labeling of CTCs.  
Decreasing the probability of CTC loss by lysing unwanted RBCs and then distinguishing 
among nucleated cells to identify CTCs is another CTC enrichment strategy. Using what they 
described as fluid phase biopsy, Marrinucci and colleagues reported on developing a CTC 
isolation approach that is label free, requiring no surface-protein based enrichment and so allows 
a wider range of CTCs to be identified regardless of their surface protein expression. The 
protocol involves lysis of blood samples and subsequent collection and immunofluorescent 
staining for the remaining nucleated cells followed by CTC detection using fiber-optic array 
scanning technology. (FAST) They analyzed blood samples from 18 pancreatic cancer patients 
and were able to identify CTCs in 50% of patients. 
75, 76
 
Developing platforms that make viable CTCs available, which can later be cultured or 
gene profiled for example, has been a topic of interest for some time. In one study, 24 pancreatic 
cancer patients were enlisted to evaluate the performance of the CTC isolation platform 
MetaCell and to subsequently attempt CTC cultivation on the filter. Of the 24 samples tested, 
CTCs were detected in 16 patients. The study showed that 88.9% of patients with grade III 
tumors had detectable CTC levels.
77
 
One of the anticipated clinical uses of CTCs is as a non-invasive diagnostic tool for 
cancerous lesions. In 2013 Iwanicki-Caron et al reported on a study done with 40 PDAC patients 
to determine the usefulness of CTC detection from blood compared to conventional use of 
endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) as a first diagnostic procedure. 
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The ScreenCell platform was used to detect CTCs in 10mL of peripheral blood. Interestingly, the 
study found that CTC detection had a 70% diagnostic accuracy compared to 85% for EUS-FNA. 
The conclusion was made that CTC detection could be used as a first-line diagnostic procedure, 
with the aim of avoiding the invasive EUS-FNA procedure in about 50% of patients that present 
with a solid mass in their pancreas in need of a tissue diagnosis.
78
 Despite the fact that CTCs are 
yet to be proven as a biomarker for decision making among oncologists, such studies point to 
their potential clinical usefulness as well as the urgency to understand the extent to which they 
can be used.  
A spectrum of studies has been carried out on PDAC derived CTCs, from attempts to 
determine the technical feasibility of isolating them to preclinical studies to determine their 
clinical potential. However, robust studies that allow clinicians and other scientists to draw any 
impactful conclusions are yet to be reported. Before CTCs can be used as a routine tool in 
treating patients with pancreatic disease, more extensive, multicenter, prospective randomized 
trials need to be conducted on human samples to establish metrics that can be used based on 
CTCs. Standardized protocols and objective data analysis need to be deployed that encompass 
the multiple forms and presentations of PDAC.  
 
1.3.3 Molecular Technologies to Assess CTCs  
Once CTCs have been isolated, sensitive and reproducible assessment of cells is integral 
to the clinical impact they can have. Moreover, the platforms used to enrich CTCs determine 
both the downstream assessment methods that can be used as well as the specificity with which 
CTCs can be evaluated. The caveats associated with various platforms can impact upon the 
subset of CTCs that are isolated and thereupon, information that CTC assessments give. In light 
of the inherent differences among the various platforms when it comes to CTC enrichment, 
rigorous characterization of each platform to determine recovery and purity rates, as well as false 
positive expectations will be useful in pooling data among CTC studies in PDAC. Assessments 
of CTCs at both the cellular and molecular level have taken several directions some of which are 
further discussed.   
Protein Expression: 
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So far, one of the more standard approaches of CTC evaluation is immunostaining to identify 
proteins that characterize putative CTCs. As described by the FDA approved CellSearch® 
system, protein expression patterns of CTCs include a positive stain for cytokeratins, (CKs) 
combined with a positive stain for nuclear content using DAPI, and negative staining for CD45 
expression, which is a putative leukocyte surface protein. These three criteria are the bare 
minimum criteria for CTC identification through immunofluorescence (IF). Therefore, the 
availability of three fluorescent channels with distinct spectral ranges is required to image and 
confirm CTCs with immunofluorescence techniques.
8-11, 79
 Additionally, protein immunostains 
that are specific to solid tumor malignancies have been used to further corroborate the presence 
CTCs in peripheral patient blood. For instance several studies have incorporated protein 
immunostains for PSA and PSMA which are specific to prostate cancer.
80-82
 Moreover, CTCs 
have been assessed for protein expression of clinically relevant proteins, such as HER2 which 
has important implications about therapy selection. 
83-85
 
Protein expression assessment has also been leveraged in a number of studies to support 
the existence of distinct subset of populations of tumor cells within a given patient sample. For 
instance, Theodoropoulos and colleagues reported on the use of triple marker IF to assess stem 
cell marker expression of CD44, CD24 and ALDH1 in metastatic breast cancer, (MBC) CTCs. 
Results from the study supported the existence of stem cell-like CTC subpopulations in the 
peripheral blood of MBC patients.
86
  Similar studies have been carried out for other EMT and 
stem cell marker expression in CTCs in attempts to deepen what is known about the existence 
and role of certain tumor cell populations in cancer metastasis.
87-89
 
Proteins shed, secreted or released from CTCs have also been used to detect viable CTCs 
in patients using the ELISPOT assay and to study CTC protein expression patterns that may be 
relevant to metastatic disease.
90, 91
 Additionally, Alix-Panabieres reported on evaluating the 
release of CK-19 and mucin-1 to detect viable CTCs in breast cancer patients as well as the 
secretion of fibroblast growth factor, FGF2, a stem cell growth in prostate cancer CTCs.
21
 
Assessment of CTC protein expression has been useful to date in characterizing patient 
CTCs beyond simple enumeration however, the presence of contaminating cells with current 
CTC isolation platforms can produce RT-PCR results that are not specific to CTCs. 
Distinguishing the signals specific to CTCs only, represents a technical challenge. Furthermore, 
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with IF techniques that necessitate distinct fluorescent channels for IF imaging, there is a limit to 
the number of proteins that can be detected per sample.  
RNA, DNA, FISH 
The availability of CTCs with relatively high purity rates from microfluidic platforms and other 
technologies have opened up many possibilities for interrogating CTC genetic material at the 
DNA and mRNA levels. Specifically, genetic mutations and aberrations that are associated with 
patient outcomes and their response to therapy have been uncovered. Such findings can 
ultimately enable clinicians to make better decisions about patient treatment regimens. For 
instance CTCs captured using an EpCAM based microfluidic platform from patients with 
NSCLC were studied for EGFR mutations which have been implicated in drug resistance to 
EGFR targeted therapies.
92
 DNA was recovered from CTCs using allele specific polymer chain 
reaction (PCR) amplification, and EGFR mutational analysis was performed on the CTCs 
alongside matched plasma DNA as well as primary tumor DNA. The study found that the 
T790M mutation, which is responsible for drug resistance was detected in CTCs of patients who 
had received drug therapy. Moreover, serial CTC analysis revealed additional EGFR mutations 
in some cases where tumor progression was observed.
92
 
Established gene expression technologies and protocols have also been applied to CTCs 
to determine whether any information of diagnostic or prognostic value could be yielded. In one 
study, RT PCR was used to detect prostate specific antigen, (PSA) mRNA among 122 men with 
androgen-independent prostatic carcinoma (AIPC) in order to investigate whether mRNA 
detection could be used as a cancer specific biomarker. Interestingly, the study showed a 
significant correlation between mRNA detection and decreased survival. PSA detection based on 
RT PCR was also found to be independent of, and of higher quality than serum PSA.
93
 In a 
related study, real time RT PCR of localized or castration-refractory prostate cancer CTCs 
revealed close associations with detection of KLK mRNAs and survival.
94
 
Moreover, Aktas and colleagues used multiplex RT-PCR to study patterns of expression 
of EMT markers (Twist1, Akt2, PIK3α) and the stem cell marker, ALDH in CTCs from breast 
cancer patients.
95
 Similar studies have been done to evaluate the expression of genes hat have 
been deemed important in clinical decision making, such as HER2, estrogen receptor, (ER) and 
progesterone receptor (PR).
96-98
 Notably, RNA sequencing has been integral in revealing 
pathways implicated in cancer metastasis. In attempts to establish the genomic signatures of 
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pancreatic cancer CTCs, Yu et al used a pancreatic cancer mouse model to capture mouse CTCs 
and performed single molecule RNA sequencing, which identified Wnt2 as an enriched gene in 
pancreatic cancer CTCs.
99
 These findings were corroborated in 5 out of 11 patients with 
pancreatic cancer. The study found that WNT2 expression in cells suppresses anoikis and 
increases metastatic capacity in vivo. Sphere formation was also enhanced with WNT2 
expression.
99
 
Ting et al reported on a mouse model study that compared genome-wide expression 
profiles of CTCs with their corresponding primary tumors. CTC isolation was performed using 
an epitope free approach in order to isolate CTCs independent of their surface marker 
expressions. Single cell RNA sequencing was performed on the CTCs, revealing that CTCs 
showed lower proliferative signatures and high gene expression for ALDH1a2 which is a stem 
cell associated marker, compared to primary tumor cells and tumor derived cell lines. CTCs also 
demonstrated biphenotypic expression of both epithelial and mesenchymal markers as well as 
lgfbp5, a gene associated with the epithelial stromal interface. The study also showed that CTCs 
from both mouse and human origin demonstrated high expression of stromal derived 
extracellular matrix proteins, which may contribute to signals that enhance the spread of 
cancer.
100
 
The prevalence of somatic alterations to gene copy number, associated with many solid 
tumor malignancies, has garnered a lot of interest as they can potentially be used as cancer 
biomarkers associated with important clinical outcomes. Fluorescence in-situ hybridization 
(FISH) provides a rigorous platform to identify these types of alterations. For instance, through 
the use of FISH, HER2 genomic alterations have been observed in CTCs isolated from breast 
cancer patients that were not in accordance with the HER2 status of primary tumors.
101
  
Similarly, a multi FISH assay was used to confirm the amplification of the androgen receptor 
(AR) locus and increased androgen signaling observed among late-stage prostate cancer patients 
using a multi-color FISH assay.
102
  
More recently, the use of FISH to monitor genomic alterations during therapy has been 
reported. Using FISH, gene amplification of EGFR in CTCs from NSCLC patients was 
monitored during tyrosine kinase inhibitor-based therapy. Of the 20 patients monitored, 5 of 
them showed EGFR amplification, occurring within 85%-100% of EpCAM positive cells.
103
 
Interestingly, FISH was used in a dual colorimetric quantitative fluorescence assay of RNA to 
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detect epithelial (CK 5, 7, 8, 18 and 19; EpCAM; cadherin-1) and mesenchymal (fibronectin-1; 
cadherin-2; serpin peptidase inhibitor, clade E) transcripts from MBC patients. Quantification of 
RNA-ISH, among other assays, supported the EMT evidence in BC CTCs and the association of 
mesenchymal markers expression with CTC clusters versus single CTCs. 
104
 
While there is promise in the clinical relevance of genomic aberrations observed in 
CTCs, FISH analysis of CTCs still needs to be fully validated before the information can be used 
routinely in a clinical setting. Furthermore there is still a lot that needs to be understood 
regarding FISH analysis of PDAC derived CTCs, and in the clinical impact that such analyses 
may demonstrate in the of treatment PDAC.  
Single Cell Analysis:  
To circumvent the issues associated with leukocyte or other blood cell contamination of isolated 
CTCs, and to better understand the heterogeneity that exists among distinct CTCs, several 
studies have implemented single cell CTC analysis. 
15, 19, 105-108
 Using some of the commercially 
available cancer panel amplification platforms such as those provided by TruSeq® Amplicon 
(Illumina, San Diego, CA) as well as Ion Torrent AmpliSeqTM (Life Technologies, Carlsbad, 
CA), CTC DNA can be amplified and then genotyped or sequenced to identify genetic mutations 
and other genomic aberrations.  
One of the first reported studies of single cell CTC analysis utilized a PCR based 
approach to analyze EpCAM or CK positive cells from the bone marrow of cancer patients. 
These cells may be latent and are thought to play a role in early cancer dissemination. Through 
the use of comparative genomic hybridization (CGH), genomic aberrations were used to identify 
cancer cells, among which, extracellular metalloproteinase inducer (EMMPRIN) had one of the 
highest protein expression rates. 
15, 109
 
CTC single-cell analysis has been leveraged to determine the extent and nature of 
mutational heterogeneity among CTCs from the same patient sample. A clinical study which 
involved EGFR gene amplification and sequencing for KRAS (v-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog), BRAF (v-raf murine sarcoma viral oncogene homolog B1), and 
PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α) mutations in 
CTCs enriched from colorectal cancer patients showed that EGFR protein expression varied 
from CTC to CTC from a single patient. Interestingly, one patient had 2 different PIK3CA 
mutations in 2 separate CTCs.  Of the 44 single CTCs interrogated, no genetic mutations were 
 28 
 
detected for BRAF from any patient.  PIK3CA mutations were observed in 14 of 36 CTCs from 
4 patients while 5 out of 15 patients from a single patient showed KRAS mutations.
110
  
To facilitate single cell analysis of CTCs, microfluidic based platforms have been 
customized to collect and analyze very small amounts of genetic material from single cells. 
Patterns of gene expression among CTCs can be implicit of putative biological processes that 
lead to metastasis such as EMT. Using a microfluidics based PCR platform, 38 prostate cancer 
CTCs sourced from 8 patients were used to study gene expression patterns of 84 genes 
associated with EMT. Several of the genes associated with a mesenchymal transition, and 
therefore invasiveness were expressed in the CTCs, though at varied extents and combinations. 
Of note, the study showed detection of a few genes frequently expressed in cells unique to 
castration resistant patients compared to castration sensitive cases.
108
 
Apart from DNA and genomic studies, single cell analysis has also been used to extract 
information about active gene transcription and gene expression changes through single CTC 
mRNA sequencing. Smart-Seq, a single cell mRNA sequencing platform, was used to carryout 
transcriptome analysis wherein 9 transcripts of membrane proteins specific to melanoma derived 
CTCs, that were mostly absent in primary melanocytes or immune cells, were identified. 
Interestingly, there was loss of expression of epithelial cadherin (CDH1) in CTCs, which is 
associated with increased proliferation and invasiveness, and ultimately cancer spread.
106
 
Additionally, because of the improved read coverage of the Smart-Seq platform, preliminary 
studies on single nucleotide polymorphisms of the CTCs were carried out, which revealed 
thousands of genetic sites with alternative alleles in at least 2 CTCs.
106
 
As technologies become more sensitive with improved reading accuracy as well as 
multiplexing capabilities, the requirements for increased data processing and interpretation of 
bioinformatics are commensurate. The investments and costs associated with data processing can 
be a limiting factor. Additionally, there are requirements to determine what genetic information 
is clinically relevant, and to decipher to what extent some of the observed data can inform 
clinical outcomes. Another caveat associated specifically with the current technologies for single 
cell analysis are concerns about amplification errors that are inherent to the high degree of 
amplification required for propagating information from genetic material of a single cell. 
Furthermore, there is a need to standardize protocols across studies so that data can be exchanged 
and compared objectively. 
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1.3.4 Clinical Utility of CTCs in Management of Pancreatic Cancer  
CTCs and Cancer Detection:  
The early dissemination of pancreatic cancer, apart from its resistance to targeted therapeutics is 
thought to be responsible for the particularly aggressive nature of PDAC.
64
 While there have 
been advances in early detection of other cancers such as breast and other cancers, there are 
currently no reported effective methods for early detection of PDAC. 
111
  
Klapman et al discussed methods for early screening and detection of pancreatic cancer 
and detailed the screening program enforced at their respective institute.
111
 Criteria for screening 
patients are limited to those with a high risk of developing the disease based upon factors such as 
hereditary pancreatic cancer syndrome, familial breast cancer syndrome and familial atypical 
multiple mole melanoma syndrome. Yet, hereditary and familial factors only account for 10% of 
pancreatic cancer patients. They concluded that more robust, non-hereditary risk factors need to 
be established to identify those who will benefit from screening. They also stated that more cost 
effective, less invasive methods should be developed to use in patient screening.
111
  
In a recent study using a genetic mouse model of PDAC, Rhim et al reported on detection 
of circulating pancreas cells, (CPCs) in the bloodstream of mice even before any tumor could be 
seen in the mice.
23
 Using a Cre-lox-based PDAC mouse model, a RosaYFP allele was introduced 
to specifically and efficiently label cells originating from the pancreas. Using this lineage tracer, 
YFP cells were observed in circulation of mutant mice before the detection of invasive cancer. 
Moreover, through Zeb1 immunostaining and qPCR, EMT cells were identified in mice with 
premalignant lesions. This data is suggestive of the role of EMT in early disease onset in PDAC. 
Since EMT is associated with the loss of epithelial phenotype among CTCs, including a decrease 
in EpCAM expression, EpCAM based technologies with lower sensitivities may prove less 
efficient in detecting CTCs in pancreatic cancer.  
Moreover, Rhim and colleagues, further substantiated the possibility of using CTCs as a 
biomarker for early detection of pancreatic cancer, before it reaches an invasive stage, in an 
additional report. Patients with cystic tumor of the pancreas who are at increased risk for the 
subsequent development of pancreatic cancer and who routinely undergo surveillance in the 
clinic were studied. Of the 21 patients that had no clinical diagnosis of cancer but had cystic 
lesions of the pancreas, 3 or more CPCs/mL was detected in the blood of 7 of the patients. Eight 
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of the 11 patients with confirmed PDAC had 3 or more cells/mL while no CPCs were detected in 
healthy patients. Since the study suggested the presence of these circulating cancer cells in 
patients before tumor formation, at the early stages of disease, the authors propose the detection 
of these cells for risk management in early disease settings. A larger clinical trial to validate 
these results is currently underway.
25
 
Zhou and others proposed the use of CTCs as an early detection platform for pancreatic 
cancer by examining the RT-PCR expression levels of h-TERT, CK20, CEA and C-MET in 
circulating cancer cells for 25 patients.
112
 Immuno-magnetic particles were used for cancer cell 
enrichment and the study found that there was a significant difference in the positive expression 
of the 4 genes. The positive expression rates for h-TERT, CK20, CEA and C-MET were 80%, 
100%, 84% and 80% respectively. The study also found that positive expression of C-MET, 
CK20 and CEA correlated well with tumor stage.
112
 
CTCs and Prognosis in Pancreatic Cancer  
With respect to pancreatic cancer, in establishing the clinical utility of CTCs, the need for more 
robust prospective randomized studies becomes apparent. Several studies aimed at evaluating the 
prognostic value PDAC derived CTCs have been reported (see Table 1.4). Such reports have 
gone further in establishing the clinical relevance of CTCs by monitoring patients through their 
clinical course and investigating how CTCs could yield prognostic information They represent a 
step towards understanding how CTC detection in pancreatic disease can ultimately be used in 
disease monitoring and treatment.  
In order to evaluate whether cancer cells detected in bone marrow aspirates are indicative 
of micro metastases or give rise to cells in circulation, Z’graggen et al developed an 
immunocytochemical assay to detect tumor cells in blood and bone marrow. The study enlisted 
105 pancreatic cancer patients and 66 control patients and CTCs were isolated using a density 
separation medium, Nycoprep (Accurate Chemical & Scientific Corporation, Westbury, NY). 
Tumor cell counts were compared with disease stage, and survival analysis was performed using 
a multivariate Cox regression. Tumor cells were detected in 26% of blood samples and in 24% of 
bone marrow specimens. Interestingly, it was seen that tumor cell prevalence increased with 
tumor stage in blood samples unlike with bone marrow samples (P=0.52). Tumor cell prevalence 
in blood also correlated with resectability (P=0.02), disease progression, (P=0.08) and with 
peritoneal dissemination (P=0.003). 
113
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Since CTC levels have demonstrated correlations with disease prognosis among several 
other solid tumor cancers, their potential as a similar biomarker in PDAC would prove quite 
beneficial, given the inaccessible position of the pancreas to do routine tissue sampling. In an 
early study involving 26 pancreatic cancer patients Kurihara et al set out to see if CTCs levels, as 
isolated by CellSearch, could be used for predicting survival in pancreatic cancer. Eleven 
patients with chronic pancreatitis and 10 healthy volunteers were enlisted. The study showed that 
42% of patients had detectable CTCs in 7.5mLs of blood while those with benign conditions 
showed no CTCs. Among the 15 patients with CTCs, this group demonstrated a median survival 
time of 110.5 days while the 11 patients with no detectable CTCs showed a median survival time 
(MST) of 375.8 days (P<0.001). For the 14 patients that were at an advanced stage, IVb, the 
MST of those with and without detectable CTCs were 52.5 and 308.3 days respectively 
(P<0.01).
114
 
Given the interest in enumerating CTCs, questions arise about the sensitivity and 
isolation yields among the commercially available platforms. Khoja et al reported on a pilot 
study done in 2012 to compare two CTC enumeration and detection platforms across pancreatic 
cancer blood samples, obtained from 54 patients. They compared CTC numbers using 
CellSearch, the only FDA approved diagnostic platform for CTCs, with isolation by size of 
epithelial tumor cells (ISET) technology. ISET detected CTCs in 93% of patients while 
CellSearch detected CTCs in 40% of patients. Khoja et al report that among the patients with 
detectable pancreatic CTCs, burden of disease and performance status correlated with CTC 
numbers as measured by CellSearch.
115
 
In efforts to assess the prognostic value of CTC levels in patients with pancreatic cancer 
Han et al carried out a meta-analysis of previously reported studies.
116
 Using an extensive 
literature search for relevant studies done up to July 2013, the meta-analysis incorporated 9 
cohort studies which included 623 pancreatic cancer patients, 268 of which were positive for 
CTC, and 355 negative. The analysis found that patients who had CTCs were significantly 
associated with poor progression free survival (HR=1.89, 95% CI=1.25-4.00, P<0.001) and 
worse overall survival compared to those patients in whom CTCs could not be detected, 
regardless of platform used.
116
 
Detection of CTCs with tumor-associated antigens has garnered significant interest since 
the presence of these proteins on cells support the tumor origin of CTCs.  Soeth et al reported on 
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a prospective study that investigated the diagnostic potential of Cytokeratin 20 (Ck-20) in 
detecting disseminated tumor cells (DTCs) in bone marrow and blood samples of patients with 
PDAC.
117
 The study, which involved 172 PDAC patients, also looked at the prognostic value for 
overall survival. Bone marrow samples and venous blood obtained preoperatively were analyzed 
using nested CK-20 RT-PCR. The study reported that 47.1% of patients had detectable CTCs 
with detection rates of 33.3% in bone marrow and 33.8% in blood samples based on CK-20 
positivity. Using the Kaplan Meier univariate survival analysis, a statistically significant 
relationship was observed between overall survival and the radicality of the operation 
(P<0.0001), tumor stage, (P<0.0011) and DTC detection in bone marrow and/or blood. 
117
 
Similarly, Hoffman et al reported on a study that evaluated the diagnostic value of 
cytokeratin 19 (CK-19) mRNA for CTC detection in blood, peritoneal fluid and bone marrow 
involving. The study which included 37 pancreatic cancer patients, 16 patients with chronic 
pancreatitis and 15 patients with benign disease, also sought to distinguish between pancreatitis 
and pancreatic cancer based on the data obtained. Nested PCR and fluorogenic RT-PCR were 
used to analyze blood samples that were taken preoperatively, intraoperatively, and 
postoperatively, as well as bone marrow aspirate and lavage taken preoperatively. CTCs were 
detected in 15 patients. Results showed that 64% of blood samples from pancreatic cancer 
patients had elevated CK-19 expression while 30% of lavage samples from cancer patients 
showed elevated CK-19 levels. A trend towards shorter survival was observed in cancer patients 
with at least 1 CK-19 positive sample. The study also found that tumor cell detection rate 
correlated well with disease stage and differentiation in peritoneal lavage.
118
 
Multiplexing genes and using multiple cancer specific biomarkers in CTC detection 
allow more robust confirmation of CTCs, as well as more detailed CTC characterization. A few 
studies reported on such rigorous methods of CTC detection and the related clinical implications. 
For instance, De Albuquerque et al developed an immunomagnetic/real time reverse transcript 
polymerase chain reaction (RT-PCR) assay and assessed its clinical value for detecting CTCs in 
34 pancreatic cancer patients. The assessment was done before systemic therapy. CTCs were 
enriched through the use of immunomagnetic capture with Dynabeads magnetic microbeads, 
(Invitrogen), coupled to BM7 and VU1D9 antibodies, which target mucin 1 and EpCAM 
respectively. Real-time RT-PCR analysis of KRT 19, MUC1, EPCAM, CEACAM and BIRC 
genes was also carried out. The study showed that shorter progression free survival (PFS) was 
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observed for patients with detectable CTCs before treatment compared to patients having no 
CTCs before treatment. Using a log-rank test (P=0.01) it was seen that patients with positive 
CTC detection showed a median progression free survival time of 66 days (95% CI=44.8-87.2) 
while patients having no detectable CTCs had approximately double the median PFS of 138 days 
(95% CI= 124.1-151.9). Additionally, correlations were seen between tumor grading and CTC 
detection rates.
119
 
In addition to CTC gene analysis, genomic studies have also been used to detect CTCs 
arguably with more specificity. Zhang et al reported on one such study where fluorescence in situ 
hybridization of the chromosome 8, (CEP8) centromere was used to enumerate CTCs. 
Additionally, patterns of CTC immunostaining with CEP8, CK and CD45, were used for CTC 
detection in the study which involved 22 pancreatic cancers, 3 borderline pancreatic solid 
pseudopapillary tumors, 6 pancreatic benign tumors and 30 healthy individuals.
120
 CTCs were 
isolated by negative depletion of white blood cells with CD45 antibodies. Dynamic monitoring 
of pancreatic patients was performed and the study reported that CTC detection had a sensitivity 
rate and a specificity of 68.18% and 94.87% respectively. Moreover, they found that CTC counts 
decreased 3 days after surgery but increased 10 days after surgery in most patients, and patients 
with increased numbers of CTCs showed enhanced rates of metastasis and worse survival rates at 
the 1.5 year follow-up.
120
 
Many of the reported trends and associations of PDAC CTCs with clinical outcomes are 
for a heterogeneous collection of CTCs. These data support the eventual use of CTCs to inform 
clinical decision. With the availability of single cell resolution analysis, studies similar to those 
reported for other cancer types can be applied to pancreatic CTCs, to better characterize the 
distinct components that are involved in disease spread. This understanding can potentially 
facilitate the development of more potent and strategic therapy regimens.   
CTCs and therapy monitoring 
The relative ease with which CTCs can be obtained and the development of increasingly 
sensitive and time efficient isolation platforms enable the use of CTCs in real time, routine 
biopsies. In this vein, CTC detection rates and prognostic value were studied in a prospective 
cohort of locally advanced pancreatic carcinoma (LAPC) patients by Bidard et al using a 
subgroup of 79 patients from an LAP07 international center randomized study.
121
 The study 
evaluated whether CTC counts assessed before the start of chemotherapy and after 2 months of 
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chemotherapy treatment correlated with patient characteristics and survival. To be recruited for 
the study, patients had to be de novo histologically confirmed stage III LAPC as per UICC 
classification, without consideration for curative resection, and with a performance status of 0-2, 
among several other clinical indicators. The treatment course involved an initial random 
assignment of gemcitabine alone or in combination with erlotinib for 4 months. After 4 months 
patients with controlled disease were randomly assigned either gemcitabine again or radiation 
therapy alongside capecitabine. Patients initially assigned erlotinib continued after 4-month 
phase except when receiving radiation therapy. The study found that CTC detection was 
associated with poor tumor differentiation (P=0.04) and with shorter overall survival.
121
 
In a study that investigated whether pharmacogenomics (PGx) profiling of CTCs from 
unresectable PDAC patients could predict tumor response, progression and resistance, Yu et al 
enlisted 50 advanced or locally advanced patients in a prospective preclinical trial. Using single 
agent response data, a number of chemotherapy agents were profiled including FOLFIRINOX 
(5-FU, irinotecan, and oxaliplatin), FOLFOX (5-FU and oxaliplatin), Gem-nab (gemcitabine + 
nab-paclitaxel), Gem-Ox (gemcitabine + oxaliplatin),  Gem-Cap (gemcitabine + capecitabine), 
and GTX (gemcitabine, docetaxel, and capecitabine). 
122
 Of the 35 patients that were deemed 
evaluable, analysis of the patients CTCs showed good correlation between PGx predictions of 
effectiveness of chemotherapy regimens. Specifically, the study showed clinical benefit such as 
progression free survival, was observed in participants treated with chemotherapy regimens that 
were predicted to be effective, compared to regimes predicted to be ineffective. These results 
demonstrate the applicability of CTCs in determining the suitability of chemo regimens to 
unique patient groups. 
Taken together, these preliminary results demonstrate the possibility of CTC biopsies to 
influence important clinical decisions. Specifically, they underscore the feasibility of using CTCs 
to predict and monitor patient response to therapies, and the effect of treatment regimens on 
patient outcomes. 
CTC Culture for Therapeutic Drug testing   
Attempts have been made to culture CTCs, a foreseeable benefit of which is to generate a 
replenishable source of these aberrant cells, particularly for therapeutic drug testing. Recently, 
Yu and colleagues reported on the ex-vivo expansion of EGFR positive breast CTCs in the 
establishment of 5 CTC cell lines. The cultured CTCs were used to test the effect of standard 
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clinical regimens as well as targeted drugs as standalone agents or in combination, across the 5 
different CTC lines. Studies show that for each cell line, specific drugs were effective based on 
the genetic mutations that were unique to each cell line. For instance with the BRx-07 cell line, 
which harbored newly acquired activating mutations in both PIK3CA and FGFR2, the CTCs 
were very sensitive to the PIK3CA inhibitor BYL719 and the FGFR2 inhibitor AZD4547. 
Cooperative effects were also observed using combined inhibition of both PIK3CA and 
FGFR2.
123
 
Particularly with early stage cancer patients where CTCs detection rates are typically 
low, the ability to culture CTCs may provide increased opportunities for molecular 
characterization and therapeutic testing of CTCs. Our group recently reported on the successful 
use of pancreatic cancer associated fibroblasts (CAFs) in establishing a 3D co-culture platform to 
culture early stage CTCs form lung cancer patients. From the CTCs that were cultured in 14 of 
19 early stage patients, next generation sequencing (NGS) analysis revealed a number of 
matched, cancer related mutations between primary tumors and CTCs.
124
  
Indeed, these studies show the potential to develop similar platforms that can be 
customized to explore pancreatic CTC ex vivo drug testing. With the ultimate goal of 
personalized treatment in mind, future development of such studies can involve detailed genomic 
analysis of patient tumors to compare the signature of the primary tumor and CTCs in actual 
patients with expanded CTCs.  
CTCs and Xenotransplantation models 
Mouse models of pancreatic cancer have allowed for in vivo studies of genetic alterations and 
other molecular studies that are pertinent to metastasis and the resistant nature of pancreatic 
cancer. Additionally, they have enabled in vivo CTC studies and access to mouse pancreatic 
CTCs. Recently, Torphy et al developed patient derived xenograft (PDX) mouse models to study 
whether CTC burden could be used as a facile biomarker of treatment response in PDAC.
125
 
Using an orally administered therapeutic agent BKM120, which acts to inhibit 
phosphatidylinositol-3-kinase, EpCAM positive CTCs were isolated and enumerated to 
determine CTC burden. A vehicle was used as a negative control and PDX mice were given 
treatment for 28 days. The study showed that CTC counts had a significant reduction in the 
BKM120 group after treatment, (26.61 to 2.21 CTCs/250uL, p=0.0207), while the decrease in 
CTCs from vehicle group was not significant (23.26 to 11.89 CTCs/250uL, p=0.8081). Tumor 
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growth inhibition correlated with CTC burden and with occurrence of sequenced CTC KRAS 
G12V mutations, which matched the respective tumors.  
The studies described demonstrate the potential and functionality of CTCs in managing 
cancer. Microfluidic technologies have been pivotal in CTC detection and isolation in a viable 
manner. As a result, sensitive molecular characterization of CTCs as well as CTC culturing have 
enabled studies that have enhanced our understanding of mechanisms thought to be important to 
the invasive metastasis cascade. Additionally next generation sequencing has facilitated genomic 
characterization of mutations that are potentially relevant to gene therapy. As our understanding 
of metastasis evolves, development of more effective therapies to treat pancreatic disease is 
anticipated.  
 
1.3.5 Comparison of CTCs versus circulating cell free DNA 
The portion of DNA that is thought to be derived specifically from tumors, and not bound 
to leukocytes or erythrocytes, and therefore circulates freely in the plasma has been designated 
circulating free DNA (cfDNA).
126-128
 Analysis of cfDNA, released from tumor cells into the 
blood represents another non-invasive approach to studying cancer.
129, 130
 In fact, studies have 
demonstrated that elevated levels of serum and plasma cfDNA were associated with elevated 
tumor markers and tumor metastasis in various forms of cancer, including pancreatic, breast, 
ovarian and prostate.
128, 131, 132
  
With the availability of increasingly sensitive technologies to identify characteristic 
genetic and epigenetic aberrations, genetic profiling of cfDNA fragments can potentially lead to 
clinical use in prognosis, treatment response assessment and disease recurrence, for instance.
21, 
128, 133
 As such, some studies have compared the clinical value of cfDNA to that of other tumor 
markers. These comparisons have yielded data to support greater sensitivity of cfDNA as a 
predictive marker for recurrence and progression free survival than carcinoembryonic antigen in 
colorectal cancer patients, and a more reliable marker for tumor burden compared to plasma 
circulating tumor antigen CA 15-3 in metastatic breast cancer (MBC) patients. 
132, 134
 
The clinical applicability of cfDNA has also been compared to CTCs among the same 
cohort of patients. 
132, 135
 Dawson and colleagues reported on a study of 30 MBC patients who 
were on systemic therapy, in which radiographic images of tumors were collected along with 
cfDNA, CTCs and CA15-3 levels.
132
 Using detection of somatic alterations, the study identified 
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gene alterations to cfDNA in 29 of 30 patients while CTCs could be detected in only 26 of 30 
patients. Additionally, among 19 patients with progressive disease, increased cfDNA levels was 
associated with disease progression in 17 patients while increased CTC counts was observed in 
only 7 of the 19 patients. While both the CTC and cfDNA levels correlated with treatment 
response, cfDNA levels were more amenable to response monitoring and showed a greater 
correlation to tumor burden than CTC levels.
132
 Interestingly, this study and others outline the 
ability of cfDNA to give insight into therapy resistance up to 10 months before disease 
progression occurs.
136-138
 
Other studies have demonstrated the clinical potential of cfDNA such as its use in 
predicting treatment response. With the use of single molecule PCR, activating EGFR mutations 
that confer resistance to EGFR targeted therapies have been detected in NSCLC patients.
139
 In 
another study, sequencing of advanced cancer patient cfDNA at different time points during 
treatment allowed for identifying increased mutant DNA associated with onset of therapy 
resistance.
138
  Several studies involving cfDNA have looked at the role of genetic and epigenetic 
aberrations associated specifically, with pancreatic cancer.
140-142
 
Indeed cfDNA isolation and analysis allows for sensitive and dynamic studies of cancer 
metastasis and hold promise in developing monitoring platforms for cancer treatment and 
therapy response. Compared to CTCs, the isolation, preparation and characterization platforms 
are not as technically challenging.
127
 However, there are some associated challenges with the use 
of cfDNA. For instance, in determining which cancer specific cfDNA to monitor, individual 
somatic mutations have to first be identified to confirm the cfDNA.
127, 132
 Moreover, the small 
amounts of cfDNA in circulation are still few and can present technical challenges. As is the case 
with CTCs, cfDNA isolation requires very sensitive detection platforms. Furthermore, 
identification of the source of cfDNA may pose a challenge since cfDNA can be derived both 
from lysed non-viable cells as well as from intact, viable cells.  
With CTCs, since cells are isolated as intact entities, additional and pertinent information 
such as cell morphology and phenotype can be obtained. Since evidence supports the importance 
of cellular migration in metastasis, studying cell properties as well as multiple genetic 
aberrations specific to the same cell may be more telling of metastasis. From one cell, both DNA 
and mRNA aberrations can be studied to elucidate how mutations and pathways interact. 
Particularly with the subset of CTCs that persist after therapy, CTC studies allow for direct 
 38 
 
analysis of these recalcitrant cells to identify mechanisms of therapy resistance. There is a lot 
that remains to be understood about the biology of pancreatic cancer and each method provides 
unique opportunities to do so. There are advantages unique to either of these minimally invasive 
approaches and combining both approaches may prove beneficial to studying pancreatic cancer 
metastasis. 
Pancreatic cancer maintains one of the more aggressive, untenable disease manifestations 
of most other cancers, and strides in addressing patient outcomes have been marginal. CTCs 
isolated from pancreatic cancer patients represent a tool that can be used in several ways to 
improve our understanding of PDAC onset and metastasis, and to unveil potential therapy targets 
arrayed against disease spread. Before CTCs can be routinely used in patient treatment, isolation 
protocols and platforms need to be standardized and data from prospective randomized trials, 
with specific endpoints need to be conducted.  
A deeper understanding of the biology of pancreatic cancer will lead to unraveling 
important details about the cause and the role of heterogeneity within tumors and how this relates 
to heterogeneity among CTCs. Identifying and studying CTCs that are resistant to therapy will 
improve our understanding of more effective therapy targets and regimens. Establishing CTC 
cultures and development of xenotransplantation models will allow for more extensive testing 
and revamping of treatment therapies. Furthermore insight into disease onset and early 
dissemination will be exigent to identifying early biomarkers for PDAC so that the disease can 
be treated before it is deemed untreatable. Because of their putative role in cancer metastasis, 
pancreatic cancer CTCs and their studies bring new hope and opportunities for improving patient 
outcomes. As isolation platforms, as well as molecular assays continue to develop, the ultimate 
expectation is that CTCs will allow for strides in our understanding of pancreatic disease and 
thereupon, lead to clinical impact.  
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Chapter 2  
Development of an integrated microfluidic 
immunomagnetic (IMI) device for CTC isolation in 
Pancreatic Cancer 
 
2.1 Abstract  
While substantial evidence exists to support the clinical potential of circulating tumor cells 
(CTCs) in elucidating metastasis, achieving high CTC isolation purities from blood remains a 
challenge. To this end, we report an ultra-specific microfluidic CTC isolation approach that 
enables significant CTC enrichment in a continuous, high-throughput manner (24 mL hr
-1
), 
through strategic combination of size based-inertial, on-chip CTC labeling with magnetic 
microbeads, and magnetic cell sorting. The clinical relevance of the platform was demonstrated 
by processing 14 pancreatic ductal adenocarcinoma (PDAC) patient samples, which resulted in 
unequaled CTC isolation purity rates, averaged at 82.5%±23.5 across 14 PDAC patients. 
Detection of >13 CTCs/mL was observed in 100% of patient samples (median = 69 CTCs/mL, 
mean = 146± 231 CTCs/mL). To leverage the availability of the highly enriched CTCs, both 
MicroRNA and mRNA profiling of CTCs were carried out from CTCs isolated within the 
system.  CTC molecular profiling revealed that RNAs previously reported as PDAC-associated, 
were among those most abundantly expressed. Overall, we describe a microfluidic platform that 
enhances CTC purity and permits detailed molecular characterization of isolated CTCs. 
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2.2 Introduction 
Not surprisingly CTC biology has sparked burgeoning interest within recent years 
because of the postulated role of these rare cells in metastasis. CTCs initiate from the primary 
tumor and migrate in the blood then occupy a secondary site to subsequently metastasize.143 
They inherently carry information about the tumor that could be useful for understanding 
metastasis and developing novel therapeutics to more effectively treat these potentially harmful 
cells. Since CTCs can be isolated from a simple blood draw, they can be used, routinely to yield 
insight into tumor pathology and treatment response without invasive procedures.144  
However CTC detection and isolation from whole blood is quite challenging. Firstly, 
CTCs are rare; there may be only 1 CTC in 7.5mL of blood containing billions of blood cells. 
Secondly, there is limited knowledge of specific CTC markers, due in part to CTC heterogeneity, 
such that they vary phenotypically and genotypically among patients.119 Considering CTC rarity 
and heterogeneity, engineering a device to isolate them from blood presents an important and 
interesting challenge.  
Two chief approaches used for CTC collection are immunoaffinity capture and label free, 
size-based filtering.145 Immune-based methods commonly rely on expression of epithelial cell 
adhesion molecule (EpCAM), a surface protein, to isolate CTCs and typically require low flow 
rates (1-3mL hr-1) to ensure that CTCs have sufficient time to be immobilized by functionalized 
surfaces.30, 146 Issues concerning cell release of the immobilized cells also arise.147 In contrast 
label-free isolation does not rely on specific biomarkers but instead on inherent CTC properties 
such as size, deformability, or dielectric susceptibility. Size-based sorting usually offers higher 
throughputs since bulk sorting of appreciable sample volumes is typically used.  
Moreover, since the discovery of microfluidic inertial size-based sorting, enhanced size-
dependent sorting was demonstrated by incorporating curvature into microfluidic channels. 
Curvature introduces Dean Forces that augment the inertial forces acting on particles under flow 
at typical sample flowrates ranging from 500-2000 µL min-1.51-53, 56  
Whereas label-free methods are rapid, specificity is lacking and operation is limited by 
overall high blood cell counts. The recently reported CTC iChip combines hydrodynamic, 
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inertial and magnetic sorting to isolate CTCs from whole blood.61 A throughput of 8mL hr-1 was 
achieved using positive immunomagnetic selection, with an average of 1500 contaminating 
white blood cells (WBCs) from 1 mL whole blood. Non-specific WBC labeling with magnetic 
beads affected purity rates.61 
We report the development of an ultra-specific microfluidic device that combines inertial 
microfluidics and immuno-magnetism in a uniquely designed workflow that minimizes non-
specific cell labeling for efficient isolation of CTCs from whole blood with ultra-high CTC 
purity rates and high throughput.148 We hypothesized that beginning the CTC isolation process 
by rapid inertial pre-sorting would greatly reduce the number of unwanted cells from whole-
blood so that micron-scale, on-chip passive mixing and brief on-chip incubation would facilitate 
specific and extensive CTC magnetic bead labeling. In turn, reduction in the required incubation 
time leads to reduced non-specific bead labeling of blood cells, which has been reported with 
other bulk-labeling approaches. Then, ultra-specific sorting of the pre-enriched magnetized 
CTCs could be achieved via magnetic sorting.  
Specifically, the microfluidic design would allow whole blood to be processed rapidly yet 
meticulously on a single chip, requiring no blood preparation or long incubation times. This 
would minimize the extent of non-specific binding to promote CTC isolation purity. Unlike most 
other platforms, our approach negates bulk CTC labeling and instead uses on-chip CTC-bead 
labeling which improves the labeling chances of target cell magnetization and successful 
isolation from blood samples.148 
Our device, the integrated microchip, is a polydimethylsiloxane (PDMS)-based, 
microfluidic device, which consists of three distinct modules that have been strategically 
combined to allow for consecutive processes of inertial sorting, passive mixing coupled with 
incubation, and continuous-flow magnetic cell sorting. The functionality of each component is 
illustrated in Figure 2.1, showing cell distribution throughout the device. The first stage of 
inertial sorting takes an input of whole blood and buffer, simultaneously diluting the blood while 
depleting the sample of red and white blood cells. Next, the CTC enriched stream from the 
innermost outlet of the inertial sorter is sent through the passive mixer, where it mixes with pre-
labeled magnetic beads for targeted labeling of CTCs via antibody-antigen interaction. After 
mixing, the sample is briefly incubated on-chip in four reservoirs to ensure magnetic bead 
attachment.  
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Finally the suspension of magnetized CTCs in the reservoirs is drained through the 
magnetic sorter, where proximate permanent magnets deflect the magnetically labeled CTCs 
away from other unlabeled blood cells to an outlet. The final collection is a highly enriched 
sample of CTCs in suspension. Each component was designed and tested individually prior to 
integration in a single system, after which the integrated system was optimized to operate as a 
seamless entity. The goal engendered for each module was to contribute towards producing a 
high CTC recovery while concurrently reducing the rate of leukocyte contamination, within a 
reasonable amount of time. 
2.3 Methods  
2.3.1 Inertial Sorter module design and development  
For size-based inertial sorting of cells, an inertial sorter with a spiral configuration was 
employed which was fabricated using polydimethylsiloxane polymer. It has been demonstrated 
that enhanced inertial sorting is achieved in microfluidics by incorporating curvature into 
microfluidic channels, thereby introducing Dean forces that augment the inertial forces that act 
on particles under flow50. The separation principle of the spiral is based on the concept that 
particles flowing along a rectangular, curved channel will experience a combination of inertial 
lift forces, FL and Dean drag forces, FD, the magnitudes and directions of which, are dependent 
on particle size and the relative position of the particle across the channel cross section. 
The net lift force is composed of two lift forces that are oppositely directed.  FL focuses different 
streams of particles within the microchannel and is given by, 
FL=ρG
2
CLap
4
     
where ρ is the fluid density, G, the fluid shear rate is given by G=Umax/Dh, Umax is the maximum 
fluid velocity and Dh is the hydraulic radius of the channel. CL represents the lift coefficient 
which is a function both of the channel’s Reynolds number, Re and the particle position along 
the channel cross section.
52, 53
 Particles experience a transverse drag force from the Dean 
vortices, which is calculated by assuming Stokes drag such that 
FD=3πµUDeanap      
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where UDean is the average Dean velocity given by  UDean=1.8 x 10
-4
De
1.63
 where De is the Dean 
Number given by De=Re(Dh/2R)
1/2
 . R is the radius of curvature of the channel and μ is the fluid 
viscosity. For the spiral device studied, the estimated ratio of FD/FL for a CTC (ap ~20μm) is 
2.148 while FD/FL for a WBC (ap ~10μm) is 0.468 so that the 2 particles equilibrate at different 
cross sectional positions. Essentially, the magnitude of the ratio of FD/FL which varies with ap
3
 
(ap being particle diameter), determines the equilibrium position adopted by particles of different 
sizes.
52
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Figure 2.1: Design of ultra-Specific CTC isolation platform (A) Schematic showing inertial 
sorting, passive mixing with incubation and magnetic sorting (B) 3D illustration of PDMS device 
(C) Reservoirs allow for brief incubation and flowrate reduction to enable sensitive magnetic 
sorting. 
 
Thereupon, the spiral device can be engineered so that particles of different diameters 
occupy single, focused streams along the channel length. Ideally, in the present study, when a 
patient’s blood sample is flowed through the inertial spiral separator, all of the small blood cells 
 45 
 
will be focused to the outer wall thus resulting in a suspension consisting mainly of cancer cells 
and some WBCs in the innermost channel outlet.  
In determining the final design configuration of the inertial sorter, routine experiments 
were carried out using fluorescent polystyrene beads of various sizes (7-20µm) which 
recapitulate the size, and therefore the anticipated behavior of the various blood cells. By 
evaluating the flow dynamics of different-sized polystyrene beads along the spiral inertial sorter, 
design parameters such as height, width and length of the device were modified so that the 
chosen configuration enabled focusing of the different-sized particles to distinct outlets, thereby 
separating larger particles (15 and 20µm) from smaller particles (7 and 10µm). 
The optimized spiral design for the integrated chip consists of a 500µm wide channel that 
expands to 1000µm at the outlet and branches into one collection outlet (innermost outlet, width 
of 200µm) and three waste outlets. The largest radius of the spiral is 15mm and the height of the 
microfluidic channels is 100µm. The spiral device operates at 1700µL min
-1
 as a stand-alone 
platform, for effective sorting of large (15-20 µm) particles from smaller particles (7-10 µm).  
Once the inertial sorter is fitted into the integrated device, the spiral operating flow rate is 
decreased to 1200µl min
-1
 to maintain effective CTC sorting. To determine the purity and 
efficiency of the inertial sorting process, cell line experiments were also performed using cell 
suspensions that were prepared by spiking pre-stained PANC-1 cells and WBCs into PBS. 
Fabrication of PDMS Microfluidic Chip 
Microfluidic channel designs were produced and modified using AutoCAD and photoresist 
masks were generated from these designs. Master molds were fabricated using SU8-100 negative 
photoresist (Microchem Corp.) following standard photolithography procedures, at the Lurie 
Nanofabrication Facility (LNF), at the University of Michigan. Specifically, to fabricate these 
reusable silicon molds for PDMS device fabrication, photoresist was deposited on a preheated, 
clean 4 inch silicon wafer (UniversityWafer). The wafer was initially spun at 500rpm for 10 
seconds for spreading, immediately followed by spinning at 2530rpm for 60 seconds. It was then 
baked on a hot plate at 65 ⁰C for 10 minutes followed by baking at 95 ⁰C for 40 minutes. Then 
the SU-8 was UV exposed for 30 seconds under UV light in a MJB 45S Mask/Bond Aligner in 
the Wet Chemistry room of LNF. The exposed wafer was again baked at 65 ⁰C for 5 minutes 
followed by baking at 95 ⁰C for 10 minutes. To develop the photoresist, the wafer was immersed 
in SU-8 developer for 7 min. The developed SU-8 mold was further baked at 150 ⁰C for 3 
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minutes. All molds were fabricated with a thickness of 100µm. The Dektak 6M Surface 
profilomter was used to measure feature height of the molds. Then to fabricate the PDMS 
devices, a 10:1 ratio of PDMS polymer : curing agent (Dow-Corning) was mixed and de-bubbled 
prior to pouring over the SU8 molds. The PDMS was allowed to cure at 65⁰C overnight.  
 
Figure 2.2: Inertial Sorter Optimization: parameters and devices studied during the 2nd 
generation device optimization to arrive at final spiral design (A) Optimized device dimensions 
showing resistance matching channels (B) Different outlet designs tested to facilitate optimal 
inertial cell sorting in stand-alone spiral. 
 
After curing, the PDMS chips were manually cut and peeled from the mold, trimmed to size, and 
inlet/outlet holes were punched. PDMS chips were bonded by oxygen plasma to cleaned glass 
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slides. Tygon tubing was inserted to connect device inlets and outlet ports to syringes. Sample 
flow was driven and controlled using Harvard Apparatus syringe pumps. Prior to running 
samples, tubing and chips were primed with 0.05% Pluronic F127 solution (Sigma Life 
Sciences), followed by PBS rinsing to prevent cells from sticking to the PDMS surfaces.  
Table 2.1: Parameters and devices studied to arrive at a final spiral design. 
 
 
Polymer Micro Beads  
Device prototypes for the spiral inertial sorter and the passive mixer were first evaluated using 
fluorescent polymer beads. 20µm (FITC, Polymer Sciences), 15µm (DAPI, Invitrogen), 10µm 
(Dragon Green, Bangs Lab), and 7µm beads (Sky Blue, Spherotech) were used for flow 
characterization at concentrations ranging from 104-105 beads mL-1. Also, magnetic fluorescent 
polymer beads (8µm, Bangs Lab) were used to characterize the magnetic sorter.  
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Cancer Cells 
A PANC-1 cell line (human pancreatic carcinoma, epithelial-like cell line), obtained from ATCC, 
was maintained at 37°C with 5% C02 and 95% relative humidity in DMEM, supplemented with 
10% FBS. PANC-1 cells were harvested on the third day after seeding, once they achieved >60% 
confluence, to exploit optimal cell surface EpCAM expression. Cells were labeled with 
CellTracker Green dye (Thermo Fisher Scientific) for easy visualization and counting. Human 
white blood cells, (WBCs), which were used for spiking experiments, were obtained from 
healthy donor blood using a dextran-mediated, centrifugation technique for WBC isolation.  
The cells were then fixed and made permeable with BD CytoPerm/CytoFix to enable nuclear 
staining with DAPI. All fixed cells were stored at 4°C. For appropriate dilutions, cells were 
counted using a hemocytometer and then diluted with PBS accordingly. For cell spiking 
experiments of 1000 cells mL-1 or less, 1 mL of cells was prepared at 104 cells mL-1 
concentration and 10-100 µL of the solution was added to a 1 mL blood aliquot for device 
testing. Two additional samples were plated during recovery experiments to be used as counting 
controls, to supplement mass balance results. 
To arrive at the final spiral design several design parameters were studied such as largest 
radius of curvature, device footprints, channel width and height, and outlet configuration (Table 
2.1). The optimized spiral design that was employed in the integrated chip consists of a 500 µm 
wide channel that expands to 1000 µm at the outlet that branches into one collection channel 
(innermost outlet) and three waste channels that have been modified with narrow serpentine 
channels to account for resistance matching once the spiral is connected to the passive mixer 
module. The collection channel is 200µm wide. The largest inertial sorter radius is 15 mm and 
the height of the microfluidic channels is 100 µm (Figure 2.2). Resistance matching allows the 
modified spiral to perform as if it were not connected to the mixer.  
2.3.2 Passive Mixer module design and development 
Cancer Cell Labeling Efficiency for Magnetic Cell Sorting  
To determine the appropriate bead dilution and incubation time for ensuring sufficient PANC-1 
cell immunomagnetic labeling, (~85% of cell with at least 1/3 surface coverage), labeling 
experiments were carried out in buffer and blood. To test the on-chip mixing and labeling 
 49 
 
procedure, cells and diluted beads were flowed through the passive mixer at 100µL min
-1
 for a 
total volume of 1-1.5 mL. The cells and beads were allowed to incubate for test times of 5, 10, 
15 and 30min in the reservoirs, with occasional rocking to prevent cell/bead settling and to 
enhance bead-cell mixing. As a negative control, equivalent volumes of cell sample and beads 
were mixed in an Eppendorf tube. The tube was occasionally rocked to prevent cell/bead settling. 
After each incubation time, a drop of mixed sample was imaged at 20X and cell bead coverage 
was evaluated. These experiments were performed with 1:10 and 1:5 bead dilutions and cell 
concentration of approximately 10
5 
cells/mL. Since both bead dilutions resulted in comparable 
cancer cell labeling regardless of reservoir or Eppendorf tube incubation, (Figure 2.7), 1:10 bead 
dilution was used. Cell labeling was further tested in diluted blood to ensure bead-cell labeling 
efficiency was maintained even in blood.  
Passive Mixer module design  
Calculations demonstrate that for a cell to experience a magnetic force sufficient  enough 
to pull it in the direction perpendicular to flow, and therefore allow it to be sorted, a cell of 
average diameter of 20µm requires less than 1/3 bead coverage to be deflected to the desired 
magnetic sorter outlet. Therefore, mixer designs were evaluated and compared based on the 
quality of bead coverage resulting after the bead-cell mixture emerged from the mixer (see 
Figure 2.3A). For each design simulations of laminar flow were performed with COMSOL finite 
element fluidic solver to fluid shear rate since high shear rates could impact cell viability (Figure 
2.3B). Several different designs were tested for passive mixing which are shown in Figure 2.3C 
including a planar micromixer,
149
 the tesla mixer
150
 and various serpentine mixer designs.  
The serpentine configuration for the passive mixer was chosen since cell labeling 
efficiency with this design was deemed adequate, requiring a module footprint that operated in 
combination with the other modules. The turns in the serpentine channels give rise to centrifugal 
Dean Forces that allow particles to cross fluid stream lines and become mixed. These forces 
increase with increasing fluid flow rate to lead to rapid mixing and high mixing efficiencies.
151
 
Typically, for the microchannel-based passive mixer, flows through the device are primarily 
laminar with values of Reynolds’ number, (Re), in the range of 0.01<Re<100 (Re~30 in the 
passive mixer studied)
152
. Because both viscous and inertial forces are appreciable in this range 
of Re, flow around the serpentine bend generates “secondary flows” in both the axial and radial 
directions thus increasing the interfacial area over which diffusion and mixing occur. The 
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serpentine channel has a height of 100µm and a width of 250µm and is capable of mixing 
particles at flow rates of 50µL min
-1
 or higher. As the flow rate increased, mixing occurred 
sooner and was primarily dependent on chaotic advection rather than diffusion, which arises at 
slower flow rates where Dean forces are weak.  
 
 
Figure 2.3: Passive Mixer Development. (A) Metric of bead attachment to cells to evaluate 
passive mixing efficiency (B) COMSOL simulation of fluid shear rate in mixer (C) Different 
passive mixer designs tested. 
 
Preliminary evaluation of mixing was done by observing the mixing patterns of yellow- 
and blue- dyed buffer solutions generated in the mixing module. Using flow rates of 10-100µL 
min
-1
, the mixing quality was characterized by the distance along the mixer required for the two 
distinct streams of yellow and blue, to become one well-mixed green stream (Figure 2.4). At a 
flow rate of 100µLmin
-1
. The highly compact mixer design enabled fluids to be completely 
mixed by the third channel segment, at a channel length of ~4cm.  
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Figure 2.4: Mixing progression through passive mixer. Dyed PBS was used to demonstrate 
how increasing flow rates lead to mixing occurring closer to the beginning of the channel (a)10 
µL min
-1
 (b)40 µL min
-1
 (c)70 µL min
-1
 (d)100 µL min
-1
. Scale = 250µm. 
The efficiency of cancer cell labeling with EpCAM coated magnetic beads was examined 
through static experiments (PANC-1 cells and EpCAM-labeled beads in an Eppendorf tube) and 
on-chip experiments (on-chip passive mixing of PANC-1 cells and EpCAM-labeled beads then 
flowed into reservoirs). The quality of mixing was validated by immediately observing the mixed 
effluent to quantify the extent to which cells were labeled with magnetic beads for each 
incubation time point. Since cells demonstrate a range of sizes, and extensive bead-cell 
attachment made individual bead counting problematic, cells were characterized as having no 
coverage, 1/3 to 2/3 coverage, and greater than 2/3 coverage, as illustrated in Fig. 2.3A. 
 
2.3.3 Reservoirs design and development  
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The mixture of magnetic beads and cancer cells that emerges from the passive mixer 
flows into four reservoirs where the mixture incubates briefly to allow more time for cell 
labeling. Use of the reservoirs also allow the flow rate of the sample to be decreased since the 
magnetic sorting process necessitates a lower flow rate than the inertial sorting and mixing 
processes. Therefore, the function of the reservoirs is twofold. To fabricate the reservoirs, 3D 
cone-shaped mold designs were generated in AutoCAD and machined in the Mechanical 
Engineering machine shop at the University of Michigan. Molds were fabricated using brass and 
Teflon but the Teflon molds were utilized to make the molds. Four of the molds were screwed to 
a petri dish and PDMS was poured over the molds and allowed to cure overnight at 65⁰C. Molds 
were then unscrewed and the PDMS reservoir device removed from the dish. Holes were 
punched at the base of the reservoirs before bonding to the rest of the integrated system. Each 
reservoir is capable of holding 0.5mL of sample in the final fabricated system. 
 
2.3.4 Magnetic Sorter Module design and development  
The magnetic sorter channel has three inlets so that the two outer buffer streams flank the 
sample stream in the center of the 250µm channel. Flow of the buffer streams was biased by 
using two different size syringes at a fixed syringe drive setting so that the top and bottom 
streams could simultaneously flow at two different flow rates. Notably, biasing the flow in this 
manner significantly improved magnetic sorting by establishing a sample distribution pattern in 
the magnetic sorter channel that directed the non-target cells to the waste outlet. This flow bias 
also allowed magnetized cells to flow slow enough to maximize magnetic trapping magnetized 
cancer cells into the collection channel. At the same time, the established design and flow rates 
used prevents the buildup of magnetic beads in the channel, which could result in blockage of the 
magnetic sorter. The outlet is split into two channels, with a 35µm collection channel and a 65 
µm waste channel. The channel length is 25 mm with a height of 100 µm. Permanent magnets 
(500 mT, K&J Magnetics) are aligned end-to-end and positioned parallel the channel with a 
1mm separation gap between the channel and the magnets.  The sample continuously flows 
through the sorter at a rate of 50µL min
-1
 and cells with as few as one-third surface bead-
coverage can be deflected into the collection channel. The sample waste, which consists of 
unwanted RBCs and WBCs and other blood components, continues along streamlines to the 
waste outlet.  
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2.3.5 The Integrated Device operation 
Before processing sample in the devices, each module was primed with 0.05% pluronic 
solution followed by a rinse with PBS buffer. In establishing the proof of concept of the 
integrated magnetic sorter device, 1mL of whole blood was routinely processed, both for device 
optimization and for testing patient samples. Once the modules are connected to operate as a 
continuous system, 1 ml of whole blood can be processed in an approximated 30 minute, which 
includes a 5-minute on-chip incubation of the blood sample with the antibody-coated magnetic 
beads. At the inertial sorter inlets, the initial whole blood input flows at approximately 400µL 
min
-1
, while the corresponding buffer input flows at 1200 µL min
-1
. The higher buffer flow rate 
readily establishes stable flow prior to the blood sample introduction and concurrently dilutes the 
blood sample. At the inertial sorter outlets, the innermost outlet (where the large cells align) is 
connected to one of the two passive mixer inlets. The other passive mixing inlet introduces the 
antibody-coated magnetic beads (1µm, Dynabeads) at a rate of 100µL min
-1
. Then, the outlet of 
the passive mixer leads the sample into four reservoirs where beads and cells undergo a brief 
incubation period to ensure more extensive magnetic bead binding to the cancer cell targets.  
After incubation, a syringe filled with air is used to pressurize the reservoirs and drive the 
flow of the sample through the magnetic sorter. In addition, buffer flows through two of the outer 
inlets of the magnetic sorter to flank and align the sample stream. The buffer stream closest to 
the magnet flows at a rate of 75µL min
-1
, the sample flows at a rate of 50µL min
-1
 and the buffer 
stream furthest away from the magnet flows at a rate of ~25µL min
-1
. These flow rates enable 
efficient magnetic attraction and redirection of the flowing, magnetically labeled cells for 
collection.  
 
2.3.6 Cell Viability Assay 
To ensure cells processed through the integrated magnetic device would be viable for 
further cellular studies, cell viability was assessed through the MTT assay (Figure 2.5). PANC-1 
cells were either seeded directly into a 96-well plate (Control), processed through the integrated 
device in media without magnetic beads (Test 1), or processed through the integrated device in 
media with the addition of magnetic beads (Test 2). Magnetic beads were exposed to UV light 
for 8 hours prior to use in these experiments to promote experimental sterility.  After collecting 
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the output of the integrated device, the processed cells and control cells were plated in 96 well 
plates at 4000 cells/well. Every 24 hours, cells were subjected to MTT protocol and absorbance 
at 570nm was recorded. Control cell absorbance on Day 1 was used as the basis to normalize the 
results. Media was changed on Day 3.  This experiment was repeated 3 times and similar growth 
patterns were observed among the three trials.  As seen in Figure 2.5, absorbance among the 
different tests was comparable for the duration of the assay. This indicated that cells processed 
through the device were viable, thus resulting in nearly the same growth rate as the control cells 
and therefore similar levels of dye absorbance.  
 
Figure 2.5: MTT assay to determine cell viability. Cells were processed through the integrated 
device either without magnetic beads (Test 1) or with magnetic beads (Test 2). Control cells 
were unprocessed. Then cells were plated in 96 well plates and grown for 5 days – with MTT 
assay performed on one plate per day to assess growth. Growth was normalized to control cells 
on Day 1. (n=5, bars indicate standard deviation) 
Therefore, processing patient samples through the device should not be detrimental to their 
viability. Furthermore, these results support the use of isolated CTCs for subsequent studies such 
as molecular profiling and CTC culturing.  
2.3.7 Patient Blood Testing with the IMI Device  
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Blood samples from pancreatic cancer patients were collected using institutional IRB 
guidelines with informed consent from the patients or the next of kin while blood from healthy 
donors were collected with informed consent according to standard protocol. The patient 
samples, (courtesy of the University of Michigan Comprehensive Cancer Center) and the healthy 
donor samples were collected in EDTA tubes and tested within four hours of blood draw. 
Table 2.2: Patient statuses for samples processed and enumerated.  
DATE ID VOL. 
(mL) 
CTCs
/mL 
WBCs/
mL 
AGE SEX DISEASE STAGE 
3/3/2014 P1 1.2 938 7 73 F Metastatic to lymph nodes outside of 
surgical   field 
4/14/2014 P2 1.0 80 0 81 F Locally Advanced/unresectable 
4/21/2014 P3 1.0 16 0 75 M Likely PDA/resectable (pending 
Pancreatitis) 
4/21/2014 P4 1.0 22 0 50 F Locally PDA 
7/29/2014 P5 1.3 141 12 63 M pT4 N1 MX-Stage III 
7/29/2014 P6 1.4 190 25 53 M PDA Stage IV 
8/4/2014 P7 1.2 38 0 58 F PDAM Stage IB-IV 
8/4/2014 P8 1.2 80 35 60 M PDA Stage IV 
8/11/2014 P9 0.7 280 49 66 M Metastatic Panc Adeno to liver Stage IV 
8/11/2014 P10 0.6 58 389 63 M Locally advanced/borderline resectable 
8/12/2014 P11 1.4 20 14 40 M Resected pT3N1- Stage IIB 
8/18/2014 P12 1.2 48 12 81 M Possible PDA, renal mass 
8/18/2014 P13 1.0 14 0 61 M Metastatic Panc Adeno Stage IV 
8/18/2014 P14 1.4 113 51 65 M Metastatic Panc Adeno Stage IV 
 
To evaluate the ability of the optimized IMI device to isolate CTCs from patient samples, 
fourteen metastatic or locally advanced PDAC samples and 4 healthy controls were processed 
through the device. Up to 1.4 mL of whole blood was processed for each patient. CTCs were 
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identified via fluorescent immunostaining for CK+/DAPI+/CD45-. Additional confirmation of an 
epithelial cell type was garnered by brightfield images of CTCs, showing bound EpCAM 
magnetic beads on the cells. WBCs were identified as CK-/DAPI+/CD45+. The corresponding 
patient clinical data is shown in Table 2.2. 
 
2.3.8 Immunofluorescent Staining for CTC Identification 
The resulting CTC suspension from the IMI device was processed using the cytospin 
technique where 300μL of sample was spun onto a poly-lysine coated glass slide at 600-800rpm 
for 10min. The sample was then demarcated with the hydrophobic pap-pen and the sample fixed 
with 4% PFA for 20min. The slide was then rinsed and the sample covered in PBS buffer and 
refrigerated in 4⁰C until immunofluorescence staining was performed. Slides were stained for 
CTC markers using a primary antibody for anti-cytokeratin-19 (CK-19, epithelial cell marker, 
(Santa Cruz Biotechnology, rabbit polyclonal IgG) and nuclear stain 4',6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI, Invitrogen). Negative staining with the leukocyte marker 
anti-CD45 (BD Pharmigen Purified Mouse Anti-Human CD45, HI30 clone, isotype Mouse 
IgG1, ƙ) was also performed. Samples were then stained using secondary antibodies with 
fluorescence conjugation namely, AlexaFluor 568 (Life Technologies), for CK-19 detection and 
AlexaFluor 488 (Life Technologies), for CD45 detection. For the primary antibody stains, 
overnight incubation was carried out, while for secondary staining, 1hr was allowed. For DAPI 
staining ProLong Gold anitfade mountant with DAPI, (Life Technologies) was applied 
overnight. Immunofluorescence imaging for anti-CD45 was performed using a FITC filter while 
anti-CK was performed with a PE filter and DAPI, a UV filter, all at x20 magnification. 
 
2.3.9 M-RNA Profiling of pancreatic CTCs isolated with the IMI device  
To further demonstrate the potential of the integrated device in allowing sensitive CTC 
molecular interrogation subsequent to CTC isolation, mRNA profiling was carried out on eight 
additional patient samples. Of these, three were categorized as borderline and two as locally 
advanced while three were metastatic. To isolate total RNA, after enriching CTCs from 6.5 mL 
of patient blood, 300μL of the fraction was fixed and stained to enumerate for CTCs and the 
remaining portion was processed for total RNA isolation. RNA was isolated using the Norgen 
Single Cell RNA Purification kit (Norgen Biotek Corp.), according to the manufacturer’s 
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protocol with minor modifications. After lysing the cells the CTC lysates were then stored in -
80⁰C until total RNA purification was ready to be carried out. For total RNA purification, 
samples were thawed on ice and 200μL of 96-100% ethanol was added to the cell lysate and 
vortex mixed for 10 seconds. At this point the manufacturer’s protocol was followed for total 
RNA extraction. RT was carried out on the purified RNA followed by pre-amplification (18 
cycles) using cDNAs corresponding to 96 genes of interest from a CTC-specific panel. The 
pooled TaqMan Gene Expression Assays and Cell-to-CT Kit (Ambion, Invitrogen) were used. 
To carry out gene expression profiling of the pre-amplified cDNAs, TaqMan Gene Expression 
Assays for the 96 genes and the BioMark HD qPCR platform (35 cycles) were used. For genes 
undetected during qPCR, a cycle number of 40 was assigned for analysis purposes. To normalize 
CT values among different genes, GAPDH was used as an internal reference. Statistical analysis 
was performed based on –ΔCT of gene expression. 
 
2.3.10 MicroRNA Profiling of pancreatic CTCs isolated with the IMI device 
MiRNAs are important regulators of cancer cell properties however they have been in 
general, understudied in the context of CTCs. Currently, the relatively low purity rates proffered 
by most CTC isolation technologies limit specificity in genomic characterizing. The high CTC 
purities of the integrated device enable CTC-specific miRNA profiling. Accordingly, we profiled 
372 miRNAs in CTC enriched samples from 2 locally advanced PDAC patients alongside a 
healthy control sample. 
After enriching for CTCs from 6.5 mL of patient blood, 300μL of the fraction was fixed 
and stained to enumerate for CTC levels and the remaining portion was processed for total RNA 
isolation. RNA was isolated using the Norgen Single Cell RNA Purification kit (Norgen Biotek 
Corp.), according to the manufacturer’s protocol with minor modifications. After lysing the cells 
a mix of 3 synthetic Caenorhabditis elegans, (C. elegans) miRNA oligonucleotides, cel-miR-39, 
cel-miR-54 and cel-miR-238 was added to the sample to be used for miRNA normalization. The 
CTC lysates were then stored at -80⁰C until total RNA purification was ready to be carried out. 
For total RNA purification, samples were thawed on ice and 200μL of 96-100% ethanol was 
added to the cell lysate and vortex mixed for 10 seconds. At this point the manufacturer’s 
protocol was followed for total RNA extraction. Once total RNA was extracted, samples were 
profiled for the abundance of 372 miRNAs. To carry out reverse transcription, 13μL of each 
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sample was processed using miRCURY LNA Universal RT microRNA PCR kit (Exiqon) 
according to the manufacturer’s protocol. UniSP6 spike-in control was added to each reaction for 
normalization. Once reverse transcription was completed, the products were diluted and 
combined with SYBR Green master mix (Exiqon) and ROX reference dye (Applied Biosystems) 
and loaded into the commercially available, Ready-to Use- PCR, Human panel I, V4.M qRT-
PCR arrays (Exiqon). QuantStudio ViiA7 PCR system (Applied Biosystems) was used for 
carrying out quantitative PCR. CT values were calculated by exporting the data using automatic 
threshold values. Normalization was carried out across all plates based on the data obtained for 
the UniSP6 and Inter-Plate Calibrator control assays. The blanks of all the assays were 
undetectable. Any miRNA assay having a CT value beyond the limit of detection or greater than 
the blank control array were considered as not detected (ND). All other assays that were reliably 
detected were median normalized. Based on these CT values, fold change for each miRNA was 
calculated based on the expression levels in the healthy control. Fold change values were then 
uploaded to Ingenuity Pathway Analysis (IPA) software (Qiagen), and analysis was carried out 
using Ingenuity Knowledge base reference set, with filters for Human species alongside an 
“experimentally observed” confidence. 
 
2.4 Results  
 
2.4.1 Evaluation of the Inertial Spiral sorting module  
The spiral design was optimized as a stand-alone device and subsequently, the three 
waste outlets were re-designed to allow for resistance-matching once it was connected within the 
fully integrated system (Figure 2.2A). The inertial sorter separates larger particles (15 -20µm) 
from smaller particles (7-10µm). Figure 2.6A shows the fabricated polydimethylsiloxane 
(PDMS) device, Figure 2.6B illustrates the arrangement of cancer cells (green) versus WBCs 
(blue) at the outlet of the sorter and Figure 2.6C demonstrates how the polystyrene particles (20 
µm (green), 15 µm (blue), 7 µm (orange)) separate into distinct, focused streams at the outlets of 
the spiral channel. Similarly, in Figure 2.6D, PANC-1 cancer cells (green streak) focus to the 
innermost outlet and WBCs (blue streak) focus to the second outlet. Figure 2.6E shows how the 
larger PANC-1 cells, (indicated by red arrows) spiked into diluted blood focus to the innermost 
outlet amidst the other blood cells. 
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Figure 2.6: Optimized Spiral Module. (A) PDMS device (B) Larger CTCs (green) go to 
innermost outlet channel. (C) Fluorescent beads, (D) fluorescent cells and (E) high-speed 
imaging demonstrate cancer cell sorting. Analysis of cell distribution in outlets both in PBS 
buffer (F) and blood (G). 
To quantitatively evaluate inertial sorting PANC-1 cells and WBCs were spiked into PBS 
and processed through the module. The effluents from each outlet were collected and analyzed 
for cell counts. Notably, 90.95% ±3.61 of cancer cells spiked in PBS buffer were collected in the 
desired outlet, as shown in Figure 2.6F. Whole blood was routinely diluted x10 for blood-spiked 
experiments to facilitate conditions amenable to microscope visualizing. Figure 2.6G shows cell 
distribution in the four outlets after repeating the experiments in diluted blood. Results consistent 
with PBS-spiked experiments were achieved such that 91.99% ±4.94 of cancer cells were 
enriched in the innermost spiral outlet.  
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The increase in WBC contamination in moving from PBS buffer (4.4%) to diluted blood 
(32.9%) may be as a result of spiking stained WBCs into the diluted blood for enumeration 
purposes, even though the original WBCs were still present in the blood sample. The heightened 
concentration of WBCs may have interfered with focusing of the cells to a distinct position 
across the channel cross section. 
 
Figure 2.7: Magnetic bead labeling efficiency of PANC-1 cells. Bead concentration and 
incubation times were varied. Scanned images of cells were used to quantify bead coverage. 
Each experiment (data point) was repeated in triplicate. Bars indicate standard deviation. 
 
2.4.2 Evaluation of the Passive mixing module  
For static incubation tests of PANC-1 labeling with EpCAM beads, time points of 5, 10, 
15 and 30 min were evaluated and compared with the use of the passive mixer module, at the 
same time points. Also, bead dilutions of 1:10 and 1:5 were evaluated. After characterizing cells 
as having no coverage, 1/3-2/3 coverage, and greater than 2/3 coverage, in static conditions, at 
least 15 minutes of incubation time was required to achieve at least 1/3 surface coverage on 85% 
of cells (Figure 2.7). With the use of the passive mixer and reservoir for cancer cell labeling, 
after only 5min incubation, over 90% of cells have appreciable bead labeling. Moreover, at all 
the time points, use of the passive mixer and reservoir demonstrate superior cancer bead 
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attachment. Additionally, Figure 2.8 shows that 92% of cells from the reservoirs have sufficient 
coverage after only 5 min incubation after repeating the experiment in diluted blood. 
 
 
Figure 2.8: Incubation times for bead-cell labeling in diluted blood. Plot showing percentage 
PANC-1 cells labeled within the reservoirs at times of 5, 10, 15, and 30 minutes. Beads were 
diluted 1:10 beads to buffer before entering the reservoir. (n=3, bars indicate standard deviation). 
 
2.4.3 Evaluation of Magnetic Sorting Module  
After the final designs for the magnetic module were narrowed down, to determine the 
flow conditions that would facilitate the highest purity rates for cancer cell sorting using the 
magnetic sorter module, two flow conditions were tested. The conditions included biased buffer 
stream flows with one at 50µl/min bottom-17 µL min
-1
 top (50 µL min
-1
 bias), and the other at 
75 µL min
-1
 bottom-25 µL min
-1
 top (75 µL min
-1
 bias). For the 50 µL min
-1
 bias condition, 
contamination was 2.35% ± 2.72 and efficiency was 88.39% ± 5.79 in the collection channel. For 
the 75 µL min
-1
 bias setup, WBC contamination decreased to less than 0.5% but the recovery 
efficiency was also reduced (Figure 2.9). However, since the purity was higher using the 75 
µl/min bias conditions this setup was implemented. Using 75 µL min
-1
- bottom, 25 µL min
-1
-top 
buffer and 50 µL min
-1
 flow rate for the sample, results show that for blood spiked tests, WBC 
contamination was 2.28% ±0.68 and recovery efficiency was 94.60% ± 1.48. Of note, the few 
PANC-1 cells in the waste were poorly labeled and so not expected to be magnetically sorted. 
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Figure 2.9:  Magnetic Sorter Operation. (A) Schematic of device operation. Only magnetically 
labeled cancer cells get attracted and flow to the collection outlet. (B) Representative images of 
the categories of bead coverage used to characterize labeling of cells collected (C) Graph 
showing the recovery and contamination rates of PANC-1 cells and WBCs spiked in buffer for 
50 and 75μL min-1 bias conditions and diluted blood for 75μL min-1 bias condition. 
 
2.4.4 Evaluation of the  IMI Device  
Once the individual modules of the integrated device were fully optimized, the next step 
involved optimizing the connected, integrated device.  Device performance was evaluated with 
simulated patient samples. Specifically, whole blood was spiked with PANC-1 cells and pre-
isolated WBCs. Buffer and the blood sample were driven through the inertial sorter at an initial 
flow rate of 1200 µL/min for the buffer stream and 400 µL/min for the blood through. Magnetic 
beads at a 1:5 buffer dilution were flowed into the passive mixer at 100 µl/min, along with the 
cell suspension that emerged from the innermost outlet of the inertial sorter. The beads and cells 
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traveled to the reservoirs and were incubated for 5 min. After 5min, the reservoir inlet was 
connected to air flow to pressurize the reservoirs and then the reservoir outlet was opened for 
draining into the magnetic sorter to processed. The output from the collection channel of the 
magnetic sorter, which presumably contained a majority of magnetically labeled cancer cells, 
was then analyzed. The integrated device was tested with both 1000 and 100 PANC-1 cell spikes 
in whole blood.  
 
Figure 2.10: Integrated Device Operation (A) Magnetic Sorter outlets show highly enriched 
cancer cells separating from waste cells (B) Immunofluorescence staining used in identifying 
cancer cells (PANC-1) and WBCs with inset of magnetically labeled cancer cell (10 µm scale 
bar) (C) Recovery of PANC-1 cells spiked into whole blood at 100 and 1000 cells mL
-1
. (D) 
Number of contaminating WBCs for 100 and 1000 PANC-1 cells spiked into whole blood. 
 
As seen in Fig. 2.10 the efficiency of PANC-1 collection was nearly 90% after 
accounting for PANC-1 cells in all outlets. For both the 1000 and 100 PANC-1 cell spikes, WBC 
contamination ranged from 82-801 WBCs/ml, resulting in purities of up to 75% (Fig. 2.10D). 
Additionally, as previously described, cell viability of the isolated PANC-1 cells was assessed 
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through MTT assays and was comparable to unprocessed control cells (Fig. 2.5) ensuring culture 
of collected cells is feasible. 
Overall, the rate limiting step of the integrated device is the magnetic sorting of the 
samples however this process can be sped up by multiplexing the magnetic sorters. Using the 
commercially available 10-syringe holder for the Harvard Apparatus syringe pumps, up to 5 
magnetic sorters are easily operated simultaneously. Moreover, the combined purity and viability 
of the isolated PANC-1 cells makes it possible to complete sensitive downstream assays 
subsequent to enriching the cancer cells in the integrated device. In addition, the unprecedented 
purity rate achieved by the device facilitates RNA profiling at the single cell level. The purity 
will also contribute to successful culture of isolated cancer cells without the inconvenience of 
blood cells that can potentially interfere with cancer cell growth and cell imaging. The purity 
demonstrated by the integrated magnetic sorter is comparable to some of the other reported 
technologies including GEDI (68%), herringbone (14%), Ichip (1500WBCs/mL), and the CTC 
chip(9%) platforms for CTC enrichment. 
30, 61, 153, 154
  
 
2.4.5 Pancreatic patient CTC Isolation with the IMI Device 
The patient samples (n=14) and healthy controls (n=5) were enumerated and CTC purity 
percentages are as reported in Figure 2.11. For all 14 patients, CTCs were isolated with counts 
ranging from 14-938 CTCs mL-1, which was higher than the average 3 CTCs mL-1 for healthy 
controls. Notably, CTCs have been recovered from patient blood with significant depletion, on 
the order of 106 WBCs, with average CTC purity being 82.5% ±23.5. Figure 2.11A shows 
representative images, both of a fluorescently labeled CTC and a WBC.  
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Figure 2.11: Processing PDAC patient samples (A) Fluorescent and brightfield image of a 
CTC (20 µm scale bar) and a WBC (10 µm scale bar) identified through immunofluorescent 
staining (B) Cell counts of CTCs in 1mL of patient blood. (Percent purities are indicated) (C) 
Corresponding WBCs for the same samples.  
 
 
Table 2.3: Patient statuses for samples processed, enumerated and RNA profiled. 
 
micro RNA Profiling  
Date  ID Vol. 
(mL) 
CTCs/mL WBCs/mL Stage 
02/09/15 P1 5 7 2 Borderline resectable-Resected 
02/09/15 P2 5 15 1 Borderline resectable 
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05/19/15 HC1 5.5 0 0 N/A- Healthy Control 
mRNA Profiling 
Date  ID Vol. 
(mL) 
CTCs/mL WBCs/mL Stage 
1/12/15 M1 6.5 11 0 
Metastatic PDAC-deceased Aug 
2015 
1/26/15 L1 6.5 1 3 Locally advanced PDAC 
12/15/14 B1 12 9 0 Borderline resectable 
1/12/15 B2 5 161 27 Borderline resectable-Resected 
12/15/14 B3 12 6 0 
Borderline – Eventually developed 
metastasis 
12/15/14 M2 12 9 0 
Metastatic PDAC- Showed 
Progression 
01/20/15 L2 5.5 12 0 
Locally advanced PDAC concerning 
for metastasis 
12/8/14 M3 7 62 1061 
Metastatic- Resected – deceased Mar 
2015 
 
 
2.4.6 Comparing CTC mRNA profiles of metastatic versus other stages 
Patient statuses for CTC samples that were molecularly profiled are reported in Table 2.3. 
As seen in Figure 2.12A, hierarchical clustering of mRNA expression levels from patients CTC 
samples resulted in all borderline profiles (B1-B3) clustering closely while two of three 
metastatic cases clustered apart from all other profiles. Moreover, seven mRNAs Zeb1, KLF4, 
cMYC, BRCA1, HER2, CD3D, and HPRT1 expression levels (indicated by the green box in 
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Figure 2.12A) were able to distinguish metastatic sample profiles from the other borderline or 
locally advanced CTC sample profiles. SPARC was also higher-expressed in the metastatic 
group (LogFC=4.7, p=0.037). Specifically, Zeb1 (LogFC=11.6, p=0.037) has shown to be an 
independent predictor of mortality in pancreatic cancer while overexpression of cMYC 
(LogFC=9.9, p=0.037) in pancreatic cancers was previously studied.155, 156 The role of KLF4 
(LogFC=11.6, p=0.037) as both as a tumor suppressor and an oncogene in cancer progression 
was previously reported.157 Interestingly, BRCA1 (LogFC=10.9, p=0.037) was reported to be 
down regulated in cases of pancreatitis and sporadic PDAC.158 Additionally previous reports 
have speculated on the potential of targeting HER2 amplification (LogFC=10.1, p=0.037) among 
PDAC patients for therapeutic purposes.159 Aberrantly high expression of SPARC (LogFC=4.7, 
p=0.037) in pancreatic CTCs was also observed in both mouse and human samples.100 Even 
among a small patient cohort, corroboration of reported studies by the results of CTC molecular 
profiling enriched by the described device shows promise in its use to ascertain information that 
may be specific to pancreatic CTCs. 
 
2.4.7 Analyzing microRNA profiles of CTC samples versus healthy control samples 
Of the 372 miRNAs profiled, 106 miRs demonstrated abundance in expression in both 
samples compared to the healthy control. 81 miRs had low expression and were categorized as 
not reliably detected (NRD).  Interestingly, several miRs previously reported as PDAC 
associated, including, miR-221-3p, 210, -23a-3p, -143-3p and -21-5p were among those highly 
expressed in the CTC samples (Figure 2.13A).160-163 Additionally, based on pathway analysis, the 
top network functions enriched in the profiles were for cancer and organismal injury and 
abnormalities. Pathways involving Smad2/3 and MAP2K1/2 were implicated in PDAC CTC 
biology (see Figure 2.13B). Moreover, for the first time we report that PDAC CTC miRNA 
profiling revealed a trend towards high expression of miRs 17-5p, 19b-3p, 320b and let7a-5p. 
Also, miR-96-3p, 216b, 155-5p, 212-3p and -31-5p which demonstrated decreased expression 
have been previously reported to exhibit down regulation in pancreatic cancer.160, 161  
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Figure 2.12: Messenger RNA profiling of CTCs enriched from PDAC samples from 3 
borderline (B), 2 locally advanced (L)  and 3 metastatic (M) patients p (A) Heat map plot reveal 
that 2 of 3 M profiles cluster together separately from others. Seven genes (green box) 
distinguish between the two groups. (B) Log fold increase plot of mRNAs increased in 
metastatic versus borderline patients. (* indicates samples with p=0.036).   
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Figure 2.13: MiRNA profiling (A) Log Exp values for 10 highest expressed miRs (B) network 
generated in IPA that infers relationships among miRNAs with highest levels of expression. 
Lines, referred to as “edges” indicate inferred relationships between molecules. MAP2K1/2 and 
Smad2/3 pathways appear to be impacted based on the miRNA expression profile of the PDAC 
CTCs. 
 70 
 
2.5 Discussion  
 
The integrated microfluidic device described is capable of isolating significantly enriched 
cancer cells that are viable. The capability of collecting highly pure populations of CTCs in 
suspension is advantageous for subsequent cell studies including DNA or RNA analysis, gene 
expression profiling, or even CTC culturing and expansion. Moreover, single-cell analysis and 
efforts geared towards understanding the implications of tumor cell heterogeneity are gaining 
significant prominence. CTCs isolated in suspension are ideal for single cell analysis and related 
CTC studies. The device reported uses inertial sorting to perform rapid pre-sorting and de-
bulking of the original sample. De-bulking the sample significantly reduces the volume to be 
further processed, and thus reduces the overall sample processing time required. On-chip 
magnetic labeling not only allows very sensitive cancer cell tagging in the absence of the 
majority of blood cells, but also allows for specificity, and presents an opportunity to reduce the 
required quantity of antibodies. Moreover, the antibodies used for on-chip labeling can be 
modified to select for specific populations of CTCs through use of epithelial markers, stem cell 
markers, or other biomarkers. Finally, with the magnetic sorter module, multiplexing the device 
can significantly reduce the time taken to process large sample volumes. 
 Since the integrated system provides the opportunity to isolate and enrich for CTCs from 
patient samples, we were able to perform CTC-specific mRNA and miRNA profiling for patient 
samples to study expression patterns unique to PDAC CTCs. The analysis of the profiling results 
recapitulated patterns of miRNA expression obtained from biomaterial specific to pancreatic 
cancer such as tumor tissue, whole blood, as well as blood plasma. Moreover, miRNAs 
previously reported to be dysregulated in pancreatic cancer, such as 221-3p, 23a-3p, 143-3p, 21-
5p, 103 and let-7a, among others, demonstrated abundance in expression in the patient CTC 
samples compared to the healthy control.163-165 Additionally, mRNA profiling revealed that 
mRNAs Zeb1, KLF4, cMYC, BRCA1, HER2, CD3D, and HPRT1 in were highly expressed 
among metastatic PDAC derived CTCs. The platform presented enables senstive studies of CTC 
RNA expression which, in turn, can help to identify their putative roles in cancer metastasis. 
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Chapter 3  
Microfluidic Continuum Sorting of Sub-Populations of 
Tumor Cells via Surface Antibody Expression Levels 
3.1 Abstract  
The extent of inter- and intra- tumor cell heterogeneity observed in a patient’s tumors appear to 
be directly associated with the patient’s prognosis. Moreover, studies indicate that targeting 
distinct subpopulations of tumor cells may be more relevant to successfully managing cancer 
metastasis. The ability to distinguish and characterize unique tumor cell subpopulations within a 
given sample is thus exigent. Existing platforms separate cells based on some threshold level of 
phenotypic characteristics without consideration of the continuum levels of biomarker expression 
and the associated implications. Herein we describe how specific tumor cell groups have been 
immunomagnetically enriched according to a continuum of EpCAM surface marker expression 
levels. Even among a relatively homogenous group of cells such as the PANC-1 cell line, cells 
could be separated according to their EpCAM levels into low, moderate and high expression. To 
functionally assess each subpopulation, a wound healing assay was performed which revealed 
distinct invasive potentials among each subset. Furthermore, the clinical relevance of the 
approach was demonstrated by isolating pancreatic cancer CTCs from the same patient sample 
based on their EpCAM levels. We demonstrate a robust method of isolating CTCs based on 
varied levels of EpCAM expression, which enables studies of tumor cell heterogeneity. 
Interestingly, 5 of 6 patient samples had CTCs that could be recovered at all three levels of 
EpCAM expression, though the majority of CTCs were recovered as low expression events. 
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Preliminary studies that compare tumor cell subpopulations in this continuum manner can 
potentially increase our understanding of the dynamic nature of tumor cell heterogeneity and 
how it relates to patient outcomes. Furthermore investigations as such may reveal therapeutic 
targets among the different tumor cell subpopulations. 
3.2 Introduction  
The clinical ramifications of tumor heterogeneity have been demonstrated in a number of 
studies that investigate the levels of heterogeneity among patients and how these levels correlate 
with patient outcomes.
166-168
 It is believed that genetically distinct subclones that comprise 
tumors cooperate to facilitate tumor growth and progression and as such, tumor heterogeneity is 
thought to be necessary for sustained tumor growth progression.
169, 170
 Identifying the 
heterogeneous populations of cells that comprise tumors has influenced decisions in patient 
treatment as interpatient tumor heterogeneity provides a platform for molecular biomarker 
testing and predictions of patient response.
171
 Moreover observations that such biomarkers may 
evolve over the clinical course, has led to increased focus on the impact of intratumor 
heterogeneity in patients.
171
 In light of the significance that tumor heterogeneity plays, whether 
among different patients or within a single tumor from a patient, the need to sensitively and 
reproducibly interrogate tumor heterogeneity is imminent. 
Furthermore, a small subset of tumor cells is thought to be responsible for the metastatic 
cascade in many solid tumors.
172, 173
 These cells acquire the ability to disseminate from the tumor 
and travel through the vasculature before initiating a secondary tumor at another site, 
demonstrating biological properties that are distinct and crucial to metastasis. Circulating tumor 
cells, (CTCs) represent prime targets in the fight against metastasis. Therefore the ability to 
isolate and interrogate different subtypes of CTCs can potentially open many clinically beneficial 
avenues towards cancer management. 
15, 100
 
One approach that adopted for tumor cell sorting is fluorescently activated cell sorting 
(FACS) with tumor cells that have been digested from tumor tissue or tumor derived cell 
lines.
174, 175
 FACS has been universally employed for sorting cell subpopulations as it 
conveniently allows rapid cell measurement readouts of 10
4
 cells s
-1
. Additionally the limit of 
detection of 1 fluorescent cell is 10
-6 
and multiple cell surface markers can be analyzed 
simultaneously.  Typically cells are sorted according to high and low levels of surface markers of 
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interest based on their fluorescence intensity where most studies so far, gate and separate cell 
subpopulations based on very high (positive) and very low (negative) expression of proteins of 
interest. Thus cell sorting is carried out without considering the continuum levels of phenotypic 
characteristics and the associated implications with respect to tumor cell heterogeneity. Apart 
from its costliness, FACS sorting becomes less advantageous when small numbers of cells are 
considered, as is often the case with rare CTCs from patient samples. Using FACS to sort the 
few CTC events that occur among billions of other blood cells represents a less sensitive 
approach that can potentially become time consuming and impractical.
173, 176, 177
 
To sort cells according to their varying levels of surface marker expression one study 
reported development of a nanoparticle mediated microfluidic cell sorting approach that used 
velocity valleys to slow and trap cells.
178
 Purities were 19% when target cells were trapped from 
blood and overall throughput was 2mL hr
-1
.
178
 Currently, the majority of molecular assays that 
are performed subsequent to CTC isolation necessitate high purities so that molecular profiling 
and analysis that is specific to CTCs can be obtained. Previously, the integrated magnetic system 
demonstrated highly sensitive and robust CTC isolation through inertial presorting of whole 
blood, followed by immunomagnetic CTC labeling and magnetic CTC sorting.
148
  
By implementing simple alterations and a strategic workflow to the magnetic sorter 
module, we demonstrate the ability to isolate distinct groups of tumor cells immunomagnetically, 
according to their levels of surface protein expression. Essentially the magnetic field strength 
experienced by magnetic particles under flow in the microfluidic channel was manipulated by 
adjusting the distance of the external magnet from magnetic particles flowing in the sorter. As a 
result, cancer cells that were immunomagnetically labeled with 1µm magnetic beads were sorted 
based on the different levels of magnetic bead attachment among them. In addition, the clinical 
utility of the device was demonstrated by processing pancreatic ductal adenocarcinoma (PDAC) 
blood samples from 6 patients and characterizing the isolated CTCs from these samples. Tumor 
cells were isolated based on low, moderate and high EpCAM levels and were studied and 
compared to determine any detectable differences such as detection rate, and morphological 
features. Thus, we demonstrated that even with cells that occur at a low frequency among non-
target cells, this approach can be applied in their isolation. 
3.3 Methods 
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3.3.1 Evaluating Cancer Cell EpCAM protein levels 
The feasibility of the immunomagnetic continuum sorting concept is predicated on 
heterogeneity in surface protein expression levels among the target cell. Thus we evaluated the 
differences in surface protein expression levels of cells within the same cell line passage to 
establish the practicality of the approach. EpCAM protein expression was studied since EpCAM 
is widely expressed among CTCs and is extensively used as the CTC capture antibody.
179
 
Additionally, the pancreas adenocarcinoma PANC-1 cell line was selected as a relevant 
reference alongside the PDAC patient samples that were included in the study. To characterize 
the levels of EpCAM on PANC-1 cells, it was assumed that for viable cancer cells that are mixed 
and allowed to incubate with antibody-coated, magnetic microbeads, the quantity of magnetic 
bead attachment to a cell indicates the available protein on the cell surface, provided that neither 
incubation time nor bead availability are limiting factors. To determine the distribution of 
EpCAM protein level among PANC-1 cells, cells were incubated with magnetic beads for 5, 10, 
15 and 30min and then immediately imaged for the level of bead coverage on the cells. After 
30min, there was negligible increase in cell bead coverage with beads compared to the 15min 
incubation period which supported the idea that incubation time was not a limiting factor. Each 
cell was categorized as having a surface coverage level of magnetic beads of either none, <1/3 
(low), 1/3 to 2/3 (moderate) or >2/3, (high) coverage (see Figure 3.1A). 
The magnetic sorting module is part of the previously reported integrated 
immunomagnetic microfluidic device shown in Figure 3.1B.
148
 The device was previously 
implemented to isolate rare CTCs from whole blood at a throughput of 24 mL h
-1
. The blood 
sample is first presorted to reduce erythrocyte and leucocyte contaminants, after which the 
sample mixes with magnetic beads on chip, followed by immunomagnetic sorting of 
magnetically labeled CTCs. Typically, the resulting sample is a significantly enriched suspension 
of CTCs.
148
 Based on the continuum of protein expression levels displayed by cells from the 
same passage, the next step was to determine whether the magnetic sorter module (outlined in 
Figure 3.1B) could be leveraged to effectively separate cell subpopulations based on incremental 
differences in protein expression. Figure 3.1C shows that for a cell suspension under flow in the 
magnetic sorter, an external magnet which is placed parallel to the main sorter channel attracts 
only magnetized cells to the collection outlet with high purities by separating them away from 
unlabeled cells.  
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We hypothesized that by adjusting the separation distance between the flowing cell 
suspension and the magnet at the micron scale, the magnetic field strength experienced by the 
magnetized cancer cells could be tuned. In so doing, the magnetic force experienced by cells 
could be tuned so that subsets of cells could be isolated based on their varying levels of magnetic 
bead coverage and thus, according to their levels of protein expression. Figure 3.1D illustrates 
the approach we hypothesized to separate cells from the same cell suspension according to low, 
moderate and high levels of EpCAM expression. For a wide separation gap only cells with very 
high magnetic bead attachment would experience a magnetic force strong enough to separate 
them from the flowing cell suspension. The effluent waste of the first magnetic sorter, now 
depleted of cells with high magnetic bead coverage  would then be processed through a magnetic 
sorter with a narrower separation gap so that cells having moderate bead attachment would be 
separated from the rest of cells into the collection stream. Ideally, the effluent waste of the 
second magnetic sorter, now depleted of cells with moderate bead coverage would contain cells 
having low to no bead attachment. Therefore cells from the same population would be separated 
according to low, moderate and high EpCAM levels. 
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Figure 3.1: Implementing Magnetic Sorter module for continuum sorting (A) Sorter 
outlined in illustration of the integrated magnetic cell sorting platform (B) Schematic of 
magnetic sorter outlets used to collect magnetized cancer cells (Scale bar represents 10μm). (C) 
Categories used to evaluate cell-magnetic bead coverage (D) Schematic of 2-tier magnetic sorter 
process used to isolate 3 cell populations based on low, moderate and high levels of protein 
expression. 
 
3.3.2 Tuning Magnetic Flux density to isolate cell subpopulations  
The magnetic flux profile in Figure 3.3A, generated in COMSOL, shows the variation of 
magnetic flux densities developed by a magnetic bead in the microfluidic channel, positioned at 
either the near edge (blue line) or far edge (black line) of the magnetic sorter where “near” and 
“far” represent distances from the magnet. Since the magnetic flux density decreases with 
increasing distance from the magnetic source, adjusting the distance between the magnetic 
particle and the external magnetic source alters the strength of the magnetic force experienced by 
the magnetized particle. Additionally, the intensity of the magnetic force is dependent on the 
magnetization of the magnetic particle, which correlates with the number of beads attached to 
each cell. By tuning the strength of the magnetic force developed via adjustment of the gap 
distance, cell subsets having low, moderate and high magnetic bead coverage and therefore 
expressing low, moderate and high EpCAM levels, respectively, could be individually isolated.  
Figure 3.3B shows the distribution of flowing cells in the magnetic sorter. As indicated 
by the rightmost arrow, the largest vertical distance a magnetized cell needs to traverse to be 
pulled into the collection channel, Ly, is 150μm. In the absence of beads or a magnet, and with 
sample input flow at set at 50 μLmin-1cells were tracked under a high speed camera in laminar 
flow through the microchannel and the cell linear velocity in the x-direction (ux) was determined 
to be 125mm s
-1
. So for a channel length, Lx=25mm in the direction of flow, the time that a cell 
is exposed to the magnetic field, or its residence time, tr was determined to be 0.2s. Based on 
these calculations, it is implied that a cell needs to travel a vertical distance, Ly, of 150μm in 
0.2s. Consequently, for tr= 0.2s and Ly= 150μm, the minimum vertical traversing velocity, uy, of 
the cell to successfully enter the collection channel is 750μm s-1. Achieving this velocity is 
dependent on cells having sufficient magnetic bead attachment to experience a sufficient 
magnetic force, FM, to magnetically pull them towards the collection channel. The minimum 
required bead attachment for a cell in turn, is dependent on the separation width, such that as 
distance increases, the minimum number of beads required increases.  
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To determine how the magnetic sorter separator width affected the minimum bead 
coverage required for a cell to be deflected and separated into the collection channel, four 
different separator widths, (400, 1200, 2300 and 3400µm) were studied. For a superparamagnetic 
microparticle exposed to a magnetic field range that saturates its magnetization, velocities are 
proportional to the magnetic field gradient. Assuming electrostatic and van der Waals forces are 
negligible and the magnetic force FM dominates, the drag force acting on the particle balances FM 
and so Stokes law can be applied.
180, 181
 Thus, under laminar flow, the magnetic force can be 
approximated such that, 
                            (1) 
where η is the fluid viscosity, ut is the terminal velocity in the direction perpendicular to flow 
(which was approximated by tracking bead movement across the channel), Dbead is particle 
diameter, and FD is the drag force.
180, 181
  
By the same token, for a magnetized cell,  
                            (2) 
Given that each bead attached to a cell contributes equally to the total FM cell, FM of the 
total number of beads is taken to be equal in magnitude to cell magnetic force and thus the cell 
drag force, FD cell. Moreover, the minimum magnetic bead attachment required by a magnetized 
cell for it to be deflected to the collection channel was determined by the magnetic force required 
to achieve a cell velocity of 750μm s-1. 
For the magnetic beads, the only unknown, ut was estimated by tracking and measuring 
the movement of a single magnetic bead in the microfluidic channel as demonstrated in Figure 
3.3C. In Figure 3.3C (i), y0, t0 corresponds to initial bead position at time 0s while y1 and t1 
correspond to positions 1 at time t1, and y2 corresponds to position 2 at time 2. For each width, to 
determine the velocities of the particles, magnetic beads were placed into the microfluidic 
channel and initially directed, magnetically to the channel edge further away from the designated 
position of the permanent magnet, at y0, t0. Then the permanent magnet was positioned at the 
designated gap distance and the movement of particles towards the permanent magnet, from y1 at 
time t1 to y2 at t2 was video recorded using a predefined frames-per-second (fps) rate. For each 
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gap width, the velocity of a single magnetic bead, ut=uy(bead) was determined based on these 
values. 
For N number of beads attached to a cell,  
 FM cell = [N • FM bead]    (3) 
By Stokes law,  
[Dcell • uy cell] = [N • Dbead •uy bead]  (4) 
Recalling that the minimum required bead velocity for successful deflection is 750µm s
-1
 and 
taking cell diameter as 20µm, for 1µm beads,  
N = [20µm •750µm s-1] /uy bead  (5) 
Using this approach, the minimum number of beads required for a cell to be isolated at each 
different separator width can be determined. In turn, this shows how cells from the same sample 
could be separated according to levels of low, medium and high protein expression, using the 
system. 
 
3.3.3 Establishing a workflow for continuum magnetic sorting of cells 
Considering the proposed workflow for separating cells according to their continuum 
level of EpCAM expression (Figure 3.1D), two different magnetic sorter gap widths, one 
narrower and one wider, were required for continuum cell sorting. To determine the most 
effective 2-sorter combination of widths that would facilitate isolation of relatively low, 
moderate and high EpCAM expressing cells, the four magnetic sorters of different gap sizes 
were each tested with magnetic bead-labeled cancer cells. This range of widths (400-3400µm) 
was specifically selected to avoid magnetic bead buildup in the channel. Bead buildup occurs 
with gaps that are too narrow, which leads to beads becoming entirely immobilized within the 
channel. Additionally, the range was selected to avoid too weak a magnetic field strength with 
gaps so wide that no magnetic particles or cells get magnetically deflected to the collection 
outlet. Firstly, each sorter was tested individually to evaluate the bead attachment on the cells 
isolated in both its waste and collection channels. A cell suspension was prepared at a spiking 
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rate of 10
3
 cells mL
-1 
from PANC-1 cells that were labeled with EpCAM conjugated magnetic 
beads.  Based on previous flow rate optimization with the magnetic sorter module, 1mL of the 
suspension was driven through the sorter at 50 µL min
-1
 with the upper and lower buffer streams 
flowing at 25 and 75 µL min
-1
 respectively.
148
 To evaluate and compare the ability of the devices 
to effectively sort magnetically labeled cells, the bead attachment of cells in the collection and 
waste outlets were analyzed.  
Then, to evaluate the effectiveness of the different 2-sorter combinations to sort cells 
according to low, moderate and high EpCAM levels, labeled cancer cells (10
4
 cells mL
-1
) were 
processed using the decided workflow. Then FACS analysis was performed to determine the 
level of EpCAM on the magnetically separated cell subsets. Once cells were sorted based on 
low, moderate and high EpCAM levels, the samples were analyzed using the MoFlo Astrios EQ 
flow cytometer. The samples were gated based on the relative EpCAM fluorescence intensity of 
the unstained, negative control using Summit 6.3 software. FACS dot plots of particle size (FSC-
1 Height) versus particle fluorescence intensity (EpCAM log FL10 height) for control unstained 
cells, and for cells sorted according to low, moderate and high protein expression levels are 
shown in Figure 3.3C. To better quantitate and compare the relative levels of EpCAM in each of 
the magnetically sorted populations, FACS readouts of cell fluorescence intensities were 
analyzed by converting the FSC files to CSV files using Flowjo software. 
 
3.3.4 Scratch Assay of Cell Subpopulations  
Traditionally scratch assays have been carried out to investigate the relative proliferation 
and migration rates of mammalian cells, which in turn, could be indicative of the invasive 
potential of cells.
182, 183
 To investigate whether the samples sorted according to varied EpCAM 
protein levels would display unique physiological differences beyond surface EpCAM 
expression, a scratch assay was carried out on cell subsets sorted according to low, moderate and 
high EpCAM levels. A control population that was not processed through the magnetic sorters 
was also investigated for comparison. To conduct the scratch assay, 3mL of a sample containing 
viable, EpCAM-bead labeled PANC-1 cells was processed through the 2300µm magnetic sorter 
gap. The cells emerging from the collection channel of this wider sorter was designated as high 
expression. Then the waste effluent was processed through the 1200µm magnetic sorter so that 
the cells emerging from the collection channel was plated and designated moderate expression 
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while the waste channel was designated low expressing cells (see Figure 3.6A). Once low, 
moderate and high expressing cells were plated, the cell count in each well was adjusted by 
resuspending the cells so that cell densities would be comparable among the four samples. 
Additionally, EpCAM-bead labeled cells from the same cell line passage, that were not 
magnetically sorted, were plated at a comparable cell density to use as a control. To perform the 
scratch, for each well, once ~80% confluence was achieved in the well, a scratch was performed 
using a micropipette tip on day 0 and the healing rate of the scratch was monitored by capturing 
images of each well on day 1 and then each day until the scratch healed or up to day 13. By 
measuring the rate at which the scratch was repopulated with new cell growth over the cleared 
surface for each sample, the invasive potential among the samples could be compared. For each 
scratch, on each day three measures of the scratch width were taken and the average width was 
recorded. The rate of scratch healing was determined for each condition by plotting the average 
scratch width (μm) as a function of time (days). 
In determining the healing rate for each sample, normalization was conducted based on 
cell density recorded immediately after plating each sample. The change in scratch width was 
divided by cell density for each condition, each day and plotted as a function of time. Figure 
3.4C is an example of a plot obtained for the control condition. As an estimate of the scratch 
healing rate, the negative slope of the scratch healing rate was compared among the four 
conditions. Additionally to investigate whether cells would maintain these relative EpCAM 
expression levels after sorting, cells sorted according to the continuum approach of low, 
moderate and high EpCAM expression were cultured for six days. On day six cells were 
relabeled with EpCAM beads and incubated for 20min. Images of cells from each group were 
immediately taken and bead attachment on cells was quantified. 
 
3.3.5 Continuum isolation of PDAC derived CTCs 
To determine whether a continuum isolation approach could be useful in the context of 
patient derived CTCs, six PDAC patient samples processed using the established sorting method. 
The goal was to determine whether subsets of CTCs in the patient samples could be isolated 
based on the level of their EpCAM expression. For each sample, 5mL of patient blood was 
presorted using the inertial spiral sorter of the previously reported integrated microfluidic 
system.
148
 The effluent of the spiral was then directly mixed with EpCAM magnetic beads on 
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chip via the passive mixer and the mixture was allowed to incubate for 20 minutes. The sample 
was then processed using the established workflow to sort the CTCs according to low, moderate 
and high levels of EpCAM. CTCs were identified as cells staining positive for nuclear content 
with DAPI, being panCK+ or CK19+ and CD45-. In most instances, EpCAM bead labeling 
served as an additional means of identifying epithelial derived CTCs. 
 
3.4 Results  
3.4.1 Cancer Cell EpCAM protein levels   
Results of cancer cell line labeling with magnetic beads are as shown in Figure 3.2. Even 
after 30min of incubation, almost 3% of PANC-1 cells still maintained <1/3 bead coverage, thus 
indicating a relatively negligible EpCAM expression among those cells. 8% of cells had >2/3 
bead coverage, indicating high expression levels of EpCAM in this subset of cells. MiaPACA-2 
cells, which are known to express low EpCAM levels, were tested as a control, using the same 
procedure. For MiAPaca-2 cells, as much as 64% of cells showed <1/3 EpCAM bead coverage 
after 30min of incubation. Based on these results from magnetic bead attachment, PANC-1 
cancer cells from the same passage, which are relatively homogenous compared to tumor cells in 
circulation, demonstrate different levels of protein expression. In turn, this supports the 
heterogeneity that exists among cells within the same tumor and points to the possibility of 
sorting cells according to some continuum of surface-protein expression levels.  
 
3.4.2 PANC-1 isolation according to low, moderate and high EpCAM levels. 
Figure 3.3D shows how bead velocity uy varies with gap widths where, as the gap width 
increases, uy appears to decrease linearly. This relationship affects the number of beads required 
for cells to be sorted successfully given the sorter dimensions and sample flow rate of 50µL min
-
1
. For instance, based on such calculations, with a gap size increase from 400 to 1200µm, the 
minimum number of beads required increases 1.2 fold while an increase to 3400µm requires a 7 
fold increase in the minimum number of beads required (see Figure 3.4A). Overall, it can be seen 
that at sufficiently large of a gap size, only cells having relatively high bead attachment can be 
magnetically deflected and collected, while cells having fewer beads remain in the waste stream. 
Based on these results, this approach enables cells from the same sample to be separated 
according to levels of low, medium and high protein expression. 
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Figure 3.2: PANC-1 and MIAPaCa-2 EpCAM bead labeling. Cells and beads undergo static 
incubation for 5-30min resulting in ~3% of PANC-1 cells and >65% MIAPaca-2 cells with <1/3 
bead coverage after 30min incubation.  
 
Among the four sorters, as the gap size increased there was an increase in the percentage of cells 
that have full bead coverage in the collection samples (Figure 3.4B). Interestingly, as the gap size 
increased the percentage of cells having entirely full bead coverage increased, yet the overall 
recoveries of cells with >2/3 bead coverage decreased. This indicated that cell isolation in the 
3400μm sorter required extremely high (full) bead attachment to be successfully isolated. As 
such, gap widths of 1200µm and 2300µm were selected for the 2-sorter separation workflow 
where there is a significant increase in the fraction of cells having extremely high EpCAM 
expression sorted from the 2300µm sorter compared to the 1200µm sorter. The procedure 
adopted to sort cells in a continuum manner involved initial cell sorting through a sorter with 
2300µm gap to collect high EpCAM expressing cells. This is followed by cell sorting of the 
waste outlet through a sorter with 1200µm gap to collect moderate EpCAM expressing cells 
from the collection outlet and low EpCAM expressing cells from the waste outlet. 
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Figure 3.3: Controlling Particle Magnetic Force (A) COMSOL simulation of magnetic flux 
density at the near edge (blue line) and far edge (black line) of the channel in relation to the 
external magnets. (B) The sample is confined to middle of magnetic sorter channel with only 
magnetic labeled cells deflected and separated (C) Tracking a single magnetic bead to determine 
bead velocity dependence on (D) Plot shows how bead velocity varies as a function of gap 
distance between magnet and channel. 
 
Analysis of the FACS data gave detailed information about the level of EpCAM expressed 
within each cell subset, beyond what was immediately observable with the FACS dot plots. As 
seen in the histogram plot in Figure 3.4D, the fraction of cells expressing the highest EpCAM 
fluorescence of logFL10 height of ≥4 increased in moving from low to moderate to high EpCAM 
expression. Additionally, in moving from low to moderate to high EpCAM expression, there was 
a progressive decrease in the fraction of cells with lowest EpCAM expression. Therefore these 
FACS results are in agreement with results obtained from brightfield imaging analysis of bead 
coverage on cells from the three samples.  
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Figure 3.4: Tuning Magnetic Force to sensitively isolate cell subpopulations (A) Effect of 
magnetic sorter gap width on amount of cell-magnetic bead coverage required for cell isolation 
(B) Effect of gap width on isolation of cells with full magnetic bead coverage and on recovery of 
cells with >2/3 bead coverage. (C) FACS dot plots and (D) FACS histogram of EpCAM protein 
detected from PANC-1 cells isolated according to low, moderate and high EpCAM protein 
expression. 
 
Figure 3.5 shows that even after six days of culturing, cells that were sorted according to 
low, moderate and high EpCAM expression appear to maintain the same relative EpCAM 
expression levels. Cells originally sorted according to low EpCAM expression showed 43% of 
cells with <1/3 coverage compared to 40% and 8% among moderate and high expressing cells 
respectively. Conversely, cells expressing high EpCAM levels had 64% of cells showing full 
surface coverage of cells compared to ~40% of cells in both low and moderate expressing 
subsets. Overall, the cells that were originally sorted as high EpCAM expressing cells maintain 
the highest percentage of cells with full bead coverage while the group of cells isolated as low 
EpCAM expressing cells demonstrate the highest percentage of cells with <1/3 bead coverage. 
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Figure 3.5: Evaluation of EpCAM bead binding to sorted and cultured PANC-1 cells. Cells 
were sorted according to low, moderate and high EpCAM expression then cultured for 6 days 
and relabeled with EpCAM beads. 
 
3.4.3 Comparing scratch-healing rates among cell subpopulations  
The procedure carried out for the scratch healing assay is illustrated in figure 3.6A where 
healing rates for cells sorted according to low, moderate and high EpCAM expression were 
monitored. Figure 3.6B is an example of the scratch healing rate plot obtained for the control 
condition showing an initial scratch width of ~1mm on day 1,  which decreases to 500μm by day 
5. Figure 3.6C shows the relative scratch healing rates for each condition, which factored in the 
initial cell seeding density recorded for each well. As seen in Figure 3.6C the level of EpCAM 
expression on cell subpopulations appears to directly correlate with the scratch healing rate such 
that, as the level of EpCAM increases, the scratch healing rate also increases. The control 
population of cells appears to heal more rapidly than cells isolated according to low protein 
levels. While the bio-physiological basis for these results needs to be further investigated, results 
demonstrate that the continuum sorting approach was able to separate cell subpopulations that 
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display unique phenotypic qualities after being cultured. This was reflected in the different 
scratch healing rates of the unique cell populations.  
 
 
 
Figure 3.6: Tumor Cell Scratch Assay of low, moderate and high EpCAM levels (A) 
Schematic of process used for isolating cells according to 3 varying levels of EpCAM and 
performing scratch assay with isolated cells (Arrow indicates time progression from day 0 to 
time of scratch healing). (B) Example of plot of scratch healing rate for control sample (C) 
Normalized growth rates for cell subpopulations based on EpCAM expression levels 
 
3.4.4 CTC isolation according to low, moderate and high EpCAM levels  
Results for the six PDAC patient samples that were sorted according to the established 
EpCAM based continuum sorting approach are shown in Figure 3.7A. Among the 6 patients, the 
majority of CTCs appear to express low levels of EpCAM (mean = 66.2% ±23.45) compared to 
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moderate (mean = 12.9% ±11.87) or high (mean = 20.9% ±20.23) expression levels.  Figure 
3.7B shows brightfield and immunofluorescent images of CTCs isolated based on low, moderate 
and high EpCAM expression levels. Especially with brightfield capture, the heterogeneity among 
CTC EpCAM expression can be readily observed. In turn, this points to the potential to 
discriminate among different CTC subpopulations according to their surface protein levels using 
the approach described.  
 
 
Figure 3.7: Continuum isolation of PDAC CTC (A) Percentage of CTCs isolated according to 
low, moderate and high EpCAM levels. CTCs/mL for each patient is indicated above bar. (B) 
Brightfield and immunofluorescent images of CTCs isolated based on low, moderate and high 
EpCAM expression levels (Scale bars represent 20μm). 
 
 
3.5 Discussion  
Numerous reports so far have described probable mechanisms of cancer metastasis, and 
how distinct cell subpopulations that comprise the tumor may uniquely contribute to the invasive 
metastasis cascade. Therefore, platforms to separate tumor cells according to their different 
subpopulations are crucial. Most studies characterize tumor cells according to positive and 
negative expression of proteins of interest without consideration of moderate expression of 
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protein levels. Here we report isolation of PANC-1 tumor cells according to low moderate and 
high levels of EpCAM protein. FACS analysis on the samples corroborated the ability of the 
described approach to sort cells according to EpCAM expression levels. Additionally, 
characterization of tumor cells according to such categories revealed notable differences among 
the three groups based on invasive properties. Furthermore, processing PDAC patient samples 
according to the continuum sorting approach revealed that the majority of PDAC samples 
contain CTCs that were categorized at all three expression levels. We have demonstrated a 
sensitive and reproducible approach to isolate cancer cell populations according to a continuum 
of surface protein expression levels and demonstrated the clinical relevance of the system via 
CTC isolation. The work represents a step towards studying the complexities of tumor cell 
heterogeneity, as evidenced by a detectable continuum of surface protein expression among cell 
lines as well as circulating tumor cells.  
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Chapter 4 
Dual-Marker Isolation and Characterization of 
Pancreatic Ductal Adenocarcinoma Circulating 
Tumor Cells via EpCAM- and CD44- based 
Immunomagnetism 
4.1 Abstract  
While the significance of epithelial-to-mesenchymal transition (EMT) programs to tumor cell 
heterogeneity and the invasive metastasis cascade are currently being elucidated, their 
anticipated roles have led to increased efforts to identify and characterize different tumor cells 
subpopulations. Moreover, characterization of circulating tumor cells (CTCs) based on their 
stemness or cancer-initiating potential has buttressed some proposed mechanisms of metastasis 
that implicate the concept of cancer stem cells. Apart from the established epithelial marker 
EpCAM, expression of the stem cell marker CD44, among pancreatic cancer CTCs has taken on 
particular importance since these cells demonstrate an enhanced metastatic potential. To study 
whether CD44-based CTC isolation would contribute to any immediate differences among CTCs 
enriched from pancreatic cancer samples, we analyzed CTCs from ten patient samples isolated 
via an immunomagnetic approach. Magnetic beads conjugated with anti-EpCAM as a standalone 
antibody or in combination with anti-CD44 conjugated beads were used. Results show that 
within this patient cohort there was no significant difference (p=0.328) in detection rates between 
EpCAM+CD44 dual isolation (average CTCs/mL=64±63) compared to EpCAM only isolation 
(average CTCs/mL=42±33). Additionally, among the 8 samples in which CTCs appeared in 
clusters, their detection was independent of whether standalone EpCAM or EpCAM-CD44 
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combination was used (p=0.593). Of note, CDKN1A (p=0.0140, logFC=11.586) as well as 
HSP27 (p=0.0044, logFC=10.139) were more highly expressed in samples with >50% CTCs in 
clusters, to a significant degree. In contrast, ERCC1 (p=0.0140, logFC=-2.856), CTNNB1 
(p=0.0460, logFC=-13.473), PARP1 (p=0.0068, logFC=-7.231), as well as FBXW7 (p=0.0350, 
logFC=-7.231) were all expressed more highly in samples with <50% CTCs in clusters, to a 
significantly extent. Interestingly, among patients with borderline resectable/resected disease, 
CTC mRNA profiles for EpCAM-CD44 isolation clustered distinctly from those isolated solely 
with EpCAM (n=5). This distinction was not observed among patients with borderline 
unresectable/unresected disease (n=3). Though preliminary, studies as such can be used in 
further characterization of pancreatic cancer metastatic advance. 
 
4.2 Introduction  
The putative role of circulating tumor cells (CTCs) in cancer metastasis has led to rapidly 
increasing interest in these rare, blood-borne cells as they hold the potential to understand how 
cancer thrives and spreads in a facile, clinically relevant manner.
184
 Furthermore, the epithelial-
to-mesenchymal transition (EMT) of primary tumor cells, where cells evolve from an epithelial 
state to become more motile and intravasate into the circulation, is thought to be the first stage of 
the invasion metastasis cascade.
185, 186
 After these cells extravasate from the circulation to  a 
distant site, they are thought to regain their epithelial characteristics in order to seed 
micrometastases at a distant location, in the reverse process, termed mesenchymal to epithelial 
transition (MET).
187
 More recent studies support the existence of a hybrid 
epithelial/mesenchymal phenotype wherein cells have undergone a partial or incomplete EMT. 
These cells are believed to exhibit stemness and are thought to be a major target in fighting 
disease relapse and metastasis.
185, 186, 188
  
Cancer stem cells (CSCs) represent a subset of CTCs thought to have self-renewal 
capacity with the ability to regenerate the distinct subpopulations of cells that comprise the 
original tumor.
189
 
190, 191
 Studies in breast cancer have demonstrated how progressive 
overexpression of EMT markers in carcinomas is associated with acquisition of the stem cell 
marker CD44, in addition to demonstrating that CTCs display an enhanced EMT program.
104, 192
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So far several studies have reported on CSC expression of CD44 and ultimately on the important 
role CD44 plays in the progression of many tumor types including pancreatic cancer.
193, 194
 
While these cells account for a small percentage of all tumor cells, they are highly resistant to 
apoptosis and have been implicated in metastasis even after extended periods of dormancy. They 
are believed to be directly responsible for the persistence and spread of cancer in many solid 
tumor cancers, including pancreatic cancer.
191
 
190
 Identification of a highly tumorigenic 
subpopulation of pancreatic cancer stem cells was reported that expressed the markers CD44, 
CD24 and ESA.
27
 One report described how a CD44+ subpopulation of pancreatic cancer cells 
was able to reproliferate and regenerate a gemcitabine resistant cell subpopulation after high 
dosage exposure to the chemotherapy.
195
 In fact findings from initial preclinical trials support the 
idea that CSC functioning can be ablated by therapeutic targeting of CD44.
194
  Understanding the 
role of CD44 in the functioning of these cells in metastasis is becoming more relevant to current 
efforts aimed at treating and monitoring patients.  
Additionally, the detection of CTCs grouped in cell clusters, also described as circulating 
tumor microemboli (CTMs), has been the topic of interest of more recent CTC studies 
196-198
 
173, 
177
 These cells co-express epithelial and mesenchymal markers.
186
 Studies involving cancer 
patients as well as animal models indicate that CTC clusters have an enhanced ability to mediate 
cancer metastasis compared to single CTCs.
173, 177
 The presence of multicellular clusters in one 
breast cancer patient accompanied an increase in mesenchymal CTCs. Interestingly, such 
clusters appeared to be absent from samples in which the majority of CTCs had an epithelial 
phenotype.
104
 Detection of CTC clusters was also reported in patients with varying stages of non-
small cell lung cancer (NSCLC).
196-198
 So far few studies have described the isolation and 
characterization of clusters derived from pancreatic ductal adenocarcinoma (PDAC). One report 
described the detection of clusters in 4 out of 18 pancreatic cancer patients through the use of an 
enrichment free immunofluorescence approach.
199
 Another study which employed the 
commercially available ISET platform, reported cluster detection in 3 of 10 pancreatic cancer 
patients as well as the presence of both epithelial and mesenchymal markers on cells comprising 
the clusters.
115
 A recent study reported on detection of CTMs in 81% of PDAC patients, 
demonstrating that CTM detection could be an independent prognostic factor of overall 
survival.
177
 Taken together, focus on the clinical significance of cluster appearance in cancer 
patients can potentially shed more light on metastasis.  
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The integrated microfluidic magnetic cell sorter is amenable both to single CTC isolation 
and CTMs in an enriched manner, so that the cells are made available in suspension for 
subsequent analyses.
148
 The platform first presorts cancer cells using size based inertial sorting, 
allows the enriched CTCs to be labeled with CTC-specific antibody coated magnetic beads, then 
further sorts the cells using immunomagnetism to obtain a highly enriched CTC suspension. 
Previously EpCAM was used as a standalone antibody for CTC isolation with this platform. 
Given the importance of CD44+ tumor cells in circulation and driven by the concern that 
standalone EpCAM CTC isolation could potentially preclude detection of this important subset 
of CTCs, we adapted the platform to allow CD44 based CTC isolation. Following we report on 
comparison of CTCs and CTMs isolated using both EpCAM and/or CD44 from pancreatic 
cancer patients. Molecular characterization of CTCs was also performed to determine whether 
patterns associated with the different isolation approaches could be observed.  
4.3 Methods  
4.3.1 Evaluation of cancer cell immunomagnetic isolation using cells lines 
To evaluate the dual marker immunomagnetic isolation approach with EpCAM and 
CD44 in the integrated device, cell line experiments were carried out using MIA PaCa2 and 
PANC-1 pancreatic cancer cell lines. Anti-EpCAM- and anti-CD44- antibody coated magnetic 
beads were used to magnetically isolate cells during testing. Firstly, as a control experiment each 
cells line was incubated with a mixture of both types of beads to evaluate bead-cell labeling. As 
seen in Figures 4.1A and 4.1B, different size beads were used to distinguish between antibodies. 
1μm beads are coated with anti-CD44 antibody while 2.85μm beads are coated with anti-
EpCAM antibody. Figures 4.1A and 4.1B are representative images of the extent of magnetic 
bead labeling of PANC-1 and MIAPaca2 cells respectively. Overall, MIAPaca2 showed 
negligible labeling with EpCAM beads with more significant labeling with CD44 beads. PANC-
1 cells experienced a significant extent of labeling with EpCAM coated beads while labeling 
with CD44 beads appeared relatively low. Therefore PANC1 and MIAPaca2 cells demonstrated 
preferential antibody-based bead labeling with EpCAM and CD44 respectively. 
Given these results of preferential bead labeling, further experiments were carried out to 
characterize magnetic sorting and isolation of a mixture of the magnetically labeled cancer cells 
using each marker. Specifically, PANC-1 cells (dyed with CellTracker Red) and MIAPaca-2 
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cells (dyed with Cell Tracker Green) were separately incubated with 1μm EpCAM beads for 
40min and then fixed. The same procedure was carried out with each cell line using 1μm CD44 
beads.  Then for each marker, a cell suspension was prepared by evenly spiking PANC-1 and 
MIAPaca2 cells at 10
4
 cells mL
-1
 in buffer. The sample was then processed through the magnetic 
sorter module of the integrated device, using either anti-EpCAM or anti-CD44 coated beads 
separately for magnetic sorting. For each marker, experiments were repeated x3. Cells emerging 
from the collection channel of the magnetic sorter were scanned and analyzed for the number of 
PANC-1 cells (red) and MIAPaca-2 cells (green) successfully sorted. 
 
4.3.2 EpCAM- versus CD44- based CTC isolation  
Ultimately the ability to isolate and compare CTCs using dual marker isolation can 
potentially reveal tumor cell biology pertinent to EMT and metastasis.
148
 The previously reported 
integrated microfluidic immunomagnetic approach for CTC isolation was optimized to isolate 
CTCs expressing both EpCAM and CD44 surface proteins (see Figure 4.1D).With the whole 
blood samples obtained from patients, the blood was first processed through the inertial sorter to 
presort CTCs from other blood cell contaminants. The CTC enriched sample was then mixed and 
incubated for 20min with 1μm magnetic beads coated with either anti-EpCAM or anti-CD44, or 
a combination of the two types of beads. Then the sample was processed through the magnetic 
sorter to isolate CTCs labeled with magnetic beads. To directly compare EpCAM and CD44 
CTC detection rates , in one patient cohort (n=8), 5mL of sample was divided into 2, with half of 
the sample processed using EpCAM beads while the other half was processed using CD44 beads. 
The final samples that emerged from the magnetic sorter were then centrifuged to reduce the 
volume for immunofluorescence staining. The samples were then cytospinned and fixed to do 
immunofluorescence staining for CTC identification and enumeration. 
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Figure 4.1: Dual Isolation of CTCs. (A) PANC-1 cells shows significant extent of labeling with 
2.85μm EpCAM coated magnetic beads 1μm magnetic beads coated with CD44 compared to 
2.85μm EpCAM coated magnetic beads. (B) MIAPaca-2 cells shows preferential labeling with 
1μm magnetic beads coated with CD44 but negligible labeling with 2.85μm EpCAM coated 
magnetic beads (C) Magnetic Sorting  results of cancer cell line experiments using 1μm EpCAM 
and CD44 coated beads (D) Schematic depicting dual isolation workflow for CTCs using 
EpCAM and CD44. 
 
4.3.3 Comparing Vimentin expression among EpCAM- versus CD44- isolated CTCs  
Studies show that the more aggressive CSCs that are responsible for cancer relapse 
express markers that are relevant to the EMT process. One such EMT marker is Vimentin which 
is expressed by mesenchymal cells.
200
 Additionally, in this patient cohort, Vimentin staining was 
carried out with 6 of the 8 patient samples to determine if there were any correlations with 
Vimentin expression and the isolation antibody used. To identify four markers with 
immunofluorescence staining, specifically cytokeratins, CD45, Vimentin and DAPI, the CTC 
staining protocol was modified. Samples were stained for cytokeratin-19, panCK, and Vimentin 
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as positive stains while the leucocyte marker CD45 was used as a negative stain. DAPI was used 
to identify nuclear content. AlexaFluor 647 (Life Technologies) was used for immunofluorescence 
labeling of Vimentin.  
 
4.3.4 Dual Marker Isolation for molecular profiling studies 
Recent studies support the existence of a hybrid epithelial/mesenchymal phenotype 
wherein cells have undergone a partial or incomplete EMT implicit of which is the continued 
expression of epithelial markers such as EpCAM. It is these cells that are believed to exhibit 
stemness and are thought to be a major target in fighting disease relapse and metastasis. Given 
this possibility of a sustained expression of EpCAM among the more stem-like CTCs, we 
isolated and compared CTCs among patients using EpCAM and a combination of 
EpCAM+CD44. Apart from CTC enumeration studies, CTCs were also molecular profiled for 
mRNA expression levels. In this patient cohort (n=10), half of the 5mL sample was processed 
using a suspension of EpCAM beads while the other half was processed using a combination of 
EpCAM and CD44 beads. Samples were processed as previously described. In order to 
determine CTC detection rates as well as leucocyte contamination, a small volume of the 
resulting cell suspension for each type of isolation approach was immunofluorescently stained 
for cytokeratin-19 and panCK as positive stains while the leucocyte marker CD45 was used as a 
negative stain. DAPI was used to identify nuclear content. For the remaining volume of the 
resulting cell suspension, total RNA extraction was performed in order to do mRNA profiling for 
each sample. 
 
4.3.5 Immunofluorescent staining of patient samples 
Samples were stained for CTC markers using a primary antibody for anti-cytokeratin-19 
(CK-19), epithelial cell marker, (Santa Cruz Biotechnology, rabbit polyclonal IgG), panCK 
(Santa Cruz Biotechnology, rabbit polyclonal IgG), and nuclear stain 4',6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI, Invitrogen). Negative staining with the leukocyte marker 
anti-CD45 (BD Pharmigen Purified Mouse Anti-Human CD45, HI30 clone, isotype Mouse 
IgG1, ƙ) was also performed. Samples were then stained using secondary antibodies with 
fluorescence conjugation namely, AlexaFluor 568 (Life Technologies), for CK-19 detection and 
AlexaFluor 488 (Life Technologies), for CD45 detection. For the samples that were stained for 
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Vimentin, the primary antibody anti-vimentin (BD purified mouse anti-vimentin, RV202 clone, 
isotype IgG1) and the secondary antibody AlexaFluor 647 (Life Technologies) were used. 
Negative staining was done with the leukocyte marker anti-CD45 (BIO-RAD mouse anti human 
CD45, clone F10-89-4) and the secondary antibody AlexaFluor 488 (Life Technologies). For the 
primary antibody stains, an overnight incubation period was carried out, while for secondary 
staining, 1hr was allowed. For DAPI staining ProLong Gold anitfade mountant with DAPI, (Life 
Technologies) was applied overnight. Immunofluorescence imaging for anti-CD45 was 
performed using a FITC filter while anti-CK was performed with a PE filter and DAPI, a UV 
filter at x20 magnification. 
 
4.3.6 Messenger RNA profiling of CTC samples isolated using EpCAM and CD44 
To isolate total RNA, after enriching CTCs from 5 mL of patient blood, RNA was 
isolated using the Norgen Single Cell RNA Purification kit (Norgen Biotek Corp.), according to 
the manufacturer’s protocol, with minor modifications. After lysing the cells the CTC lysates 
were then stored in -80⁰C until total RNA purification was ready to be carried out. For total 
RNA purification, samples were thawed on ice and 200μL of 96-100% ethanol was added to the 
cell lysate and vortex mixed for 10 seconds. RT was carried out on the purified RNA followed 
by pre-amplification (18 cycles) using cDNAs corresponding to 96 genes of interest from a CTC-
specific panel. The pooled TaqMan Gene Expression Assays and Cell-to-CT Kit (Ambion, 
Invitrogen) was used. TaqMan Gene Expression Assays for the 96 genes and the BioMark HD 
qPCR platform (35 cycles) was used to carry out gene expression profiling of the pre-amplified 
cDNAs. For genes undetected during qPCR, a cycle number of 40 was assigned for analysis 
purposes. To normalize Ct values among different genes, GAPDH was used as an internal 
reference. Statistical analysis was performed based on –ΔCt of gene expression. 
 
4. 4 Results 
 
4.4.1 EpCAM- and CD44- based immunomagnetic isolation of cells lines 
For experiments done to evaluate immunomagnetic isolation of cells lines, cells emerging 
from the collection channel of the magnetic sorter were scanned and analyzed for the number of 
PANC-1 cells (red) and MIAPaca-2 cells (green) successfully sorted. Upon quantifying the 
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magnetic sorting process, Figure 4.1C shows that for each marker, magnetic sorting was able to 
recover comparable quantities of each type of cell, especially among MIAPaca-2 cells. For 
EpCAM isolation, a larger fraction of PANC-1 cells (67% versus 33%) were isolated probably 
because these cells showed preferential EpCAM labeling, compared to the negligible EpCAM 
bead attachment shown among MIAPaca2 cells. Likewise with CD44 isolation, MIAPaca-2 cells 
had slightly higher isolation efficiency (53% versus 47%) since MIAPaca-2 cells showed 
preferential CD44 labeling. Overall, the magnetic sorting process demonstrated the ability to 
isolate cells expressing a range of magnetic bead attachment, regardless of the marker used for 
immunomagnetic attachment of beads to cells. 
 
4.4.2 EpCAM- versus CD44- based CTC isolation 
After processing the 8 patient samples for EpCAM- and CD44- based CTC isolation, 
samples were analyzed for their CTC counts. CTC detection rates for the two sets of CTCs 
isolated using either EpCAM or CD44 are as seen in the boxplot in Figure 4.2A. While there was 
no significant difference in CTC detection rates (p=0.722) between the two groups, the average 
CTC detection rate was higher in CD44 isolation (average CTC/mL=5.5±4.09) compared to 
EpCAM isolation (average CTC/mL=3.7±2.80). Notably, CTC counts appear lower than counts 
among the other patient cohort later discussed possibly due to centrifugation process for volume 
reduction that was carried out with all samples. 
 
4.4.3 Vimentin expression among EpCAM- versus CD44- isolated CTCs  
For samples processed with EpCAM- and CD44 based CTC isolation, Vimentin staining 
was carried out with 6 of the 8 patient samples. The fraction of CTCs staining positive for 
Vimentin was calculated as a percentage of all detected CTCs for each sample. Figure 4.2D 
shows to sets of cells that stain positive for Vimentin. Results show that across the six patient 
samples analyzed Vimentin expression among CTCs isolated with the two markers did not yield 
any significant difference. While there was no significant difference in CTC detection rates 
between the two groups (p=0.465), the average percent of Vimentin+ CTCs detected was slightly 
higher with CD44 isolation (average % vim+ CTCs=39.2±33.2) compared to EpCAM isolation 
(average % vim+ CTCs=34.4±33.6).   
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Figure 4.2: Patient CTC Analysis isolated using EpCAM and/or CD44. (A) Box plot of CTC 
enumeration using EpCAM isolation versus CD44 isolation. (B) Box plot of CTC enumeration 
using EpCAM isolation versus EpC+CD44 dual marker isolation. (C) Detailed CTC enumeration 
among 10 patients using EpCAM isolation versus EpC+CD44 dual marker isolation. (D) CTCs 
staining positive for the mesenchymal marker Vimentin. 
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Figure 4.3: Analyzing CTC clusters. (A) CTC clusters detected in patients showing two, three 
and greater than three CTCs (scale bar =20μm). (B) Percentage of cells in clusters isolated using 
either EpCAM or EpCAM+CD44 isolation. Table shows numbers of cells in clusters. 
 
4.4.4 Analysis of CTC clusters  
Detection of CTCs grouped in cell clusters, have demonstrated co-expression epithelial 
and mesenchymal markers.
186
 Studies involving cancer patients as well as animal models 
indicate that CTC clusters have an enhanced ability to mediate cancer metastasis compared to 
single CTCs.
173, 177
 Of the 10 patient samples that were analyzed, eight of them had CTCs 
grouped in cell clusters which ranged from as least two grouped CTCs to greater than 7 grouped 
CTCs. Specifically, clusters were detected in seven of the eight patients isolated with 
EpCAM+CD44 compared to six of eight samples processed with EpCAM standalone. Figure 
4.3A shows isolated CTCs that appear clustered together, consisting of two, three and greater 
than 3 CTCs. A comparison of the percentage of cells occurring in clusters between cells isolated 
with EpCAM only and cells isolated with EpCAM+CD44 revealed that here was no significant 
difference (p=0.593) with both methods of isolation. Moreover results demonstrated that very 
similar percentages of cells appeared in clusters, with EpCAM having on average 35.7%±22.7 
and CD44 having 35.3% ±20.8 cell in clusters. 
 
4.4.5 EpCAM versus EpC+CD44 CTC enumeration and molecular profiling  
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For the 10 samples processed using both EpCAM and EpC+CD44 CTC isolation, Figure 
4.2B shows CTC detection rates across all samples. Moreover, Figure 4.2C gives detailed CTC 
enumeration among these 10 patients using EpCAM isolation versus EpC+CD44 dual marker 
isolation. While there was no significant difference (p=0.328) in CTC detection rates between 
the two method of isolation, overall EpCAM based isolation appeared to have a higher detection 
rate with an average of 64.3 ± 65.6 CTCs/mL compared to EpCAM in combination with CD44 
which had an average of 40.1±34.7 CTCs/mL. 
Also, mRNA profiling was conducted on CTCs samples obtained from this 10-patient 
cohort. RNA samples were stored at -80⁰C until was carried out on the samples. For mRNA 
profiling a CTC-specific array of 96 genes was used. Of the twenty samples profiled from the ten 
patients, only nine pairs were considered since the RNA quality from one pair was deemed unfit 
for profiling. Interestingly, unsupervised hierarchical clustering showed that CTC profiles 
clustered independent of the marker(s) of isolation used such that EpCAM isolated CTC profiles 
grouped with EpCAM+CD44 profiles (see Figure 4.4A). Moreover, among the eighteen sample 
profiles 2 resected pancreatic ductal adenocarcinoma patients, 2 borderline patients that were 
resected but later showed suspicious pathologies, and 2 resected patients with recurrence or 
metastases clustered together. These pairs occurred regardless of the isolation method used. A 
log fold change (logFC) comparison of mRNA expression was carried between EpCAM and 
EpCAM+CD44 samples. As seen in Figure 4.4B, this analysis revealed that some genes such as 
MMP6, CDA, DCK, CTNNB1 and ALDH1A3, that were more highly expressed in the EpCAM 
only group compared to the EpCAM+CD44 group, having logFC of >2.  Several genes such as 
CD20, BAX, JUN and ABL1, among others, were lower expressed in the EpCAM only group, 
having logFC of <-2. Specifically, ANXA2 (p=0.0400) was significantly lower in EpCAM 
samples compared to EpCAM+CD44 samples, having a logFC of -1.08.  
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Figure 4.4: Molecular Profiling of CTCs isolated using EpCAM and or CD44 (A) Heat map 
showing hierarchical clustering among all patient samples (B) LogFC in gene expression among 
EpCAM isolated CTCs compared to EpC+CD44 isolated CTCs (C) LogFC in gene expression 
among samples with >50% of cells in clusters compared to samples with <50% of cells in 
clusters. 
 
 102 
 
 
Figure 4.5: mRNA expression profile comparison among Borderline patients: (A) Heat map 
showing clustering of CTC mRNA profile among resectable/resected patient (B) Heat map 
showing clustering of CTC mRNA profile among unresectable patients. 
 
Another interesting result was seen in the comparison of samples in which >50% of cells 
appeared in clusters versus samples in which <50% of cells appeared in clusters, regardless of 
the isolation approach employed. Specifically, 5 out of 18 samples showed >50% of cells in 
clusters while the remaining 13 samples had <50% of cells in clusters. Figure 4.4C shows genes 
that were more highly expressed in samples with >50% CTCs in clusters, having logFC >2 as 
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well as genes that were lower expressed having logFC <-2. Of note, CDKN1A (p=0.0140, 
logFC=11.586) as well as HSP27 (p=0.0044, logFC=10.139) were more highly expressed in 
samples with >50% CTCs in clusters, to a significant degree. In contrast, ERCC1 (p=0.0140, 
logFC=-2.856), CTNNB1 (p=0.0460, logFC=-13.473), PARP1 (p=0.0068, logFC=-7.231), as 
well as FBXW7 (p=0.0350, logFC=-7.231) were all expressed more highly in samples with 
<50% CTCs in clusters, to a significantly extent. 
 
4.4.6 Comparison among Borderline patient profiles  
As previously shown, unsupervised hierarchical clustering of all 18 samples revealed a 
tendency of CTC profiles pairing according to patient pathological conditions, irrespective of the 
CTC isolation approach used. Given this preliminary finding, we investigated whether there were 
trends among CTC profiles of patients with similar disease presentation. Since the majority of 
patients were deemed borderline resected/resectable or borderline unresectable, CTC mRNA 
profiles were grouped accordingly and unsupervised hierarchical clustering was performed with 
these two groups. Of all 8 borderline patients, 5 of them were borderline resected/resectable 
while the remaining 3 were borderline unresectable. Interestingly, among the 10 CTC mRNA 
profiles generated from EpCAM and EpCAM+CD44 isolation from the 5 borderline 
resected/resectable patients, 4 out of 5 EpCAM profiles clustered together while, as well as for 
EpCAM+CD44 mRNA profiles as seen in Figure 4.5. In contrast, among the 3 unresectable 
patients, the mRNA profiles grouped irrespective of the CTC isolation approach used. These 
preliminary results possibly support the idea that at the molecular level, CTCs among patients 
with a less advanced disease can be distinguished according to epithelial phenotype (EpCAM) 
versus a more stem-like phenotype (EpC+CD44). Additionally, at a more advanced disease 
stage, this distinction is not immediate.  
 
4.5 Discussion 
   The implicit role of tumor cells that express CD44, among other proteins, in rendering an 
enhanced tumor initiating capacity has been reported among several studies. Furthermore, 
mounting evidence suggests that cells displaying biphenotypic epithelial/mesenchymal 
expression may be more appropriate targets for abrogating cancer metastasis than cells 
displaying an exclusively mesenchymal phenotype.
185, 186, 188
 In an effort to enhance CTC yields 
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through immunomagnetic labeling and isolation of CTCs that express CD44 more significantly 
compared to EpCAM, a dual EpCAM-CD44 CTC isolation approach was implemented versus 
standalone EpCAM. Interestingly among the pancreatic cancer patients studied, the dual marker 
isolation approach did not result in increased CTC yields or CTC cluster yields. Additionally, 
there was no significant difference in Vimentin expression between CTCs isolated with EpCAM 
and CTCs isolated with CD44. These findings suggest that among these patients EpCAM is 
expressed by the majority of CTCs such that the addition of CD44 as an isolation antibody is 
unable to significantly increase CTC yields. Moreover, the population of cells that exclusively 
express CD44, without EpCAM expression may be negligible to none. At the molecular level, 
there appeared to be a level of distinction among CTCs isolated with EpCAM and those isolated 
with EpCAM+CD44. Specifically, among patients with a less advanced pathology, 
EpCAM+CD44 isolated CTCs were distinguishable from CTCs isolated with only EpCAM such 
that the mRNA profiles of dual isolation clustered separately from CTC profiles obtained via 
standalone EpCAM isolation. In patients with more advanced disease, this distinction was not 
made such that patient CTC profiles clustered together regardless of the isolation approach used. 
These preliminary results possibly support the idea that at the molecular level, CTCs have the 
potential to discriminate disease pathology. Moreover, among patients with a less advanced 
disease CTCs can be distinguished according to a more epithelial phenotype (EpCAM) versus a 
more stem-like phenotype (EpC+CD44). While these studies are preliminary, at the molecular 
level, they support the idea that EpCAM expression may not be lost entirely as the disease 
progresses, yet tumor cells evolve to become more stem-like. Finally, while acquisition of more 
patient data will be required to validate such findings, the initial results point to the practicality 
of the reported CTC isolation studies to help in answering important questions about tumor 
biology and metastasis. 
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Chapter 5  
Inertial Sorting of polymer particles based on particle 
shape and porosity 
 
5.1 Abstract  
The notion that a fraction of CTCs is responsible for driving metastasis has led to increased 
efforts to distinguish among different CTC subtypes. One primary motivation behind such efforts 
is the idea that targeted analysis of CTC subpopulations will progressively uncover important 
characteristics of their unique roles in metastasis. In most instances, cells of interest are expected 
to express multiple surface proteins, the extents and combinations of which may vary. Moreover, 
with evidence to suggest that particle shape at the micron-scale enhances antibody specificity 
and avidity to antigens, use of a variety of particle shapes can be leveraged in multiple-marker 
immunolabeling of these CTCs. For instance, shapes that allow enhanced avidity can be coated 
with antibodies against less abundant surface proteins while other particle shapes can be used for 
immunolabeling involving more abundantly expressed CTC surface markers. This shape-based 
labeling approach can potentially reduce the amount of sample post-processing via 
immunofluorescence labeling if each particle shape specifically labels a unique CTC marker of 
interest. Moreover, the possibility of hydrodynamically sorting particles based on their construct 
opens up the prospect for rapid and high-throughput cell sorting according to unique expression 
of surface markers. Apart from particle shape as a factor to hydrodynamically separate and sort 
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particles, we set out to investigate whether particle porosity would facilitate enhanced particle 
sorting. The motivation is that separating subsets of CTC labeled with distinct micron particles 
through inertial microfluidic particle sorting, enables large sample volumes to be processed in a 
high-throughput, manner. Here we report our initial findings associated with particle synthesis 
and subsequent sorting of particles using microfluidic inertial sorting. 
 
5.2 Introduction  
In a study that compared how shapes of nano- and micro- rods, spheres and discs 
influenced antibody specificity and avidity, Barua et al reported that particle shape does 
influence the binding of these antibody-coated submicron particles to target cells. They 
demonstrated the utility of this increased, shape dependent specificity to attach nanorods coated 
with trastuzumab, an anticancer therapy, to target breast cancer Her2+ cells.
201
 Furthermore, in 
another study Hur et al showed how non-spherical particles, each categorized using a certain 
characteristic diameter, were able to attain focused equilibrium positions along microfluidic 
channels during flow as a result of inertial forces described earlier (chapter 2). They proposed the 
possibility for use of such asymmetrically shaped particles for high throughput multiplex 
bioassays.
202
 With the understanding that the shape of particles influences the extent to which 
they interact and attach to target cell, and the evidence that differently shaped particles are able 
to adopt unique equilibrium positions, we proposed the use of this shape dependent specificity to 
identify and isolate subpopulations of CTCs.  
Moreover, evidence to support the existence of a subset of cells that behave like 
pancreatic cancer stem cells, (CSCs), was furnished by Li et al, where they showed that these 
CD44+CD24+ESA+ pancreatic cancer cells demonstrated properties of high turmorigenicity, 
self-renewal and the ability to produce differentiated progeny.
27
 Since these cells demonstrate 
resistance to both chemotherapy and radiation therapy, they have been heavily implicated in the 
metastatic process, treatment failure and disease recurrence. Therefore they hold great interest to 
clinicians and researchers alike. Moreover, isolation of CTCs with similar protein expression to 
this population of stem cells, and elucidation of the signaling pathways through which their 
growth and survival are regulated will have important implications, especially for pancreatic 
cancer, which demonstrates the most robust resistance to standard therapies.
203
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With detailed information about the specific surface markers that are expressed by certain 
subsets of circulating cancer cells, we proposed synthesizing asymmetric particles and coating 
them uniquely, with antibodies against these markers of interest. Ideally, the goal would be to 
design and optimize asymmetric particles, to achieve unique particle focusing positions along 
curved microchannels. Additionally, we explored whether particle porosity or size, in 
combination with shape, would enhance particle sorting and separation efficiency using this high 
throughput approach. Once a set of particles that uniquely separate from each other along the 
channel cross-section was identified, a combination of these particles would be selected for 
antibody labeling tests. Ultimately, the goal was to evaluate and optimize cancer cells sorting 
according to proteins of interest, using this combination of particles to label and then separate 
cancer cells. To this end, our collaborators synthesized both dextran and poly(lactide-co-
glycolide) (PLGA) particles based on variable porosities, shapes and sizes. Previously they 
demonstrated the ability to synthesize particles that are compartmentalized with different 
sections demonstrating unique porosities.
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For the antibody labeling tests involving the combination of micro particles, the idea was 
that each type of particle would be surface functionalized with a particular antibody arrayed 
against a CTC surface markers. To initially test and validate the system, particles would be 
screened with pancreatic cancer cell lines to determine which combinations of particle-antibody 
functionalization proffered the most effective antigen-antibody binding with cancer cell. 
Specifically, anti-CD44, anti-CD133 and anti-EpCAM, which are all relevant surface markers in 
pancreatic cancer CTCs were considered for testing with the synthesized microparticles. Thus 
far, the behavior of micron sized discs, cylinders and rods have been tested in curved channels to 
determine particles focusing behavior in the microfluidic channel. Additionally, we report on 
initial particle surface functionalization with EpCAM. 
 
5.3 Methods 
 
5.3.1 Polymer particle fabrication  
PLGA and dextran particles were synthesized by collaborators in the Lahann lab at the 
University of Michigan. Briefly, these particles are synthesized by co-jetting organic polymer 
solutions through a side-by-side capillary system under laminar flow. The application of an 
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electric potential on the pendant droplet causes it to be distorted. The particles can also be 
stretched to result in elongated shapes. Subsequent to particle distortion and reshaping, rapid 
solvent evaporation from the structures results in well-defined particles.
204
 To alter the porosity 
of particles, PLGA was co-jetted with another polymer and upon incubation at pH 5, the polymer 
would degrade and become porous. After synthesis, particles were filtered to enrich for those of 
interest and then enumerated and analyzed to determine particle size standard deviation. Particles 
were then fluorescently labeled to allow them to be distinguished during microscope 
visualization for device optimization. Flat discs, rods and biconcave discs (termed RBCs) were 
synthesized for analysis. Spheres were also synthesized and made porous to test the effect of 
particle porosity on particle focusing. Once particles were counted they were stored in 1% 
Tween solution at 4⁰C to prevent clumping until they were ready to be sorted.   
 
5.3.2 Particle preparation for inertial sorting  
To prepare polymer particles before inertial sorting experiments, stored particles were 
sonicated to disrupt any aggregation of particles which would potentially interrupt microfluidic 
flow, or result in particle flow behavior artifacts. Next particles were pre-sorted twice using a 
spiral inertial sorter to enrich them based on size, so that the overall size range of the particle 
suspension would be narower. Presorting also facilitated removal of debris and any persistnet 
clumps from the sample that remained after sonication. Particles were collected from the spiral 
outlet from which the majority of particles emerged, and then re-processed through the sorter, to 
further enrich the target particles. Once the entire sample was presorted, particles were 
enumerated and the particle size distribution was determined. To obtain porous particles, after 
presorting the orignal non-porous dextran particles, the resulting suspension was incubated at pH 
5 to enable compartments of the polymer particles to become porous. Particles were again stored 
in 1% Tween at 4⁰C until ready for use. 
 
5.3.3 Particle sorting using inertial sorter module  
Polymer particles of differnent physical make up were uniquely dyed with fluorescnce  to 
identify them if and when a mixture of particles were tested and to facilitate fluorescence 
imaging of the particles under flow in the microfluidic device. Once particles were pre sorted and 
enumerated they were sonicated and resuspended to comparable concentrations (~10
6
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particles/mL). The inertial spiral sorter was primed with 0.05% pluronic solution before sample 
processing. The design used has a 25mm outer diameter with four outlets of 200, 150, 200 and 
250μm widths. To determine how shape affected particle focusing in the inertial sorter, 
biconcave shaped particles (termed RBCs), and flat discs were tested at flow rates ranging from 
500-2000μL/min. Both type of particles had diameters ranging from ~8-10μm. To test the effect 
of porosity on particle focusing, nonporous and porous particles of the same effective diameter 
were also tested at flow rates ranging from 500-2000μL/min. Particle flow in the inertial sorter 
outlets was visualized with fluorescence microscopy and images of the outlets were take. From 
these images the relative fluorescene intensity across the channel outlets was analyzed as a 
measure of the particle focusing. The point of maximum fluroescence intensity was taken as the 
the postion of focusing of the particles while the width of streaks was taken as a measure of the 
spread of particles. For particles of different shape or posrosity, a larger distance between 
particle focus points, and a narrower spread of particles allow more effcient sorting of particles. 
 
5.3.4 PANC-1 Cell labelling with porous particles  
To determine the labeling effciency of anti-EpCAM coated porous particles with the 
EpCAM expressing PANC-1 cell lines, the porous particles were first coupled with anti-EpCAM 
antibody. PLGA/dextran/acytylene/PLA-Alkyne particles were surface modified with an azide-
PEG-Biotin group using copper click chemistry over a 10 hour period. Then 50mg/mL of 
Neutravidin was mixed with the biotinylated particles for 3 hours, after which 10μg/mL of 
biotinylated-EpCAM was incubated with the particles for 1 hour. To fluorescently label the 
particles, they were incubated with 1 μg/mL of Alexa Fluor 568 donkey anti-goat secondary 
antibody for 1 hour. As a labeling control for cell EpCAM expression, cells were incubated with 
1μm anti-EpCAM coated magnetic beads. Another control was to incubate cells with polymer 
spheres that were not surface functionalized with EpCAM. PANC-1 cells were incubated with 
the polymer particles for periods of 5, 10 and 15min at a 1:2 cell: particle ratio, after which the 
labelling efficiency was quantified. 
 
5.4 Results  
5.4.1 Pre-sorting particles using inertial separation   
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After polymer particles were presorted to get rid of debris and to enrich particles over a 
narrower range of sizes, the sample was assessed and compared to the original sample 
distribution before presorting. Figure 5.1 shows results obtained directly after jetting particles 
(black bars), and after using a commercially available particle filter (yellow bars). In addition, 
particle distribution was evaluated after combining commercial filtering with 1 pass of inertial 
sorting from the first outlet (green bars) and second outlet (lilac bars), to enrich particles based 
on their size are shown.  
 
 
Figure 5.1: Polymer particle distribution before and after sorting. Plot shows distribution of 
particles sizes directly after jetting, after filtering, and after inertial sorting, both in first and 
second outlets of inertial sorter device.  
 
Results show that compared to filtering, 1-pass of inertial sorting was able to remove outlier 
particles and therefore narrow the range of particle size.  A similar analysis was carried out on 
the particles after they were presorted in the inertial sorter and made porous. Once sorted the 
sample of porous particles was assessed and compared to the original sample distribution before 
presorting. As seen in Figure 5.2, once particles were made porous, further inertial sorting 
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resulted in increased enrichment of particles, both porous and nonporous, at 8μm.  The number 
of outlier particles though negligible, did increase.  
 
 
Figure 5.2: Porous particle distribution before and after inertial sorting. Plot shows 
distribution of porous particles sizes directly after filtering, and after making porous followed by 
inertial sorting and collection from the second outlet of inertial sorter device.  
  
5.4.2 Separating Particles based on shape 
After presorting the particles synthesized as biconcave discs (RBCs), and flat discs, 
particles were reconstituted to the same concentration (10
6
 particles/mL) and processed as 
separate samples through the inertial sorter. Figure 5.3 shows fluorescence overlays of the flow 
behavior of flat discs (dyed green) and RBCs (dyed blue) at the inertial sorter outlets, which 
appear as streaks of green and blue. As seen in Figure 5.4A, across the range of fluid flow rates 
tested, the focusing positions of flat discs (dyed green) and RBCs (dyed blue) in the device were 
almost indistinguishable across the flow rate range tested. 
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Figure 5.3: Fluorescence imaging of differently shaped particles under flow. Behavior of flat 
disc (dyed green) and RBC (dyed blue) microparticles was captured at different flow rates.  
 
 
Figure 5.4: Flow rate effect on focusing point and spread of different particle. (A) Focusing 
positions of flat discs and RBCs and (B) particle spread of flat discs and RBCs as functions of 
flow rate of suspension. 
 
This reflected what appears to be the primary role of particle size in determining focusing 
position of particles and the limitation of the specific device design to sort these particles, since 
both types had comparable effective diameters. Additionally, based on the measures of particle 
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spread in Figure 5.4B, it appears that flat discs were more effectively focused across this 
flowrate range compared to the RBC discs, though at higher flow rates the difference in particle 
spread between flat discs and RBCs becomes less evident. 
  
 
Figure 5.5: Quantification of particle inertial sorting based on porosity. Plot showing 
distribution of porous and nonporous particles emerging from the four outlets of the inertial 
sorter.   
 
5.4.3 Separating Particles based on porosity  
Once polymer particles were presorted and made porous, they were processed through 
the inertial sorter and analyzed for particle distribution from the four outlets of the device. Figure 
5.5 shows that with the inertial sorter design tested, particle distribution in the four outlets is 
largely independent of particle porosity. Particle distribution in all four outlets is the same, 
irrespective of particle porosity. Once again, particle effective diameter appears to be the 
dominant factor in determining particle distribution in the device. Finally, upon comparison of 
particle behavior of all four sets of particles at the flowrate range of 500-2000μL/min, it was seen 
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that polymer spheres, whether porous or not, focused separately from both types of discs (see 
Figure 5.5). Flat discs and RBC discs focused together in the second outlet while spheres focused 
in the first outlet. Since discs and spheres showed separation, the next step is to test separation of 
nonporous spheres and flat discs since both types of particles display higher size and shape 
uniformity compared to their counterparts.  
 
 
Figure 5.6: Comparing focusing of porous, non-porous, flat disc and RBC disc. Discs focus 
and at and emerge from the first outlet channel while spheres focus at and emerge from the 
second outlet channel.  
 
5.4.4 Efficiency of PANC-1 Cell labelling with porous particles  
After nonporous spheres were surface functionalized with anti-EpCAM antibody and 
allowed to incubate with PANC-1 cancer cells, an aliquot of the sample was quantified for the 
cells that showed particle attachment with at least 1 polymer particle, using fluorescence 
imaging. Figure 5.7 shows the results of PANC-1 cell labeling with EpCAM functionalized 
spheres after 5min and 15min of incubation. Results of the control experiment of cell incubation 
with polymer particles that were not EpCAM surface functionalized are also shown for the same 
incubation time periods.  
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Figure 5.7: PANC-1 labeling with EpCAM functionalized and unfunctionalized spheres. 
EpCAM spheres show higher labeling extents compared to control spheres at both time points.   
 
At both time points, EpCAM functionalized spheres attain higher percentages of PANC-1 
cell labeling which may be reflective of higher specific labeling of the cells with the polymer 
spheres. Polymer spheres without EpCAM also show some degree of surface attachment to cells 
which may be as a result of nonspecific binding of the spheres to the cancer cells. Overall, 
labeling efficiency can be improved and efforts to do so will include testing particle 
functionalization with increased concentrations of both Neutravidin and biotinylated EpCAM, 
among other steps.   
 
5.5 Discussion 
Efforts are ongoing to develop the multiplexed assay of differently synthesized micron-
sized polymer particles coated with unique CTC antibodies for separation of CTC 
subpopulations using inertial sorting in microchannels. Preliminary data showed that neither 
particle porosity nor minor shifts in particle shape (flat disc versus biconcave RBC disc) led to 
particle separation using the selected inertial sorter design at the flow rates tested. However, 
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polymer particles of significantly different shapes, namely discs and spheres, could potentially be 
separated in the inertial sorter under study. Also, initial experiments to label cancer cells with the 
surface functionalized polymer spheres shows promise where PANC-1 cells showed almost 40% 
particle attachment compared to the unfunctionalized control spheres. Further optimization will 
require continued testing of particle physics and inertial sorter designs. Additionally, surface 
functionalization of polymer particles with antibodies of interest such as CD44, CD133 and 
CD24 among others, still needs to be explored.  
 In fulfilling the objectives of this study, we imagine that we can both identify and 
separate CTCs according to their unique surface marker expressions. With such high throughput 
segregation of CTC subtypes, to yield cells that are viable, we imagine that this approach will be 
advantageous in studies involving, for example, development of diagnostics and patient response 
to therapy. Thereupon the platform can serve as a facile method of patient monitoring. 
Additionally, sensitive molecular analyses such as mRNA profiling and sequencing can be 
compared among the different CTCs to correlate their phenotype and genotype with CSCs, 
which have been particularly implicated in the metastasis of pancreatic cancer. 
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Chapter 6 
Conclusions  
 
6.1 Summary of Research Findings  
 
6.1.1 Development of an integrated microfluidic immunomagnetic platform to isolate CTCs  
An integrated microfluidic immunomagnetic platform to isolate CTCs in suspension from 
whole blood of patient samples was developed (chapter 2). The approach enables significant 
CTC enrichment in a continuous, high-throughput manner (24 mL hr
-1
), through strategic 
combination of size based-inertial, on-chip CTC labeling with magnetic microbeads, and 
magnetic cell sorting. The clinical relevance of the platform was demonstrated by enabling 
unequaled CTC isolation purity rates (82.5%±23.5) among pancreatic ductal adenocarcinoma 
(PDAC) patient samples. Detection of >13 CTCs/mL was observed in 100% of patient samples 
(median = 69 CTCs/mL, mean = 146± 231 CTCs/mL). Since CTCs are isolated in suspension, 
the sample is amenable to CTC molecular profiling and so both MicroRNA and mRNA profiling 
of CTCs were carried out from CTCs isolated within the system.  MicroRNA and mRNA 
profiling of CTCs revealed that RNAs previously reported as PDAC-associated, were among 
those most abundantly expressed. In summary, a microfluidic platform that enhances CTC purity 
and permits detailed molecular characterization of isolated CTCs was described. 
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6.1.2 Continuum Isolation of Sub-Populations of Pancreatic Cancer CTCs via 
Immunomagnetism 
A method to enrich specific tumor cell groups immunomagnetically according to a 
continuum of EpCAM surface marker expression levels was described (chapter 3). Specifically, 
we categorized cells as having low, moderate and high EpCAM expression among levels which 
can potentially reflect different physiological contributions of each cell subset to pancreatic 
disease. We demonstrated that even among a relatively homogenous group of cells such as the 
PANC-1 cell line, cells could be separated according to their EpCAM levels into low, moderate 
and high expression. Additionally, a wound healing assay was performed to functionally assess 
each subpopulation, which revealed distinct invasive potentials among each subset. Furthermore, 
we described the isolation of pancreatic cancer CTCs from the same patient sample based on 
their varying EpCAM levels. Overall we demonstrated a robust method of capturing varying 
EpCAM leveled-CTCs, which could subsequently shed light on tumor heterogeneity. Among a 
cohort of 6 patients, 5 of 6 samples had CTCs that could be recovered at all three levels of 
EpCAM expression, though the majority of CTCs were recovered as low expression events. 
Preliminary studies that compare tumor cell subpopulations in this continuum manner can 
potentially increase our understanding of the dynamic nature of cell heterogeneity and how it 
relates to patient outcomes. Also further investigation may also reveal therapeutic targets for the 
different subpopulations.  
6.1.3 Dual-Marker Isolation and Characterization of Pancreatic Ductal Adenocarcinoma 
Circulating Tumor Cells via EpCAM- and CD44- based Immunomagnetism 
Efforts to study whether CD44-based CTC isolation would contribute to any observable 
differences among CTCs enriched from pancreatic cancer samples, compared to standalone 
EpCAM, has been described. Apart from the established epithelial marker EpCAM, expression 
of the stem cell marker CD44, among pancreatic cancer CTCs has taken on particular importance 
since these cells demonstrate an enhanced metastatic potential. CTCs were isolated using either 
anti-EpCAM as a standalone antibody or a combination of anti- EpCAM and anti-CD44 from 
each of ten patient samples. We show that within this patient cohort there was no significant 
difference (p=0.328) in detection rates between EpCAM+CD44 dual isolation (average 
CTCs/mL=64±63) compared to EpCAM only isolation (average CTCs/mL=42±33). 
Additionally, we describe that among the 8 samples in which CTCs appeared in clusters, their 
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detection was independent of whether EpCAM only or EpCAM-CD44 combination was used 
(p=0.593). Also we describe how mRNA profiles of CTCs isolated with EpCAM-CD44 among 
patients with less advanced disease clustered distinctly from those isolated solely with EpCAM 
(n=5). This distinction was not observed among patients with more advanced disease (n=3). 
Though preliminary, studies as such can be used in further characterization of metastatic advance 
of pancreatic cancer.  
6.1.4 Inertial Sorting of polymer particles based on particle shape and porosity 
In this study we proposed and described how particle physics such as shape and porosity 
could be leveraged in multiple-marker immunolabeling of these CTCs. In most instances CTCs 
that are responsible for driving the metastatic process are expected to express multiple surface 
proteins, the extents of which may vary. Evidence suggests that particle shape at the micron-
scale enhances antibody specificity and avidity to antigens. We proposed that shapes that allow 
enhanced avidity can be coated with antibodies against less abundant surface proteins while 
other particle shapes can be used for more abundantly expressed CTC surface markers. With 
such an approach, not only cells can be identified as expressing multiple markers, yet the 
approach reduces the amount of immunofluorescence post processing if shapes are specific to 
unique markers of interest. Additionally, through the use of inertial microfluidic CTC sorting 
CTCs labeled with micron-sized particles can be enriched from patient samples in a high 
throughput manner. In addition to particle shape as a factor to hydrodynamically separate and 
sort particles, we set out to investigate whether particle porosity would facilitate enhanced 
particle sorting. We reported our initial findings associated with particle synthesis and 
subsequent sorting of particles using microfluidic inertial sorting. Using the inertial sorting 
device disc shaped polymer particles could be separated from polymer spheres at the flowrates 
tested. Additionally, we demonstrated successful labeling of PANC-1 cancer cells with EpCAM 
functionalized polymer spheres.  
 
6.2 Limitations and Future Directions  
 
6.2.1 Operation of the integrated microfluidic immunomagnetic cell sorter 
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To date, implementation of microfluidic based technologies to isolate and study rare 
CTCs has led to significant advances in our understanding of mechanisms involved in cancer and 
the invasive metastasis cascade. Ultimately, studies and findings predicated on these platforms 
represent tools that can guide identification of potential therapeutic targets. The reported 
integrated microfluidic immunomagnetic platform is capable of significant CTC enrichment in a 
high-throughput manner that is amenable to sensitive molecular characterization. Furthermore 
the universality of the platform allows it to be implemented in any cell isolation context wherein 
cell surface makers of interest have been identified. Apart from the advantages of the device 
there remain opportunities for improvement of the technology, as well as the associated protocol 
for patient sample processing.  
CTC isolation with the integrated system is dependent on size-based inertial sorting as a 
first stage of CTC enrichment such that cells with a diameter >15μm get sorted to the innermost 
outlet of the inertial sorter. Previous studies have shown where CTCs with <4 μm have been 
recovered.
7
 CTCs of this size range are likely to be unfocused in the inertial sorter at the flow 
rates typically used for sample processing, and may emerge from any outlet of the inertial sorter. 
Those that emerge from the innermost outlet of the spiral and flow into the passive mixer may 
successfully be immunomagnetically labeled and isolated but the CTCs that emerge from the 
three other waste outlets remain undetected. While a fraction of these smaller CTCs may 
randomly disperse to the innermost outlet, a potentially important subset of CTCs can be lost due 
to this device limitation. 
One potential method that can be employed to recover a greater percentage of these 
smaller CTCs from future patient samples is to process the sample that emerges from both the 
first and second spiral sorter outlets. Additionally, another approach that can be tested to improve 
the recoveries of smaller CTC is to process the sample form the waste outlets a second time 
through the inertial sorter. Of the two potential methods, the second one allows for more efficient 
sample volume reduction overall, and so more rapid sample processing. Subsequent CTC 
immunomagnetic labeling and processing can be carried out as previously described. Moreover, 
for samples in which smaller CTCs have been successfully detected, molecular profiling and 
comparison of CTCs based on their size may help to identify unique molecular characteristics 
between the groups that affect this phenotypic difference.         
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The dependence of the integrated microfluidic immunomagnetic platform on 
immunomagnetic bead labeling for CTC isolation has a couple of drawbacks. If using a single 
antibody to label CTCs, cells that express the labeling antibody to a negligible degree can 
potentially go unlabeled and therefore undetected in the system.  Such concerns can be addressed 
by using a cocktail of antibodies that target a range of putative CTC markers, however caution 
needs to be taken that such markers are specific to CTCs to avoid contamination with other 
hematopoietic cells. CTCs emerge from the integrated system in suspension, which is 
advantageous for subsequent assays such as single CTC analysis, compared to methods that 
immobilize CTCs in the device. However, there are concerns that unattached magnetic beads in 
the sample may present clogging issues with some of the more recently established platforms for 
single cell and molecular analysis. Methods to address such concerns include cell-picking and 
transferring isolated CTCs from the beads or using a rapid size based filtration method to remove 
the smaller beads from the magnetically labeled CTCs. Through either method, excess magnetic 
beads can be removed to prevent clogging issues during these subsequent CTC assays.   
With the integrated microfluidic immunomagnetic device, magnetic sorting is the rate 
limiting step of the entire process occuring at 50μL/min. The simplicity of the design allows it to 
be readily multiplexed so that several magnetic sorters can be operated concurrently. Future 
work involves designing and optimizing a reusable multi-magnetic sorter where several magnetic 
sorter devices can run in parallel. To ensure reusability of the multiplexed device, the material of 
construct will be based on its ability to retain its engineered parameters and features over time in 
addition to the ease with which it can be sterilized to minimize the likelihood of cross-
contamination among patient samples.  
Once patient samples are processed in the device, CTC identification and enumeration 
are dependent on immunofluorescence staining. To reduce the cost and time associated with such 
procedures, on-chip automated counting of CTCs has been proposed. Future work will involve 
development of an on-chip CTC quantification capabilities similar to work previously described 
that use the electromagnetic resistance of magnetically labeled cells for detection. 
205
Once the 
device has been calibrated, the established characteristic resistance associated with a cell 
magnetized with magnetic beads will be used as a basis for enumeration. As magnetized CTCs 
emerge through the collection outlet of the magnetic sorter, the system will enumerate and record 
such events. Especially in a setting where numerous patient samples are being tested, an 
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automated counting system enables rapid and convenient enumeration, which in turn leads to 
rapid identification of CTC samples that may be considered for subsequent CTC assays. 
Furthermore, this approach removes concerns about the loss of CTCs during centrifugation-
dependent processes such as the currently used cytospin process required for sample 
immunofluorescence staining. Also inaccuracies surrounding the scale up of CTCs counts from 
small sample to the overall volume are eliminated if actual CTC counts can be determined on 
chip.  
 
6.2.2 Assessing larger patient cohorts stage wise 
So far, molecular profiles of <20 patient samples have been studied in any of the reported 
projects. While preliminary CTC data generated across small patient cohorts using the integrated 
system show that molecular patterns characteristic of specific disease stages may be identified 
among patients, tighter controls regarding patient treatment methods are required. To generate 
data that can have significant impact upon clinical implications of CTC studies, larger numbers 
of patients need to be studied. For instance  in a previous study among 63 PDAC patients 
persistent differences in clinical outcomes were observed  if patients were stratified according to 
early and advanced disease stages. Moreover detection of circulating tumor cell clusters before 
treatment was an independent predictor of survival.
177
   
Pancreatic cancer progresses and disseminates rapidly compared to other cancers, and so,  
especially in the context of pancreatic cancer, developing a molecular fingerprint for early 
disease detection has the potential to significantly impact patient outcomes and reduce mortality. 
206
 Since CTCs can be robustly isolated with high sensitivity in the reported integrated 
microfluidic immunomagnetic platform, its implementation in studies with larger cohorts of 
patients holds promise in identifying molecular and physiologically distinct fingerprints of 
pancreatic cancer. Furthemre, characterizing pancreatic disease at relatively early stages may 
increase our understanding of what leads to disease onset and so diagnostic tools can be 
developed. To this end, CTC molecular profiles enriched from patients with less advanced 
diseases can be compared to those with more advanced disease staging. patients that are either 
treatment naïve or on the same treatment regimens should be compared to maintain experimental 
controls and to facilitate objective comparisons.   
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Moreover, the system can be implemented to monitor intra-patient differences that occur 
at the molecular level as pancreatic cancer progresses within the patient. has the potential to 
uncover effective therapeutic targets. To this end CTCs can be isolated from patients at distinct 
stages of disease and Once a sufficiently large number of patients are profiled, analysis of CTC 
molecular profiles associated with disease stages may potentially reveal pathways and genes 
characteristic of disease advance. Interrogating these pathways more deeply has the potential to 
identifying therapeutic targets. 
 
6.2.3 Standardization of molecular profiling of small cell population 
Molecular based assays such as microRNA and mRNA profiling have traditionally been 
used to assay large numbers of cells and large tissue fragments. In general, CTC molecular 
profiling is a less developed field and so the approaches and protocols adopted by different 
groups may vary.
184, 207
 Furthermore, the low number of cells can present more technical 
challenges for specificity of profiles especially if there is contamination with other blood cells. A 
potential concern is that such variations in protocol can ultimately result in generation of data 
that cannot be objectively compared. Apart from differences in RNA extraction and profiling 
protocols, post profiling analysis is another potential cause of variation among studies. Overall, 
there is a need for standardization of molecular profiling and analysis protocols so that studies 
generated by different groups can be more objectively compared.
184, 207
  
Given these concerns, future endeavors to standardize CTC molecular profiling methods 
will involve developing a detailed standard operating procedure for sample processing so that 
results across different platforms can be compared with confidence. For samples with relatively 
low RNA content such as CTC enriched samples, establishing a reliable range of values for 
quality control parameters such as RNA concentration (ng/µL) as well as purity (260/280 
absorbance ratio) is important. Moreover, understanding how and why different RNA 
purification kits and methods affect the quality and reliability of results will be essential in 
narrowing options as a standard procedure is adopted. For the few pancreatic cancer patient 
samples that failed quality control tests, ascertaining the cause of failure will also be beneficial in 
establishing preventive measures in the future. 
 
6.2.4 Single Cell analysis of patient CTCs 
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Given the heterogeneity among tumor cells of the primary tumor and the small fraction of 
cells that successfully disseminate and circulate form the tumor, the ability to interrogate such 
cells at the single level has the potential to improve our understanding of disease evolution as 
well as tumor biology. 
184
 Single CTC analysis also addresses concerns about other blood cell 
contamination and the effect it can have on CTC profiling.
184
 With the integrated microfluidic 
immunomagnetic platform, since enriched CTCs emerge from the device in as single CTCs or 
CTC aggregates, cells can readily be made available for single cell interrogation. Future work 
will involve developing a method to identify and then micro-manipulate single cells from the 
device in order to carry out single cell molecular profiling, similar to what has been previously 
demonstrated.
208, 209
 
Once CTCs are enriched from patient samples with the integrated device, one method of 
selecting single cells can be to manually manipulate and pipette cells using a hand-held pipette, 
combined with microscope imaging. While this process may prove to be laborious, the low WBC 
contamination enabled by the integrated device combined with CTC magnetic bead labeling 
allows for a relatively facile CTC identification and selection process. Additionally, single cell 
analysis can be carried out using a platform such as Fluidigm C1 (San Francisco, California) 
where CTCs in suspension can be encapsulated as single entities in microfluidic wells and 
examined for molecular sequencing and expression data. Therefore, from a single patient sample, 
information about the frequency as well as heterogeneity of expression of mutations and 
aberrations among CTCs can be generated.    
Overall, the basis for future studies involving CTCs and cells enriched from the 
integrated device lies in molecular studies that span across large patient cohorts. Automating the 
CTC enumeration process is imminent as it enables rapid on-chip detection of CTCs. We 
imagine that detailed and well defined studies that implement CTC enrichment using the 
integrated device can ultimately bring insight into important mechanisms and pathways that 
facilitate invasive metastasis cascade in pancreatic cancer. Moreover, the idea is that with 
conclusive data as such, will inform future endeavors to establish effective therapies against 
pancreatic disease.  
6.3 Conclusion 
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Finally, the integrated microfluidic immunomagnetic device is a versatile platform that 
can be recruited in CTC studies beyond just pancreatic cancer. The tunability of the system and 
its ability to yield highly enriched CTCs enables quality CTC fingerprinting and molecular 
characterization. Ultimately, such studies hold the potential to identify effective therapeutic 
targets and agents in the fight again cancer. 
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